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Abstract 
The potential advantages displayed by biocatalytic processes for organic synthesis 
(such as exquisite selectivity under mild operating conditions), have prompted the 
increasing number of processes running on a commercial scale. However, biocatalysis 
is still a fairly underutilised technology. As a relatively new technology biocatalytic 
processes often do not immediately fulfil the required process metrics that are key for 
an economically and/or environmentally competitive process at an industrial scale 
(high concentration, high reaction yield, high space-time-yield and high biocatalyst 
yield). These process metrics can often be attained by improvements in the reaction 
chemistry, the biocatalyst, and/or by process engineering, which often requires a 
complex process development strategy. Interestingly this complexity, which arises 
from the need for integration of biological and process technologies, is also the source 
of the greatest opportunities. Indeed, recombinant DNA technology offers a superb 
complement to process technologies. Potentially this is one of the biggest advantages 
of biocatalysis when compared with conventional chemical catalysis, where all the 
reaction boundaries are fixed by the physical and thermodynamic properties of the 
reaction compounds. Therefore, the main avenue that still remains to be explored by 
process engineers is how to promote process development in a systematic way rather 
than on a case-by-case basis, as is frequently the case today.  
One of the main challenges in process development is selecting between different 
process alternatives. The development effort for a novel process is considerable and 
thus, an increasing number of conceptual process design methods are now applied in 
chemical industries. Since the natural environment of the biocatalyst is often very 
different from the operating conditions suitable for a viable process (high substrate 
and product concentrations, unnatural substrates, presence of organic solvents, etc.), 
process development strategies are particularly relevant for biocatalytic processes. 
However, state-of-the-art methodologies for process development applied to 
biocatalysis often prove to be unsuccessful. At the early development stage the 
biocatalysts are usually still under development and many of the reactions have not 
yet achieved their full potential, many of the process technologies are not yet well 
described and their relationship with the overall process is not clear. 
The work described in this thesis presents a methodological approach for early stage 
development of biocatalytic processes, understanding and dealing with the reaction, 
biocatalyst and process constraints. When applied, this methodology has a decisive 
role in helping to identify many of the process bottlenecks up-front and in a 
straightforward way, whilst indicating development targets, allowing a better use of 
resources and shortening development time. The methodology is illustrated through 
three different case studies: H-caprolactam production by a multi-enzymatic process, 
chiral amine production using Z-transaminase and finally long-chain chiral aliphatic 
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alcohol production by a bi-enzymatic system. For each case study presented, a 
different tool is used to guide development and evaluate the process when different 
levels of underlying process knowledge are available. 
The first case study presents a rational approach for defining a development strategy 
for multi-enzymatic processes. The proposed methodology requires a profound and 
structured knowledge of the multi-enzyme systems, integrating chemistry, biological 
and process engineering. In order to suggest a reduced number of feasible process 
design options, cofactor and interaction matrices are used, identifying the challenges 
and addressing them by selecting appropriate process configurations. Based on this 
information, feasible flowsheets and mass and energy balances are identified. By 
applying evaluation tools, the number of options can be much reduced and the current 
process bottlenecks identified. By applying a priori this methodology, the laboratory 
experts are better able to understand the most favourable operating conditions at full-
scale and thus be able to collect information at these relevant conditions. 
In the second case study, windows of operation are used to quantify and visualise 
process performance and feasibility when interactions between process technologies 
and biocatalyst performance (or reaction) are significant. The methodology constitutes 
a useful tool that provides easy interpretable results to enable rational design choices 
of different available process technologies. In the particular case of the asymmetric 
synthesis of chiral amines, the reaction constraints (thermodynamic equilibrium) must 
be solved prior to implementation and these fix the hard boundaries of the operating 
space. Improvements in the biocatalyst specific activity are also required for a 
successful full-scale implementation. 
In the third case study a methodology for bottleneck analysis is presented, 
incorporating process modelling and engineering evaluation tools. The benefit of such 
models, when integrated with evaluation tools, is that they can be used to predict the 
process performance and identify bottlenecks, without requiring experimental 
examination thereby reducing the resources and time for process development. The 
use of this methodology in the context of reaction engineering is to propose new 
operating conditions at which the process performance is improved, while identifying 
the remaining bottlenecks and suggesting further research efforts. 
Although the proposed methodology is still in its infancy when compared with other 
established process development methodologies, it provides a good overview of the 
whole reaction system and process. The proposed methodological approach 
establishes a systematic evaluation of different process options and indicates required 
fundamental data collection and development efforts for further development stages. 
This methodology could be greatly enhanced by the implementation and integration of 
in-silico tools for property and thermodynamic data as well as process mechanistic 
models to assist in the selection of process technologies. 
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Resumé 
De potentielle fordele ved brug af biokatalytiske processer af organisk syntese (såsom 
høj selektivitet under milde omstændigheder), har igangsat en øget mængde af 
processer på kommerciel skala. Til trods for dette er biokatalytiske processer stadig 
ikke en udbredt teknologi. Som en relativ ny teknologi er det ofte, at biokatalytiske 
processer ikke opfylder de proces krav, der er essentielle for en økonomisk og/eller 
miljømæssig konkurrencedygtig proces på industriel skala (høj koncentration, højt 
reaktionsudbytte, højt volumetrisk produktivitet og højt katalyseudbytte). Disse proces 
indikatorer kan dog oftest opnås ved at forbedre den kemiske reaktion, 
biokatalysatoren og/eller ved brug af procesteknik, der dog ofte kræver en kompleks 
proces udviklingsstrategi. Interessant er det, at den kompleksitet, der opstår ved 
nødvendigheden af at integrere biologiske- og proces-teknologier, også er årsagen til 
de største muligheder. Netop rekombinant DNA teknologi er et fremragende 
supplement til procesteknologier. Dette er potentielt en af de største fordele ved 
biokatalyse sammenlignet med konventionelt kemisk katalyse, der er begrænset af de 
fysiske og termodynamiske egenskaber af reagenser. Derfor er den største udfordring 
for procesingeniører inden for biokatalytiske procesudvikling, er at promovere 
procesudvikling på en systematisk måde, i modsætning til ”case-by-case” som er 
tilfældet i dag. 
En af de største udfordringer i procesudvikling er at vælge mellem forskellige proces 
alternativer. Omkostninger ved at udvikle en ny proces er betydelige og derfor bruges 
en øget mængde af konceptuelle procesdesign metoder inden for den kemiske 
industri. Eftersom de naturlige forhold for en biokatalysator oftest er meget forskellige 
fra de forhold der er gældende for en levedygtig proces (højt substrat og produkt 
koncentration, unaturlige substrater, tilstedeværelsen af organiske solventer osv.), er 
proces udviklingsstrategier især relevant for biokatalytiske processer. Ikke desto 
mindre har ”state-of-the-art” metodikker for proces udvikling, anvendt på biokatalyse, 
ofte vist sig ikke at være succesfulde. På et tidligt udviklingsstadie er biokatalysatoren 
som regel stadig under udvikling og de katalytiske reaktioner har stadig ikke opnået 
deres fulde potentiale. Yderligere er mange af de anvendte procesteknologier ikke 
velbeskrevet og deres forhold til den overordnede proces er stadig ikke klart. 
Arbejdet i denne afhandling præsenterer en metodisk strategi til udvikling af 
biokatalytiske processer på et tidligt stadie ved at forstå og håndtere reaktionen, 
biokatalysatoren samt proces begrænsningerne. Ved anvendelse, har denne metodik 
en afgørende rolle i at hjælpe med at identificere flaskehalsen i processen på en 
direkte måde og samtidigt indikere udviklingsmål, hvilket muliggør bedre udnyttelse af 
ressourcer og nedsætter udviklingstiden. Metodikken er eksemplificeret gennem 3 
forskellige ”case studies”: produktionen af H-caprolactam ved en multienzymatisk 
proces, chiral amin produktion ved brug af Z-transaminase og sluttelig produktionen af 
langkædet alifatiske alkohol i et bi-enzymatisk system. For hver ”case study” er der 
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brugt et forskelligt værktøj til at guide udviklingen og evaluere processen når 
forskellige niveauer af underliggende procesviden er tilgængelige. 
Det første case study præsenterer en rationel tilgang til at definere en 
udviklingsstrategi for multienzymatiske processer. Den forslåede metodik kræver en 
omfattende og struktureret viden omkring multienzymatiske systemer, der integrerer 
kemi, biologi og procesteknik. For at kunne foreslå et antal af mulige procesdesign 
løsninger, er cofaktor- og interaktionmatrixer brugt til at identificere udfordringerne og 
adressere disse ved at vælge passende proceskonfigurationer. Baseret på denne 
information blev mulige proces diagrammer, samt masse og energi balancer, 
identificeret. Ved at anvende evalueringsværktøjer (økonomisk og miljømæssig 
evaluering) kan antallet af muligheder reduceres og de nuværende flaskehalse 
identificeres. Ved at anvende denne metodik a priori er laboratorieeksperterne i stand 
til at bedre forstå de mest favorable fuld skala operationelle betingelse og dermed i 
stand til at indsamle information ved disse betingelser. 
I det andet case study er ”window operations” brugt til at kvantificere og visualiserer 
proces præstationen og gennemførlighed når vekselvirkninger af procesteknologier og 
ydedygtighed af biokatalysatore (eller reaktionen) er signifikante. Metodikken udgør et 
brugbart værktøj der gør det let at fortolke resultater som gør det muligt at foretage 
rationelle valg mellem forskellige tilgængelige procesteknologier. I det specifikke 
tilfælde af asymmetrisk syntese af chirale aminer skal begrænsningerne ved reaktionen 
(termodynamisk ligevægt) løses før implementeringen og dette udgør de hårde 
grænser for det operationelle rum. Yderligere forbedringer i den specifikke aktivitet af 
biokatalysatoren er også nødvendige for en succesfuld fuld skala implementering. 
I det tredje case study præsenteres en metodik for flaskehalsanalyse som indeholder 
proces modellering og tekniske evaluerings værktøjer. Fordele ved integreringen af 
sådanne modeller med evaluerings værktøjer er at de kan blive brugt til at forudsige 
proces præstationen og identificere flaskehalser, uden at det kræver eksperimentelle 
undersøgelser og dermed reduceres ressourcerne og tiden for proces udviklingen. 
Brugen af denne metodik i forbindelse med reaktionsteknik foreslår nye 
operationsbetingelser hvor præstationen af processen forbedres samtidig med at 
resten af flaskehalsene identificeres og yderligere undersøgelser foreslås. 
Selvom den foreslået metodik stadig er i et fosterstadie sammenlignet med andre 
mere etableret proces udviklingsværktøjer og metoder, tilbyder den et overblik over 
hele reaktionssystemet og processen. Desuden etablerer den foreslået metodiske 
tilgang en systematisk evaluering af forskellige proces muligheder (f.eks. proces 
diagrammer), og indikerer nødvendige fundamentale dataindsamlinger og 
anstrengelser for at opnå yderligere udviklingsstadie. Dog kunne den metodik 
forbedres betydeligt ved implementeringen af in-silico værktøjer for egenskaber og 
termodynamiske data forudsigelse og proces mekanistiske modeller, til at hjælpe med 
udvælgelsen af procesteknologier. 
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1 Introduction 
1.1 Biocatalysis for industrial production of chemicals 
The chemical industry has a central role in modern society, since it provides society with 
a large number of value-added products and is one of the biggest economic sectors 
worldwide [1]. More recently, the conventional chemical industry has been forced to 
innovate in order to maintain a competitive position and to successfully penetrate 
already saturated markets [2]. This has resulted in increasing focus on production of 
chemicals from renewable sources, promoting greener synthetic routes and generating 
less toxic by-products and waste, without compromising the product quality. Green 
Chemistry, defined as “the design of chemical products and processes to reduce or 
eliminate the use and generation of hazardous substances” [3], has been promoting the 
design of next generation processes and products, by providing guidelines for 
environmentally friendly and economically competitive processes (compiled in the 12 
Principles of Green Chemistry [4] and engineering [5]). 
Using alternative substrates, energy sources and innovative synthetic routes, 
bioprocesses have brought many innovations to the polymer, biofuel, textile, food, 
health care and pharmaceutical industries, amongst others [6]. Bioprocesses can be 
classified into fermentation and biocatalysis. Fermentation refers to the use of growing 
cells to make the product of interest; Biocatalysis may broadly be defined as the use of 
biocatalysts, which can be crude extracts, purified enzymes, or whole-cells (i.e. resting 
cells) and these can be in their free or immobilised form. Fermentation technologies can 
be applied to produce both large molecules, such as enzymes, peptides, therapeutic 
proteins (e.g. antibodies and insulin) and proteins used in the food industry (e.g. feed 
additives [7]), but also small molecules, such as metabolites of fermentation processes, 
e.g. ethanol, 1,3-propanediol, succinic acid and butanol [8]. Biocatalytic processes deal 
exclusively with the organic synthesis of chemicals (small molecules) such as building 
blocks for added-value chemicals, amino acids, agrochemicals and active 
pharmaceutical ingredients (APIs). [1,9]. The scope of this thesis is confined to 
biocatalytic processes. 
In the past decades, enzyme and whole-cell biocatalysis has been applied in the 
production of various chemicals, mainly optically active intermediates such as fine 
chemicals and pharmaceutical intermediates [9,10]. Contributing to such a fast growth 
is the fact that the number of commercially available enzymes isolated from different 
biological sources has increased significantly [11]. The exquisite selectivity of enzyme-
catalysed reactions yielding single stereoisomers, with few side reactions and easier 
separation of products [11,12] under mild reaction conditions (pH, temperature, often 
aqueous conditions, etc.) make biocatalytic processes well positioned to contribute to 
greener industrial processes, in line with the 12 Principles of Green Chemistry [4]. 
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Joint efforts between biologists, chemists and, more recently, process engineers have 
also created new opportunities for using biocatalysis in the production of lower value 
chemicals and biofuels [13], where the cost structure puts even higher demands on 
process intensity and productivity to achieve a competitive process. 
Despite the many potential advantages of biocatalytic processes and the increasing 
number of processes running on a commercial scale [14], when compared with 
conventional chemical industrial catalysis the use of biocatalytic processes is a younger 
technology [15] and, as with any emerging technology, many start-up difficulties are 
encountered [11]. Enzymes found in nature operate at the host conditions, which are 
typically mismatched with the conditions required for an industrial chemical processes, 
such as high substrate and product concentrations, unnatural substrates, presence of 
reaction additives (e.g. solvents), among others. Hence, often biocatalytic processes per 
se do not meet the required process metrics that are key for an economically feasible 
process at an industrial scale (high concentration, high yield, high space-time yield and 
high biocatalyst yield) [13,16]. 
In spite of some pioneering examples where biocatalytic processes (e.g. lipase catalysed) 
are already operating at full-scale for production of added-value chemicals, the true 
expansion of the enzyme toolbox1 for organic synthesis is yet to come, as the next 
generation of enzymatic synthesis involves more challenging enzyme systems and 
reactions (e.g. amination, oxidation, carbon-carbon formation reactions) both in single 
and multi-step reaction systems. Many of these promising biocatalytic reactions and the 
corresponding biocatalysts are still under development and, as a result, many of the 
reactions are neither well developed nor optimised. Hence, the process technologies are 
not yet fixed and many alternative process configurations are possible. 
The prospects of biocatalytic process lie on its multidisciplinary character: chemistry, 
biology and process engineering. This multidisciplinary character provides certain 
flexibility during the process synthesis and design since many of the identified process 
challenges can be overcome by efforts in one or more of these disciplines. This is 
probably one of the biggest advantages when compared with conventional chemical 
catalysis, where all the reaction hurdles are, to some degree, more constrained by the 
physical and thermodynamic properties of the reaction compounds and catalyst(s).  
Due to the multidisciplinary character that brings new opportunities for biocatalytic 
processes, a systematic approach for process synthesis and design should indicate the 
research efforts required in each development area. Therefore, the main avenue that 
remains to be explored by process engineers is how to promote and conduct process 
development in a systematic way (and not on a case-by-case basis, as it is currently 
done). That is to say, a truly rational and systematic approach for process synthesis and 
design, leading the research focus for each area (chemistry, biology and process 
                                                                
1 Enzyme toolbox: available enzymes for organic synthesis 
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engineering) from the early stage of process development. Such a structured approach 
would result in a better use of resources, a reduced development time and an increased 
understanding of the fundamental system constraints. 
Even though this type of systematic approach is quite common in the conventional 
chemical industry (see section 2.1), the multidisciplinary nature of biocatalytic processes 
raises many different questions that need to be addressed simultaneously. This makes 
the application of a systematic methodology for conventional chemical compounds 
difficult to apply in biocatalytic processes, especially during the early stage when the 
biocatalyst performance needs to be strongly improved.  
 
1.2 Scope of the work and specific research goals 
This PhD project aimed at developing a systematic approach able to assist process 
synthesis and design for biocatalytic systems during early development stage, which 
integrates economic and environmental analysis and other well-established engineering 
tools (such as kinetic modelling). 
This methodology has been developed for different industrial sectors (bulk, fine and 
pharmaceutical chemicals) and diverse understanding levels of the process and intrinsic 
constraints. Hence, the first goal of this methodology is to understand the information 
required for development and decision-making. Further, it is aimed at identify suitable 
process techniques (eliminating some less favourable options) and to identify the issues 
on which future research efforts should be focused.  
The following specific objectives were addressed: 
x To propose guidelines for threshold values for process metrics; 
x To develop fast and accurate methodologies for cost and environmental analysis; 
x To understand the process and the reaction constraints, identifying the 
important challenges when developing a new process, such as setting threshold 
values and guidelines for the process metrics; 
x To identify suitable process techniques (eliminating some less favourable 
options); 
x To assist in decision-making, regarding process flowsheet design, biocatalyst 
formulation (crude extract, purified enzyme or whole-cell and soluble or 
immobilised); 
x To guide research during catalyst development, providing guidelines for 
biocatalyst stability and activity at relevant working conditions. 
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1.3 Thesis Outline 
This thesis is divided into three parts: background, methodology for process 
development and case studies. 
x Part I (Chapter 2) provides an introduction and background to the next 
generation of biocatalytic processes, indicating the major challenges and process 
technologies currently available for industrial application of biocatalytic processes. 
x Part II (Chapters 3 - 5) focuses on methodologies for process design in 
biocatalysis: 
o Chapter 3 includes the current state-of-the-art in process synthesis and 
design in the conventional chemical industry and the tools currently available for 
bioprocess development (including biocatalytic processes); 
o Chapter 4 introduces feasibility and evaluation tools that have been 
developed as a part of the proposed methodology; 
o Chapter 5 is dedicated to explaining the proposed methodological approach 
for guiding development effort and the design of biocatalytic processes during 
early development stage. 
x Part III (Chapters 6 - 9), exemplifies the application of the methodology for 
process development to three case studies and explains how different tools are 
applied for different levels of information (i.e. a priori available knowledge). The case 
studies (and corresponding tools) are presented in a crescent order of pre-available 
knowledge. 
o Chapter 6 gives an overview of the case studies, including a summary of the 
information available and the tools applied in each case study. 
o Chapter 7 presents how the application of ‘cofactor and interaction matrices’ 
can assist during process design of a multi-enzymatic process in the production 
of H-caprolactam (bulk chemical). 
o Chapter 8 analyses the underlying constraints of a Z-transaminase-catalysed 
reaction using a ‘window of operation’ in order to identify suitable process 
strategies for the production of an optically pure chiral amine (pharmaceutical). 
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o Chapter 9 presents the application of a ‘bottleneck analysis’ for reaction 
optimisation of hardly water-soluble chiral aliphatic alcohols (fine chemical) 
towards a cost effective production. 
x Part IV (Chapters 10 and 11) presents a general discussion of the methodology 
and case studies, the most significant conclusions and proposes possible directions 
for further research that may lead to a more efficient system process design and data 
collection. 
 
1.4 Publications included in the thesis 
The following submitted publications have resulted from the work presented in this 
thesis and submitted manuscripts are provided in the Appendix 1. 
Tufvesson, P., J. Lima-Ramos, M. Nordblad and J. M. Woodley (2011) Guidelines and cost 
analysis for catalyst production in biocatalytic processes. Org. Process Res. Dev. 15:266-
274. 
Parts of this publication were included in Chapter 5 to explain the routine applied 
in simplified economic analysis. Furthermore, guidelines for biocatalytic yield 
presented in the Chapter 6 correspond to an adaptation of the above publication. 
 
Tufvesson, P., J. Lima-Ramos, J. S. Jensen, N. Al-Haque, W. Neto and J. M. Woodley (2011) 
Process considerations for the asymmetric synthesis of chiral amines using 
transaminases. Biotechnol. Bioeng. 108:1479-1493. 
Parts of this publication were reproduced in Chapter 2 and Chapter 9. References 
to more recent studies were included when suitable. 
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2 Overview of biocatalytic processes 
2.1 Introduction 
Despite the large portfolio of added-value products in the chemical industry there is an 
on-going tendency to innovate the conventional chemical industry towards process 
improvements, cost reductions and increased quality, safety, health and environment 
profile of production processes[17,18]. White biotechnology, also known as industrial 
biotechnology [19], has been emerging not only as a suitable replacement technology 
to the conventional chemical synthesis of these products [1], but also as a route to new 
products (Figure 2.1). During the last few decades, considerable progress has been made 
in biotechnology research, which is ultimately reflected in the increasing number of 
bioprocesses that have been implemented at industrial scale [20]. Bioprocesses have 
provided many innovative routes for the chemical industry, by fulfilling many of the 
fundamental Principles of Green Chemistry [4,5,21,22]. 
 
Figure 2.1. Production of chemical products and the White Biotechnology perspective 
 
Among the bioprocesses, biocatalytic processes are especially attractive for the organic 
synthesis of industrial relevant products, since: 1) enzymes are natural catalysts 
produced by fermentation, possibly from renewable feedstocks; 2) enzymes are usually 
non-toxic catalysts and prevent large consumption of metals (unlike many of the metal 
and organometallic catalysts); 3) the processes are generally operated at moderate 
reaction conditions (temperature, pressure and pH levels) leading to lower energy 
consumption; 4) enzyme-catalysed reactions are usually very selective leading to high 
product purity, decreased waste production, facilitating the downstream process; 5) 
biocatalytic processes are commonly run in aqueous reaction media, preventing large 
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consumption of organic solvents; and 6) the possibility of improving the biocatalyst by 
recombinant DNA technology [17,23].  
These advantages put forward a number of potential economic and environmental 
benefits, in line with the 12 Principles of Green Chemistry [4]. These benefits often meet 
the chemical industry’s requirements in response to the market demands to find 
“greener” routes and processes, preserving or improving product quality [24]. Hence, in 
the past decades, enzyme and whole-cell biocatalysis has been applied in the production 
of different chemicals, mainly optically active intermediates such as fine chemicals and 
pharmaceutical intermediates [9,10]. Contributing to such a fast growth is the fact that 
the number of commercially available enzymes isolated from different biological 
sources has expanded rapidly [11]. More recently, joint efforts between biologists, 
chemists and engineers has produced new opportunities for biocatalysis also in lower 
value chemicals and biofuels [13]. 
Currently the focus in biocatalytic processes is mostly on single-step reactions with one 
or two substrates [18]. However, multi-step reactions and multi-component reactions 
(such as reactions catalysed by cytochrome P450) have been considered as an 
alternative to chemical-catalysis [18,25] by combining different enzyme catalytic 
activities in a sequential manner. However, many challenges remain in the effective 
scale-up of processes using enantioselective enzymes in organic synthesis. 
 
2.2 Next-generation biocatalytic processes 
Some areas in biocatalysis, such as the use of hydrolases (EC 3 like acylases, amidases, 
esterases, lipases, proteases), have become well established in organic synthesis [18] 
and these biocatalytic reactions represent most of the enzyme-catalysed reactions in 
industry (such as in resolutions, deracemizations and desymmetrizations) [24]. 
However, recent reports [17,18,26] have identified other relevant enzyme classes 
suitable for organic synthesis. Oxidoreductase enzyme class (EC 1), including NAD(P)H-
dependent alcohol dehydrogenases (ADH, EC 1.1.1.X), Baeyer-Villiger monooxygenases 
(BVMO, EC 1.14.13.X), cytochrome P450 (CYP450, EC 1.14.X.X), and enoate reductases 
(EC 1.3.1.31), have been identified as a relevant enzyme class for the synthesis of many 
industrial organic products [18,23,24,26] (Table 2.1). In addition, interesting enzyme-
catalysed reactions are chiral amine synthesis applying Z-transaminases 
(aminotransferases, Tam, EC 2.6.1.X) [26] (Table 2.1) and asymmetric C–C bond 
formation using lyases (e.g. transketolase, TK, EC 2.2.1.X, and ThDP-dependent lyase, EC 
4.1.X.X) (Table 2.1).  
Enzymes within the oxidoreductase enzyme class (EC 1) catalyse oxidation and reduction 
reactions. The industrial application of oxidoreductases covers the synthesis of (non-
natural) amino acids, chiral alcohols, amines and amides [14].  
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Table 2.1. Emerging relevant enzymes for organic synthesis of industrially relevant products 
Enzyme 
Class Enzyme Example of the catalysed reaction  
Main  
challenges 
O
xi
do
re
du
ct
as
e 
(E
C 
1)
 
Alcohol 
dehydrogenase 
(EC 1.1.1.X) 
 
 
Cofactor recycling 
Enzyme stability [27] 
Baeyer-Villiger 
monooxygenase 
(EC 1.14.13.X) 
 
Cofactor recycling 
Substrate/ Product inhibition 
O2 transfer rate 
Cytochrome P450 
(EC 1.14.X.X) 
H2O2 inhibition and stability [28] 
Membrane integration [28] 
Cofactor recycling [29] 
Substrate inhibition [29] 
Electron transfer [29] 
Enoate reductases  
(EC 1.3.1.31) 
 
 
Cofactor recycling 
Tr
an
sf
er
as
es
 
(E
C 
2)
 
Z-Transaminase 
(EC 2.6.1.X) 
 
 
Thermodynamic equilibrium [30] 
Substrate/ Product inhibition 
Transketolase and 
Transaldolase 
(EC 2.2.1.X) 
 
 
Thermodynamic equilibrium 
Substrate/ Product inhibition 
Product stability 
* Chiral centre; X electron-withdrawing group 
 
Enzyme catalysed oxidations display several advantages when compared with 
traditional organic chemistry, since they circumvent the use of flammable and 
halogenated solvents, high-valent metals and the use of stoichiometric oxidants in 
excess [24]. Despite the importance of oxidoreductases in organic synthesis, many of 
the subclasses of this family are still not fully explored [14,26]. Redox biocatalytic 
processes, normally require two oxidoreductases — one for the biotransformation and 
one for cofactor regeneration. Hence, the majority of enzyme-catalysed redox processes 
make use of metabolising cells, with enzymes from all classes being active at the same 
time as oxidoreductases, in order to promote effective in-situ cofactor recycling [12]. 
Interestingly, even in the absence of cell growth, cofactors can be effectively recycled, 
as shown for reductions mediated by baker's yeast cells [31]. 
Perhaps the most established biocatalytic redox reaction is the ketone reduction 
yielding a chiral alcohol, using nicotinamide nucleotide-dependent dehydrogenases 
(also known as alcohol dehydrogenases (ADH), ketoreductases (KRED) and carbonyl 
reductases (CR)) [27], due to the enantiospecificity in reduction of prochiral ketones 
(Table 2.1). 
29
Part I Background 
 
12 
Regardless of the great progress in the application of nicotinamide-dependent 
dehydrogenases in the organic synthesis of industrially relevant compounds, other 
enzyme subclasses catalysing oxidation and reduction reactions are yet to be explored. 
Among the potentially interesting enzyme catalysed redox reactions, Baeyer-Villiger 
monooxygenases (BVMO) are notable for their ability to catalyse the selective insertion 
of an oxygen atom into a cyclic ketone to create a lactone [32], an important reaction 
for the synthesis of multi-cyclic lactones for potential use as pharmaceutical 
intermediates with high regio- and stereo-selectivity [24] (Table 2.1).  
Further, the heme-containing cytochrome P450 (CYP450) oxygenases are generally 
recognised as highly relevant biocatalysts for the fine and pharmaceutical industries, as 
these enzymes are involved in the biosynthesis of several pharmaceuticals and steroids 
[28,29] due to their ability in catalyse the regio- and stereospecific oxidation of non-
activated hydrocarbons [33] (Table 2.1).  
Finally, there is an increasing interest in enoate reductase enzymes that catalyse the 
selective reduction of carbon–carbon double bonds that are substituted with electron-
withdrawing groups [34] (such as a ketone, aldehyde, carboxylic acid, ester, anhydride, 
lactone, imide or nitro group [35]) yielding the synthesis of (up to) two chiral centres 
and thereby, of particular interest for the production of chiral materials. 
Among the industrially relevant biocatalytic aminations, transaminases have received 
increased interest for the asymmetric synthesis of amines from prochiral ketones [36-
38]. Transaminases can be applied for either kinetic resolution of racemic compounds 
or asymmetric synthesis starting from a prochiral substrate. However, despite being a 
potentially attractive technology for the industrial production of optically pure chiral 
amines due to the favourable reaction thermodynamics, asymmetric resolution is 
hampered by a maximum yield of 50% [36]. Therefore, the transaminase-catalysed 
asymmetric synthesis of chiral amines is more attractive for emerging biocatalytic 
processes, despite the frequently observed thermodynamically challenged reaction. 
Carbon–carbon bond formation reactions are significant in organic synthesis to set up 
the carbon backbone of organic molecules [39]. Currently, most C-C forming enzymes 
have been applied to the synthesis of building blocks containing hydroxylated chiral 
centres [40]. C-C bond formation reaction involves nucleophilic attack and thus often 
poses additional challenges, as it requires an exact stereochemical control over separate 
fragments [40]. Due to the exquisite selectivity of enzyme-catalysed reactions, the 
application of a biocatalytic process for the synthesis of new compounds through C-C 
bond formation is especially relevant. These enzyme-catalysed reactions can be 
performed by the transketolases and transaldolases family and by enzymes belonging 
to the lyases enzyme class (such as ThDP-dependent enzymes, aldolases, among others). 
Transketolases (EC 2.2.1.X) catalyse the reversible transfer of a two-carbon ketol moiety 
from a ketose to an aldose. However, some studies have reported substrate inhibition 
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at relevant industrial concentrations as well product degradation throughout the 
reaction [41]. Further, in the lyases enzyme class, ThDP-dependent enzymes are also 
capable of catalysing a broad range of lyase and ligase reactions. Excellent reviews have 
been published covering C–C bond formation by enzymes [39,42,43]. However, despite 
the few examples where C-C forming examples were successfully scaled-up [43], most 
of the studies are currently focused in enlarging the substrate scope and, thus, the 
underlying challenges of these reactions at industrially relevant conditions are not yet 
fully identified [42]. 
Even more interesting than to explore the unique catalytic ability of these emerging 
enzymes, is to explore multistep chemistry, since synthetic processes to generate a 
desired product often require sequential synthetic reactions. Thus, promising future 
applications are envisaged for these processes [44,45]. However, multi-enzyme 
processes feature a high degree of complexity due to the interaction of the different 
components in the reaction mixture and the often encountered mismatch between 
optimum reaction conditions of each individual catalytic step. 
 
2.2.1 Challenges and process development technologies 
In general, the promising enzyme-catalysed reactions are now well launched due to the 
continued expansion of commercially available enzyme libraries and the increasing 
number of enzymes being expressed in GRAS (generally regarded as safe) organisms. 
Although advances in recombinant DNA technology offer huge potential to improve the 
biocatalyst performance, increasing tolerance to solvents, increasing the activity under 
operating conditions (e.g. high substrate or product concentrations and unnatural 
substrates), this is a time and resource consuming activity [46]. Further, for some small-
scale products (less than 5 tons/year) and high market value, it might not be worthwhile 
to develop a biocatalyst based upon on the selling price of the product [14], as the 
biocatalyst cost contribution for high value products are often large. Developing a 
biocatalyst for a small process can lead to great investment of resources in the catalyst 
development that might not be translated in a significant decrease of the operating 
costs and thus, the investment made might not always be recovered. 
Hence, it is also necessary to keep in mind that the integration of complementary 
technology platforms in manufacturing processes, such as fermentation (being 
increasingly implemented due to significant developments in pathway engineering and 
synthetic biology) and homogenous and heterogeneous catalysis is required. This 
integration implies that the implementation of biocatalytic steps should be matching the 
conditions of both synthetic and recovery steps. Many of the emerging biocatalytic 
reactions are still finding their position in the chemical industry, due to the mismatch 
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between the bench- and large-scale requirements. As the scale of biocatalytic step 
increases, more emphasis is required in promoting more cost-effective processes. 
2.2.1.1 Process intensification 
Among the requirements for a process to be economically viable, threshold values for 
given metrics must be attained (see Chapter 5, Section 5.2.1). Product concentration is 
a particularly challenging process metric to be successfully targeted and achieved, 
especially when moving from laboratory to full-scale implementation. Depending on the 
market sector, the usual requirement is to achieve product concentrations above 50 g/L 
[13]. In their natural conditions (i.e. inside the host organism) enzymes operate at 
maximum substrate and product concentrations within the range of millimolar. Hence, 
at large-scale, enzymes operate well outside from their natural conditions, with obvious 
consequences on the biocatalyst activity and stability. Further, the high concentrations 
required in industrial processes may also lead to multiphase reactions since the 
substrate and/or product of interest in the chemical industry often displays a low 
aqueous solubility [14].  
In biocatalytic processes, efficient increase in concentration can be achieved in two 
complementary ways: protein engineering and process engineering. Protein engineering 
can be used to improve the biocatalyst tolerance to high concentrations of substrate 
and/or product [47,48]. Interestingly, process engineering solutions can potentially not 
only tackle the problem of  the inhibitory effects of high concentrations of substrate and 
product, but also overcome substrate solubility problems: substrate can be added to the 
reaction by the addition of a second phase to the reaction medium (organic solvent or 
solid resin) or by operating the reactor in a fed-batch mode. The use of organic solvents 
might bring some extra consideration during scale-up, since the list of suitable solvents 
is limited, as they are required to be GRAS approved. Further, the addition of a second 
phase (organic solvent or solid resin) requires good mixing in order to avoid mass 
transfer limitations.  
The use of in-situ product removal (ISPR) where the product is removed during the 
course of the reaction can lead to significantly higher productivity [49] by avoiding the 
build-up of inhibitory product concentrations in the reactor. Furthermore, the use of 
polymeric resins or organic solvents, may constitute an opportunity to implement ISPR 
with a controlled substrate feeding (in-situ substrate feeding, ISSS) [50] also known as 
substrate feeding and product recovery (SFPR). Further, for thermodynamically 
challenged reactions (such as Z-transaminase-catalysed reactions) the application of a 
highly selective ISPR technique is of particular relevance to displace the reaction 
equilibrium towards the product, enabling a higher conversion and thus an economically 
feasible process. The most suitable ISPR techniques are those involving partitioning of 
the product into a second liquid phase (extraction with organic solvents) or the 
adsorption onto or generation of a solid phase (resin adsorption), although other 
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examples can be found where extractive distillation, crystallisation, membrane 
separation, among others [51] are used. However, most of the ISPR techniques reported 
to date are not selective enough for a successful and significant equilibrium 
displacement.  
2.2.1.2 Biocatalyst formulation 
Using whole-cells may bring several benefits to the process, such as improved enzyme 
stability. It can also enable in-situ regeneration of expensive cofactors. However, due to 
the possibility of side reactions, the use of whole-cells requires additional downstream 
process cost for product recovery. Isolated enzymes are particularly interesting for 
synthetic routes, due to their selectivity and purity of product stream. Additionally, the 
use of isolated enzymes brings simplicity to the process (avoiding undesired side 
reactions) but the trade-off is higher upstream costs (for enzyme recovery and 
purification) [16] and therefore re-use of the enzyme is often required to design an 
economically competitive process.  
As a balance between these trade-offs (and as a rule of thumb), the crudest possible 
form of the enzyme (e.g. whole-cell or lysate) should be used, without compromising 
the product quality [13]. For economic reasons whole-cell biocatalysts are typically 
preferred over isolated enzymes [26] (see Section 7.2.2). 
Further, biocatalytic processes require a clean product stream [52], not only in terms of 
undesired by-products, but also avoiding protein contamination in the product. For this 
reason, large-scale biocatalytic processes require the use of immobilised biocatalyst, 
enabling the recycling and reuse of the biocatalyst [53]. Such recycling is also required 
for the process economic viability, in order to compensate for a costly upstream, 
comprising not only enzyme recovery and purification but also the immobilisation step. 
Moreover, operating with immobilised enzymes offers more options for alternative 
reactor design [54].  
Immobilisation is particularly relevant when using organic solvents since under these 
conditions enzymes are prone to aggregation, affecting their activity and stability [15] 
(see Section 7.2.2). To date, there is not a general routine to select an immobilisation 
technique, which encompasses an analysis of stability, activity, handling and cost of the 
immobilised enzyme and the physicochemical properties of the immobilisation matrix, 
enzyme surface interactions and the reaction media [55-57]. 
2.2.1.3 Operating mode 
The operating mode (batch, fed-batch and continuous) has a major influence on the 
liquid reactive phase of the process and thus, must be identified to correctly assess the 
mass (and energy) balances. For biocatalytic processes, the operating mode is mostly 
decided based upon on the reaction characteristics such as inhibitory effects, 
unfavourable thermodynamic equilibrium and low compound solubility. When the 
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process is operated in batch mode, all the reagents are fed into the reactor and the 
product is then recovered after the reaction is completed. Further, the conversion that 
can be obtained from the reactor is a function of the batch duration. However, this type 
of operating mode is not suitable for cases where a strong substrate inhibition is 
observed. In such cases, the process can be operated either in a fed-batch or in 
continuous mode. In fed-batch mode there is a periodic (or continuous) dosing of 
substrate into the reactor, while the product concentration builds up until the end of 
the reaction. In continuous operation mode, the reagents are continuously fed into the 
reactor and product is continuously recovered. This implies that the reactor is operating 
at the effluent substrate feed-rate; hence reaching complete conversion is impossible. 
2.2.1.4 Reactor design 
Reactor selection for biocatalytic reactions is usually based on cost, space, mass transfer, 
kinetics, heating and cooling, easiness of operation, operation mode and reusability of 
the catalyst [58]. 
A stirred tank reactor (STR) is the most common reactor set-up, due to its simple setup, 
flexibility, well-mixed behaviour and ease of operation. It can be applied to reactions 
catalysed by whole-cells as well as soluble or immobilised enzymes [15,25]. However, 
this type of reactor might cause mechanical shear stress (due to stirring and reactive 
oxygen species) on the biocatalyst, with consequent decrease in activity [52,59], which 
implies an adjustment in the operating conditions (e.g. increase the residence time) or 
dose more biocatalyst to the reactor [15]. In particular, continuous stirred tank reactor 
(CSTR) is appropriate for the enzymatic reactions with substrate inhibition [60] since it 
operates at low substrate concentrations where the reaction rate is higher.  
The packed-bed reactor (PBR, plug-flow behaviour) is an alternative reactor design when 
operating with immobilised enzymes. The main advantages of the PBR compared to a 
STR are: lower investment cost; high volumetric productivity; low voidage; low 
mechanical stress; suitable for reactions with high product inhibition [60]; simplified 
separation of the enzyme from the product stream [15] and; when run at shorter 
residence times, may lead to fewer side reactions [25]. On the other hand, drawbacks 
of using a PBR include internal and external mass-transfer limitations, channelling 
effects over the bed and PBR are therefore, not suitable when operating in multi-phase 
reactions. In addition, pH control, ISSS and ISPR is difficult during a single pass through 
a packed bed. However, these limitations can be overcome when running several PBRs 
sequentially (or in a loop), with pH adjustment, substrate feeding or product removal in 
between [15]. 
A fluidised bed reactor (FBR) is particularly advantageous when using smaller particle-
size in order to improve the contact and/or reaction of multi-phases (liquid–gas, liquid–
liquid and liquid–solid) [52], as the solid particles are held in suspension within the 
reactor by means of fluids passing through the system and is therefore, of relevance 
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when using polymeric resins for ISPR or immobilised enzymes. When compared with 
PBR, FBR display several advantages: well-mixed behaviour, lower pressure drop, flow 
field is uniform and the formation of preferential channels is minimised [61] while 
keeping low mechanical shear stress. A variant of FBR is expanded bed reactor (EBR, 
plug-flow behaviour) where the reaction mixture includes suspended solids (such as 
polymeric resins for ISPR). The particles in the liquid may pass freely through the spaces 
in the bed without becoming trapped (unlike observed for PBR and FBR).  
Some of the advantages and disadvantages of the most common reactors used in 
biocatalytic reactions are listed in Table 2.2. 
 
2.3 Concluding remarks 
In the most prominent biocatalytic processes (such as those designated in this chapter 
as the next generation of biocatalytic processes), chemists have been putting great 
effort into finding new catalytic activities, to synthesise new compounds and to find new 
chemical routes for the synthesis of chemical compounds [62,63]. On the other end, 
biologists have been focusing their efforts on broadening the substrate range, improving 
specific biocatalyst activity and stability at operating conditions, or changing the enzyme 
selectivity [64-66]. Process engineers have been exploring new avenues to overcome 
many of the process limitations in areas that cannot be fully tackled by the other 
disciplines: shifting the thermodynamic equilibrium (by ISPR); and overcoming substrate 
and product solubility limits. However, process engineers have also been trying to 
reduce the burden on the biology side by developing new technologies to overcome 
substrate and product inhibition (by ISSS, ISPR and reactor design), or to improve 
enzyme stability (by immobilisation).  
For instance, in a biocatalytic process, biologists can assist enzyme expression 
enhancement during the biocatalyst production by metabolic engineering or improved 
biocatalyst stability and activity by protein engineering. Process engineers can tackle the 
same challenges by opting for a different catalyst formulation (immobilised), altering 
the reactor configuration, applying a substrate feeding strategy (fed-batch mode, ISSS) 
and/or substrate removal (ISPR). As seen in conventional chemical catalysis, in 
biocatalytic processes, in theory, the only boundaries are the physical and 
thermodynamic properties of the system and even these can be eventually overcome 
by introducing a second liquid phase to increase compounds solubility, choosing a 
slightly different chemical route (e.g. different electron acceptor or donor) or optimising 
reaction conditions (pH, temperature etc.).  
The multidisciplinary character of biocatalytic processes brings new opportunities within 
the field. Hence, a suitable structured approach for conceptual process synthesis should 
indicate the efforts required in each research area, where the different disciplines (i.e.  
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Table 2.2. Different reactors for multi-enzymatic processes 
Reactor 
type 
Reactor  
representation Advantages Disadvantages 
St
irr
ed
 ta
nk
 re
ac
to
r 
(S
TR
) 
 
 
 
Allows soluble and immobilised 
enzymes and whole-cell 
Multiphase media 
Good operational control 
Simple modelling 
Simple construction 
Low downtime (easy to clean) 
Possible inactivation 
of biocatalyst 
Difficult soluble 
enzyme recycling 
Pa
ck
ed
 b
ed
 re
ac
to
r 
(P
BR
) 
 
 
 
Allows soluble and immobilised 
enzymes and whole-cell 
Low enzyme damage due to shear 
stress 
High conversions achieved and 
volumetric productivities 
Shorter residence times 
Easy enzyme recycling, separation and 
exchange 
Low investment cost 
Thermal gradient 
Difficult to control 
Complex modelling 
Mass transfer 
limitations 
Not suitable for multi-
phase reactions 
Fl
ui
di
ze
d 
be
d 
re
ac
to
r 
(F
BR
) 
 
 
 
Allows soluble and immobilised 
enzymes and whole-cell 
Good enzyme mixing 
Suitable for multi-phase reactions 
Lower pressure drop 
Uniform flow field 
Good operational control 
Easy enzyme recycling, separation and 
exchange 
Possible inactivation 
of biocatalyst 
Constrained by the 
particle size and 
density 
M
em
br
an
e 
bi
or
ea
ct
or
 
(E
M
R)
 
 
 
Allows soluble enzymes 
Low enzyme damage due to shear 
stress 
High conversions achieved 
In-situ separation 
Retention of enzymes and cofactors 
Dosing of a reagent 
Compartmentalisation 
Complex modelling 
Poor control 
Membrane fouling 
Restrictions on the 
volumetric flow rate  
High energy utilisation 
Bu
bb
le
 c
ol
um
n 
re
ac
to
r 
(B
CR
) 
 
 
 
Simple design 
High heat transfer area 
Low enzyme damage due to shear 
stress 
Low maintenance costs 
High sparging rates 
are required for a 
turbulent flow 
Bubble coalescence 
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chemistry, biology and process engineering) are aware of each other and of the cost of 
developing a technology. For instance, product inhibition can often be overcome by 
ISPR, which is often a less laborious and extensive task than developing the catalyst by 
enzyme engineering. This PhD project proposes a methodological approach to promote 
process development in a systematic way (and not by a case-by-case as it is currently 
done for the many of the aforementioned challenging biocatalytic processes). The 
proposed methodology can direct the research focus for each area (chemistry, biology 
and process engineering) from the early stage of process development, allowing a better 
use of resources and a reduced the development time. 
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3 State-of-the-art in methodological approaches for 
conceptual process development 
One of the main challenges in process development at early stage is selecting between 
different process alternatives (i.e. flowsheets, technologies, catalysts, among others). 
This challenge becomes even more crucial when developing biocatalytic processes, as 
the environment in which biocatalytic reactions naturally occur (i.e. inside the cell) is 
often very different from the operating conditions that ensure the economic and 
environmental viability of the process (high substrate and product concentrations, 
presence of organic solvents, etc.). Furthermore, reaction, biocatalyst and process 
constraints in biocatalysis are often correlated [36,46,67,68]. Thus, development 
strategies for biocatalytic processes require a deep understanding of the underlying 
constraints and should include a synergy between chemists, biologists and process 
engineers in order to overcome these.  
In general, chemical processes must be operated effectively and efficiently [69,70]. 
Indeed, one of the main challenges of an engineer is to select a process route among 
different process options. Conceptual process synthesis has proven to be of high 
relevance in chemical process industries [71] as process development and design 
typically constitutes a small proportion (about 10 to 15%) of the total resources during 
the development process of a new product [72]. However, the decisions made in this 
step account for a large fraction (between 70 to 80%) of the total production costs [72]. 
The importance of a correct assessment is especially significant for bioprocesses, a less 
mature technology in the chemical industry, where most of the biocatalysts and host 
organisms are still under development and many of the reactions have not yet achieved 
their full potential.  
An increasing number of conceptual process design methods are now applied in 
chemical industries in order to: design innovative processes by considering new raw 
materials, feedstock or routes [73,74]; re-design a process or; retrofit the process 
equipment in an existing process [70]. 
The following section is dedicated to the systematic methodologies developed for 
conventional chemical industries, followed by the state-of-the-art in methodologies for 
bioprocess development. Later, tools and the methodology proposed in this thesis are 
presented (Chapters 4 and 5, respectively). 
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3.1 Methodologies used in conventional process development 
In the last five decades, there have been a large number of methodologies that propose 
an expedited approach to design new or optimised processes [75]. Regardless the 
methodology followed, the conceptual process synthesis includes: problem definition; 
goal definition; synthesis of solutions; analysis of solutions; evaluation and reporting 
[73]. 
Indeed, process synthesis methodologies and tools have reached such a level of maturity 
that they are successfully applied in industry, providing several advantages in process 
selection, in particular when aiming for energy, capital and operating costs savings [73-
75]. 
There are three main conceptual process synthesis methods: optimisation-based 
methods, knowledge-based methods and hybrid approaches. The main idea of the 
optimisation-based approach is to formulate a new flowsheet in the form of an 
optimisation problem (e.g. improving the economic or environmental profile of the 
process) [71]. Whilst a knowledge-based method is focused on the representation and 
knowledge organisation of the design problem, meaning that the limiting steps are first 
identified and the conceptual process synthesis aims at overcoming the identified 
limitations [71]. The hybrid (or combined) approach combines simultaneous adoption 
of mathematical algorithms (as in optimised-based methods) and the hierarchical design 
procedure (used in the knowledge-based methods) [76]. 
 
3.1.1 Optimisation-based method 
The optimisation-based method solves an optimisation problem where a mathematical 
representation reflects the requirements for an optimal solution [77-79]. For this 
purpose, an objective function is defined, including conceivable unit operations and a 
mathematical model that connects the different units of operation, mass and energy 
flows as well as capital and operating costs. The cost optimisation function is defined 
together with all constraints and variables. The output of an optimisation-based method 
for conceptual process synthesis is an optimal value for a set of variables calculated 
using algorithms (such as mixed integer nonlinear programming, MINLP and genetic 
algorithms, GA) [71]. This method has been applied in industry both for optimising an 
existing process for the production of bulk chemicals [80] and optimising a design 
derived from a knowledge-based method [73,81]. The main drawbacks of this 
methodology are: lack of an ability to automatically generate a flowsheet 
superstructure; considerable computational effort [71]; the optimum solution found can 
only be guaranteed for the alternatives considered earlier [81]. Hence, this conceptual 
process synthesis approach encounters great difficulties when dealing with poorly 
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defined processes, such as is often the case for bioprocesses during early development 
stage. 
3.1.2 Knowledge-based approach 
Knowledge-based or heuristic approaches rely on the long-term experience and 
expertise of the engineers and researchers. These methodologies are used to narrow 
down the list of possible operating units based on the experience of the process 
engineer. A systematic heuristic methodology, also called hierarchical heuristic method, 
proposes a procedure where the heuristic rules used for decision-making are applied at 
different design levels to generate the flowsheet alternatives [82,83]. During the 
conceptual process design the level of detail increases (as well as the information 
available) and therefore the alternative process flowsheet evolves. The hierarchical 
heuristic method defines: 1) operating mode (batch, fed-batch, continuous); 2) 
flowsheet input and outputs; 3) recycle structure; 4) separation system; 5) heat recovery 
and/or integration [71]. This methodology has been applied in the synthesis of new 
process flowsheets [84-86], separation processes [84,87,88], and for waste minimisation 
[89]. Even though this approach allows a rapid identification of flowsheets that are 
“near” optimal solutions, it is sequential and hierarchical structure does not allow 
interaction between the different levels and is thus, not suitable for biocatalytic 
processes, where improvements in the biocatalyst performance influence the flowsheet 
selection. 
3.1.2.1 Conflict-based approach  
A conflict-based approach is a knowledge-based method and it rest on the identification 
of system conflicts and contradictions for the solution of a given problem [2,90]. New 
process syntheses are attained by modification of a certain system aiming to overcome 
the internal contradiction. This methodology looks at the design problem as sub-
problems, overcoming the aforementioned limitation of the hierarchical heuristic 
methodology regarding the lack of interconnection between the hierarchical design 
level and the limitations of insufficient problem representation. Conflict-based approach 
has been successfully applied to distillation column design and waste management 
[90,91] and biomass gasification [2]. However, this methodology implies an a priori 
synthesis of processes, as it only explores conflicts in synthesised solutions and is 
therefore not suitable for very early development stage. 
3.1.2.2 Case-based reasoning 
Case-based reasoning is a methodology that reuses solutions that were successfully 
applied before to similar problems. This systematic approach implies that the new 
synthesised problem is matched against previous cases by computing the degree of 
similarity in order to find the most similar problem and its solution. This methodology 
has been applied in design of distillation systems [92]. However, case-based reasoning 
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deals with very specific data and relies on reusing results and experience to solve new 
problems. In addition, the outcome solutions from this methodology are inevitably 
strongly influenced by previous designs, thus not allowing truly innovative 
breakthroughs. 
3.1.2.3 Means-ends analysis approach 
Means-ends analysis methodology sees a chemical process as sequence of different 
units of operation aiming at the sequential elimination of differences in physicochemical 
properties between raw material and final product(s) [84,93]. The means-ends analysis 
starts with an initial state and successively applies transformation operators to create 
new intermediary states with fewer property differences. This methodology has been 
applied in early systematic process synthesis for overall process flowsheets [93,94] 
where there were enough detailed specifications for the starting material and the 
product. One of the major drawbacks of this approach is that the means-ends analysis 
can only consider a limited number of properties simultaneously, while others are 
temporarily ignored and their impacts disregarded. Due to the correlation often 
observed between the different biocatalyst properties and the reaction components 
physicochemical properties this methodology is not suitable for biocatalytic processes. 
Further, the search method does not guarantee a feasible approach. 
3.1.2.4 Phenomena-driven design 
Phenomena-driven design is focused not on the unit of operation level itself but at the 
phenomena that occur within this unit of operation, exploring the relationship between 
physicochemical properties, the operation conditions and the operating unit. This 
methodology has been applied in separation process design [95] where the number of 
alternatives for each separation task is reduced by acknowledging the relationship 
between the thermodynamic data of the mixture at different operating conditions for 
each separation technique [96]. However, this methodology is based on opportunistic 
task identification (due to the predefined hierarchical levels, action and influence of the 
process phenomena) and it does not meet the general process needs [71]. 
 
3.1.3 Hybrid approaches 
Hybrid approaches combine physicochemical property insights with mathematical 
algorithms [97]. These methods are usually implemented in a systematic procedure, 
where the output of a step is the sequential input of the following step. The final step of 
the hybrid methodology involves a simulation in order to verify the generated process 
solution and corresponding flowsheet [98]. Even though this methodology has been 
successfully applied in the chemical industry [99], it requires a large computational 
effort and large amount of data along with a priori knowledge of the process. 
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3.2 Tools applied to assist process development in bioprocesses 
If for conventional chemical industries, where the process design options are well known 
and described, it is difficult to find a single suitable systematic approach for conceptual 
process synthesis. In bioprocesses, this is an even more ambitious task since many of 
the process technologies are not yet well described and their relationship with the 
overall process is not clear. Nevertheless, Grossmann and Westerberg [69] have 
identified bioprocesses as one of the areas that will receive increasing attention in the 
chemical industry and thus it is expected that the suitable methodologies for conceptual 
process synthesis and design for these processes will be developed and established. 
In comparison with other conventional chemical processes, bioprocesses (including 
biocatalytic processes) have a wider multidisciplinary character (such as microbiology, 
molecular biology, chemistry and process engineering) which brings new opportunities 
for the production of new chemicals. However, the multidisciplinary nature of 
biocatalytic processes can also be seen as a weakness for implementation of a new 
process if the efforts in each discipline are not well targeted and defined. The use of the 
concept of process systems engineering (PSE) as a guide for bioprocess development is 
still in its infancy and many of the industrially successful biocatalysed processes are the 
result of case-by-case approaches [15]. Hence, an early stage systematic process design 
would likely assist the process engineer to achieve the full potential of the bioprocess 
leading to reductions in development time and savings in R&D. 
Although a systematic design framework has not yet been proposed, solving a wide 
range of design problems based on a large range of potential solutions, there are a few 
methodological approaches that are able to assist in bioprocess development, such as 
process and kinetic modelling, sensitivity and uncertainty analysis, regime analysis and 
windows of operation. 
 
3.2.1 Process and kinetic modelling 
Process and kinetic modelling allows an efficient evaluation of different process options 
by providing a dynamic and quantitative description of the process. The design and 
optimisation of a certain process is strongly dependent on a reliable mathematical 
model that accurately describes the biocatalytic reaction(s) as well as the required 
engineering principles. Moreover, modelling saves time and manpower in experimental 
investigation [44] by predicting the system behaviour [100] and assisting in formulation 
of experimental design [101] where specific highly relevant variables can be investigated 
and thus experimental work can be focused on the information required to improve the 
process and model [101]. In order to model the process, a variety of experimental data 
is required, including thermodynamic, physicochemical and kinetic data [102]. Once this 
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data has been put together, process design software (such as ASPEN, SuperPro Designer 
or ProII) can be used to simulate different process configurations. Although these are 
fairly common tools in both conventional chemical processes and in bioprocesses, many 
compounds involved in biocatalytic processes are newer than those found in 
conventional chemical processes and therefore data is often not available [15] (e.g. 
physicochemical properties, reaction thermodynamic equilibrium constant, Michaelis 
constant and inhibition constant), or at least not available at relevant process 
conditions. Hence, it is necessary to develop a methodology that is able to identify and 
define, in early stage of the process design, the optimal process conditions. 
 
3.2.2 Sensitivity and uncertainty analysis 
Sensitivity and uncertainty analysis are methodologies that can be applied to study the 
process model’s robustness, to quantify the likely variation in the process outcome and 
to identify the source of variation in the process performance [103]. The ability to 
identify the source of variation in the process can assist in the conceptual process 
synthesis by relating the different variation sources with different process scenarios 
[15]. Uncertainty analysis quantifies the overall uncertainty of the process model 
predictions (i.e. outputs) by studying the propagation of various sources of uncertainty 
[104]. Further, this analysis also provides information about the operating variables that 
need to be controlled, and is thus relevant when designing a process control strategy. 
These tools provide a better understanding of process variations and therefore they are 
extremely useful for a correct scale-up, since it is necessary to ensure a reproducible 
process where the product has a consistent quality [105]. In addition, this analysis also 
provides a certain adaptive character to the process and kinetic modelling by indicating 
the reliable variables that require close monitoring during the model recalibration once 
the process conditions are changed [106]. Finally, this analysis provides a quantifiable 
evaluation of the parameters that are most relevant in the process or kinetic model, 
allowing model simplification [107]. However, sensitivity and uncertainty analysis 
require a fairly good understanding and definition of the process design. 
 
3.2.3 Regime analysis 
Regime analysis is a useful tool for identifying constraints in the process and analysing 
the potential benefits of relaxing these [108,109]. To set a regime analysis it is necessary 
to choose a set of process metrics (such as product concentration, reaction yield, space-
time yield and biocatalyst concentration) or different mechanisms involved in the 
process (mixing, mass transfer, reaction rate) [108] that can illustrate the effect of 
limiting regimes and simultaneously allow for sensitivity analyses of the different 
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process conditions [109]. Regime analysis based on process characteristic parameters 
(e.g. power input per volume, residency time, maximum, oxygen mass transfer 
coefficient) can give a quick estimation of the performance of bioreactors at large-scale 
[110]. Hence, for rate-limiting mechanisms (mixing, oxygen transfer, among others) the 
results of regime analysis can assist in solving scale-up problems [110]. This tool gives an 
insight how the process metric can change with alteration of one process parameter 
(e.g. biocatalyst concentration). For instance, in a whole-cell process, when the oxygen 
supply is limited, the catalyst concentration can be used to identify oxygen-limited 
regimes. An increased cell concentration leads to a reaction rate limited process due to 
competition for oxygen from metabolism. While decreasing the cell concentration 
implies an increase of the space-time yield due to a lower biocatalytic activity [111]. 
Nevertheless, this methodology does not explain the effect of altering the process 
design, such as adding an auxiliary phase, ISPR or improving the biocatalyst. 
 
3.2.4 Windows of operation 
Windows of operation are two-dimensional process maps displaying regions of 
feasibility (or operating ranges for input operating variables) where the process can be 
operated within user-defined constraints [15,112]. These constraints should reflect the 
required performance level, equipment limitations or physicochemical boundaries of 
the system [113]. Thus, this tool facilitates the prompt evaluation of the designed 
process [114]. Moreover, windows of operation allow a rapid definition of the operating 
spaces and a greater understanding of the influence that key operating variables have 
on the overall system behaviour [115]. 
Since engineering design problems are often complex and involve many interdependent 
variables, the selection of the operating variables is an essential first step when creating 
a window of operation.  
During process design, several process options are tested, aiming at matching a specific 
objective for the output variable (measuring the process performance). Throughout this 
process, some of the process option combinations will not attain the desired 
performance. Those where the process performance is achieved define the operating 
region [112].  
Hence, the selected axes must be two input operating variables that can be controlled 
and that have a strong influence on the process performance. Further, these input 
variables must be able to reflect the process options analysed, preferentially through 
precise relationships (e.g. mathematical models) between the two selected variables. 
To create a window of operation, the collected process data is represented for a single 
output variable (Process metric 1 in Figure 3.1) as a function of two input variables 
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(Variable 1 and 2 in Figure 3.1) in a 3D plot, or in a contour plot [113]. The output variable 
is thus represented as a series of contour lines for combinations of input independent 
variables [113]. The relationship between two input variables and the process metric 
defines a window of operation [112]. By specifying required performance limits for the 
output variables of interest, one single contour line can be selected. Overlaying multiple 
contour plots for different dependent output variables enables the identification of 
windows of operation, where both independent control variables (Variable 1 and 2 in 
Figure 3.1) are feasible and the output variables reach a defined performance level 
(Figure 3.1) [113]. This approach allows the determination of the operating space, where 
all the performance criteria can be achieved simultaneously, leading to one single 
window of operation. These features allow the examination of multiple operating 
strategies and the ability to compare alternative processes whilst assessing their relative 
performance levels. 
 
Figure 3.1. Generic window of operation; the area confined by the constraints is the 
resulting window of operation 
 
Furthermore, the shape, size and position of the window of operation are dependent on 
the level of relaxation of each of the user-defined constraints [113]. Constraints have 
different origins such as performance-related constraints (e.g. biocatalyst specific 
reaction rate, minimum reaction yield or final product concentration), physical 
constraints (e.g. water-solubility of the reaction components), thermodynamic 
constraints (e.g. reaction equilibrium) and/or biological constraints (e.g. enzyme 
inhibition, stability). However, some of the defined constraints cannot be modified. 
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Hence, constraint relaxation aiming to enlarge or enable an operating space might not 
always have a physical meaning. It is thus essential to distinguish between hard 
constraints and soft constraints. Hard constraints are typically physical constraints (such 
as water-solubility and reaction thermodynamic equilibrium) in which constraint 
borders do not change when there is a slight variation of the operating conditions. On 
the other hand, common soft constraints in biocatalysis are those related to the 
biocatalyst (e.g. specific biocatalyst activity). Adjusting these soft constraints is, in part, 
dependent upon the amount of effort placed on biocatalyst development [112], since a 
more demanding soft constraint (e.g. specific activity) requires an extended 
development effort [65]. Soft constraints can be modified in two ways: 1) by relaxing 
the threshold of the process performance metric; 2) by putting in place a different 
process technology (e.g. soluble enzyme replaced by an immobilised enzyme). 
In addition, when several dependent variables are included in the analysis, it is likely 
that relaxation of user-defined performance metrics will be necessary in order to obtain 
a feasible operating region where all the dependent variables can be accommodated 
(Figure 3.2). 
 
Figure 3.2. Enlarged generic window of operation; the area confined by the constraints 
is the resulting window of operation. Constraint 3 and 5 are soft constraints. 
Constraints 1, 2 and 4 are hard constraints. 
 
Studying the size of the window of operation might be enlightening for a more complete 
process understanding. The size of the window of operation is related to its robustness. 
If the window of operation is large or there are multiple windows, it is easier to achieve 
the desired performance. Furthermore, a combination of windows of operation and 
Pareto optimal point approach2 [116] might be beneficial in examining the impact of the 
                                                                
2 Pareto optimal point approach: "constraint-oriented method" where a multiple-objective optimisation 
problem is converted into a scalar optimisation problem by minimising or maximising one objective-function 
while the other objective-functions remain constrained [320]. The set of Pareto optimal solutions is then 
generated by replacing each objective-function sequentially for different constraints. Pareto optimal point is 
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process operating input variables on the dependent variables, leading to a maximized 
performance. On the other hand, if the feasible space is small and tightly constrained, 
there is a limited range for the operation input variables (i.e. reduced window of 
operation), implying working at a more rigorously controlled process [117,118].  
The window of operation methodology allows visualisation of data to aid decision-
making by providing a process map for the feasible window of operation where a user-
defined level of performance is achieved [112]. Further, this methodology also provides 
a graphical understanding and management tool for the several trade-offs between the 
input operating variables and the performance variables [113], as well as between 
different process options available in the process design. 
To date, windows of operation have been used mainly for process control and 
development of suitable process control strategies by defining suitable operation spaces 
[117,119]. Further, windows of operation were also used as a tool to identify key process 
constraints, for process debottlenecking and assessing process feasibility at different 
process development stages (e.g. process design, scale-up and optimisation) [115,118].  
Windows of operation to assess process control are probably the most common 
‘windows’ in the scientific literature. Examples can be found in many areas in chemical 
engineering such as: distillation columns [120,121], syngas production [122], hydrogen 
production by iodine-sulphur cycle [119], but also within bioprocesses during 
production process of intracellular protein production [114,116,117,123], refolding of 
recombinant protein [124], design of chromatographic steps [125-127], to optimise 
cultivation conditions of mammalian cells [113,128] and to improve reaction conditions 
in multi-enzymatic systems [25,129]. One example of the use of the windows of 
operation is the selection of optimum operating conditions (e.g. substrate, product or 
biocatalyst concentration, temperature, pH, pressure, etc. [112]) and identifying 
suitable trade-offs between them [117] in order to achieved defined performance 
metrics (e.g. reaction rate, biocatalyst yield, operational cost, etc.). Figure 3.3 shows the 
window of operation for the process of a generic bi-enzymatic reaction system. The 
window of operation for a bi-enzymatic one-pot process is built by overlapping the 
individual window of operation for each enzyme. The resulting window of operation 
marks the operating range for the assessed control variables (in Figure 3.3, Variable 1 
and Variable 2) where the performance metric is achieved. 
                                                                
a point in the feasible space, where no other point in this space exists yielding an improvement in one objective 
function without causing deterioration in the other criteria(on) [320]. 
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Figure 3.3. Schematic illustration of a window of operation for a bi-enzymatic reaction  
system for a generic performance metric 
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4 Tools developed in this thesis 
In this chapter, ‘cofactor and interaction matrices’ and ‘windows of operation’ are 
described as engineering tools for assessing process feasibility. These feasibility tools 
endeavour to establish feasible flowsheets where reaction, biocatalyst and process 
constraints are all fulfilled. Further, performance evaluation tools assessing the 
economic viability of the process and its environmental impact are also discussed.  
The engineering feasibility tools integrate the concepts introduced in the previous 
chapter (in particular those developed for bioprocesses, Section 3.2) and goes beyond 
these by coupling them with evaluation tools. Hence, the procedure applied when using 
these feasibility and evaluation tools takes into account the biocatalyst limitation(s) 
(such as inhibition and stability), reaction stoichiometry, mass and energy balances and 
process flowsheets, for specific raw material(s) and product(s). These tools are 
extremely useful in evaluating the effects of process improvement efforts (including 
reaction, biocatalyst and process development) on the process feasibility and 
performance at a very early stage of development. Further, when different routes 
and/or flowsheets are under consideration, a comparison by applying the presented 
feasibility and performance evaluation tools to the various options allow the elimination 
less favourable process configurations, thereby focusing the development efforts on 
those most likely to be successful at industrial scale. 
 
4.1 Process feasibility tools 
4.1.1 Cofactor and interaction matrices 
Many of the biocatalytic reactions of interest for organic synthesis are oxidative and 
reductive reactions (redox reactions), which require the use of so-called “free 
coenzymes” (e.g. NADP(H), NAD(H), FAD(H2)) [130]. However, these cofactors are 
complex, unstable [131] and quite expensive [130]. Therefore, an efficient regeneration 
system is required in order to ensure process economic viability. 
For a redox biocatalytic process, running with isolated enzymes the reaction system 
must be designed in such way that it includes in-situ cofactor regeneration routes. This 
may be achieved by implementing a network multi-enzymatic system. If such a multi-
enzyme system is applied, it is convenient to analyse the flow of the electron donor and 
acceptor in order to decide which reactions should proceed in the same vessel. 
Alternatively, whole-cells where these cofactors are synthesised and regenerated as a 
part of cellular metabolism may be used [130]. The selection of whole-cell biocatalysts 
can offer a continuous source of cofactors, which, in some cases, could simplify the 
reaction structure, as no extra enzymes would be required for cofactor recycling [130].  
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An interaction matrix is a process design tool to assess feasibility. This is a particularly 
important evaluation tool when dealing with multi-enzyme systems, as it provides a 
better understanding of the overall system. This tool has proven to be extremely useful 
in gathering information related to reaction and process characteristics that must be 
considered for kinetic modelling [44]. However, within the framework of process 
development, this feasibility tool assists process design by narrowing down the number 
of process options.  
The tool identifies the different interactions that may occur between the different 
compounds (e.g. substrate(s), products, by-product(s), intermediate(s), cofactors, etc.) 
and enzymes catalysing a specific biocatalytic step. In order to build an interaction 
matrix the different components are arranged in rows and the enzymes arranged in 
columns [44]. The matrix is then filled by defining the relationship between each 
compound and enzyme, e.g. substrate (S), product (P), inhibitor (I), activator (A), or non-
interactive (x) (see also Chapter 7). This information can be gathered directly from the 
reaction structure, from scientific literature and/or experimental data from the 
laboratory. 
For kinetic modelling of multi-enzyme processes, the interaction matrix can be used to 
identify an inhibitory compound and indicate that a new parameter should be added to 
the reaction rate kinetic model. 
However, in the context of process design, the interaction matrix indicates the key 
reaction considerations that will affect or modify the flowsheet and/or mass and energy 
balances by indicating if the consecutive reaction can be carried out in the same vessel, 
the requirements for ISPR, inhibitory intermediates, etc. Hence, this tool indicates a 
limited number of viable (and preliminary) process options to be evaluated later using 
economic and environmental analysis. Detailed description of this tool can be found in 
Chapter 7. 
 
4.1.2 Windows of operation 
The ultimate role for windows of operation is to be used as a tool for process 
improvement. However, to date this methodology has only been applied for process 
debottlenecking or to assist during control design (see Section 3.2.4). Therefore, it was 
proposed that a methodology based on windows of operation principles to be applied 
during the early stage of process design and development, assisting during selection of 
process technologies and possible process flowsheets.  
This rational approach highlights the most critical constraints during process selection, 
which are used in the methodology to plot the process performance (i.e. axes for the 
windows of operation). Further, the methodology is able to represent graphically the 
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effect of the design choices. In this methodology, it is clear that different process 
alternatives lead to different constraint values (e.g. modifying the ISPR method put in 
place). Thus, the application of windows of operation in this context serves as a 
feasibility analysis of the different process technologies available and the potential 
effects of future improvements. 
This methodology provides a systematic approach for data collection and allows the 
exploration of conceptual scenarios to find the conditions under which a given process 
would be both feasible and competitive, while providing guidelines for directing future 
research in the performance of process options adopted throughout process 
development (see Chapter 5).  
Moreover, this tool aims at supporting decision-making actions, not only for the process 
technologies available, but also for the synthetic route itself. For instance, when a new 
pharmaceutical compound is desired, being able to make accurate decisions regarding 
its synthetic route in a very short time is of great value to the process success as the 
speed of development is crucial for the economic feasibility of the process [132]. This 
approach provides a short-cut methodology to quickly and approximately assess the 
feasibility of a given synthetic route. On the other hand, for large-volume and low-price 
compounds (such as bulk chemicals) and also for generic pharmaceutical compounds, 
there is an increasing pressure to provide quality and efficiency, while improving safety, 
reducing production costs and pursuing greener processes [133]. For these processes, 
windows of operation are a useful tool to direct future research efforts and assist during 
selection of process design options. Detailed description of this tool and the systematic 
methodology to build a window of operation can be found in Chapter 8. 
 
4.2 Performance evaluation tools 
4.2.1 Economic evaluation 
Economic evaluation is a decision-making tool to quantitatively estimate the expected 
profitability of a process, often in comparison with other choices [134]. The four 
essentials of an economic study are: problem definition; cost estimation; revenue 
estimation and profitability analysis as well as; a characterisation of the uncertainty and 
risk (Figure 4.1).  
Cost estimates should be made throughout all the early stage of a project even when 
complete specifications (or other data) are not available [135]. Cost estimation is 
extremely useful during the development of a chemical process since it allows cost 
control and debottlenecking. At a research level, it plays an important and useful role in 
research guidance by pinpointing the process weakness [136]. 
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Cost estimation can be divided into two categories: capital investment (CAPEX) and 
operating cost (OPEX) (Figure 4.1). 
 
Figure 4.1. Cost estimation categories and sub-categories that are important for cost 
analysis.  
Underlined costs are calculated separately, while other costs are estimated using rules 
of thumb and factors ( ) based on the cost estimation of the underline costs 
 
4.2.1.1 Capital costs (CAPEX) 
Capital investment corresponds to the sum needed to get the project started, for the 
machinery and equipment installation and can be classified in fixed capital and working 
capital [135]. Fixed capital stands for the capital necessary for all installed equipment 
and accessories required in the process operation and start-up [134,137]. Fixed capital 
comprises the price of purchasing, delivery and installation of equipment, piping, 
automated control, buildings and structures, site preparation, land (direct plant costs), 
engineering and construction (indirect plant costs) and contractor fees and contingency 
allowances (non-plant costs) [134,135]. Working capital is the sum required for the day-
to-day operation and includes the cost of inventories, supplies and some of the start-up 
56
4 Tools developed in this thesis 
 
39 
expenses. The working capital cost was not accounted for in the cost evaluation 
methodology presented here. 
The accuracy of a fixed capital estimate is a function of the design effort involved [134]. 
As the project design is refined, the estimate evolves from the various preliminary 
phases into more detailed construction estimates [134]. Evaluation of costs in the 
preliminary design phases involves guesses and the application of rules-of thumb [137]. 
Equipment cost 
In simpler approaches, the calculation of CAPEX is focused on the process itself, 
excluding site-wide auxiliaries, off-site and land-related items [134,135,137,138]. The 
basis of a fixed capital estimate is equipment cost data. From this information, and by 
application of factors, the fixed capital investment can be calculated [135,137,139]. To 
obtain current equipment cost data, one should ideally solicit bids from vendors [137]. 
Other useful tools available to estimate the equipment cost are the available databases 
and process design software (such as ASPEN or SuperPro Designer). Unless stated 
otherwise, in this thesis, equipment cost data was obtained consulting the MatChe Inc. 
website3. 
The cost-capacity plot (or six-tenths rule) was applied when the effect of equipment 
scale was desired (Equation 4.1). However, one must be aware of the limited 
extrapolation capacity of this estimation [134,135]. 
ൌൈ ൬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
 Equation 4.1 
In the equation, n may vary between 0.4 and 0.9, depending on the type of the 
equipment and the operation conditions (pressure and temperature), 0.6 is the average 
value for all the equipment [134,137]. 
Other capital investment costs 
In the early stage of process development, the level of detail does not usually allow for 
an accurate and reliable calculation of these expenses. Hence, in order to obtain the 
total investment cost, the equipment cost is multiplied by a factor to cover the costs for 
all supporting equipment and services [135]. In order to obtain the other costs that 
constitute the fixed capital (other direct capital costs - excluding equipment – and 
indirect capital cost), a multiplying factor (Lang, Hand, Wroth, Garrett and Guthrie 
factors) can be applied to the cost of the equipment delivered. These factors include the 
cost related with piping, automatic controls, insulation, painting, electrical work, 
engineering costs, etc. [137] (Figure 4.1). The selection of the most suitable factor to be 
applied depends on the level of detail in the cost estimation. Detailed information 
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concerning the aforementioned factors can be found in several process design 
handbooks [134,135,137]. 
Total capital cost/Annuity 
A total capital investment, or a fixed capital investment, can be converted to an 
equivalent annual capital investment cost using an approximate capital charge factor 
(amortisation or annuity factor, k, Equation 4.2), which multiplies the capital investment 
to give a yearly capital cost, providing a convenient short-cut approach to use in annual 
cost estimation [134].  
ൌ ͳǦሺͳ൅ሻǦ Equation 4.2 
The capital charge factor (or interest factor, i in Equation 4.2), which is provided by 
finance groups, is typically around 7% for the chemical industry [134]. The typical 
equipment economic lifetime (t in Equation 4.2) is 10 to 15 years [137]. 
4.2.1.2 Operating costs (OPEX) 
The operating (or manufacturing) cost is an important part of the economic evaluation. 
It consists of direct, indirect and fixed costs. At the early development stage, the 
operating costs that need to be determined are raw materials, utilities (including waste 
management) and operating labour. Other direct production costs (such as supervision, 
repair and maintenance), indirect and fixed operating costs might be calculated through 
direct labour cost and/or annual capital investment cost (Figure 4.1). 
Raw materials  
Estimates for raw material consumed are obtained directly from the mass balances. The 
prices of many raw materials can be obtained from the suppliers, by consulting trade 
journals (European Chemical News or Chemical Marketing Report) [134,137], through 
personal contact with the chemical companies, or using a chemical market information 
provider, such as ICIS4. A list of the raw materials prices used in this thesis is compiled in 
Appendix 2. 
Utilities 
Utility requirements, including the cost of heating and energy (for agitation), can be 
obtained from mass and energy balances. The energy necessary for heating can be 
calculated directly from the physicochemical properties of the materials used. While the 
energy necessary for mixing and aeration can be calculated using rule of thumb values 
[140]. Suppliers or purchasing agents should be contacted for the latest prices. 
Although waste treatment is not usually part of the process design and cost model, 
waste disposal is an important process cost that should not be disregarded [137,141]. 
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Typically wastewater treatment costs are 0.5-2 €/m3 (dependent on location), and non-
hazardous solid waste disposal has a cost of around 25 €/ton [141]. 
Labour 
Labour needs are highly dependent on the plant scale. However for processes within the 
same capacity range, the labour needs do not increase in a direct correlation with the 
process volume. Therefore, in this study it was assumed that labour needs did not 
increase with scale. Direct (or operating) labour costs are normally estimated from the 
flowsheet, typical labour needs (personnel per unit of operation) [134], by applying the 
Wessel method, using the Ulrich table [137], using design software such as SuperPro 
Designer, or by experience about labour requirements for the whole process. Typically, 
the operating labour costs account for up to 15% of the total operating cost [135]. The 
direct labour needs are determined through typical labour requirements and in 
discussion with industry. Labour rates can be obtained from the union contract, from 
company labour relation supervision or from local statistical institutes (e.g. Eurostat, US 
Bureau of Labour Statistics). 
Other operating costs 
Other production costs can be calculated from direct labour costs or from annual capital 
investment estimates. Supervision costs (direct operating costs) and indirect operating 
costs (including payroll overhead, quality control, royalties and plant overheads) 
correspond normally to 80% to 115% of the total direct labour costs (Figure 4.1). Annual 
maintenance (direct operating costs) including labour and material make up for 6% to 
10% of the fixed capital investment [134,137] (Figure 4.1). Fixed operating costs are 
insensitive to the production level and include depreciation, taxes, property rents, 
insurance, etc. corresponding to 12% to 17% of the annual capital investment cost Figure 
4.1. Annual maintenance and fixed costs were not considered when determining the 
production cost. 
4.2.1.3 Assumptions in simplified cost estimation 
Within the scope of this thesis, one objective was to develop a fast and accurate method 
for cost analysis. Since many data are not widely available, in particular where the 
process design is not fixed, assumptions have to be made (see also Appendix 2). Table 
4.1 summarises the main considerations in constructing the proposed economic 
assessment methodology.  
When difficulties in obtaining raw material prices from the suppliers were experienced, 
the prices were estimated from laboratory chemical suppliers, and subsequently divided 
the original price by 10 to 30 depending on the original package size. Although, 
uncertainty of this approach is high it is still considered a good starting point for cost 
estimations. In any case, raw materials, utilities and equipment costs have been 
confirmed with industry (see Appendix 2). 
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Table 4.1. Summary of the considerations and sources of information used in the 
economic model 
Cost Contribution to Cost Consideration 
CA
PE
X 
Equipment cost MatChe Inc., process design software (ASPEN or SuperPro Designer) 
Other capital investment costs Lang factor [140]: 5.0 (typical for fluid processing units [143]) 
Annuity From equation (Equation 4.2) k= 0.142, based on i=7% and t=10 years 
Equipment scale-up n=0.6 
O
PE
X 
Raw materials Market quotations, laboratory chemical suppliers 
Utilities 0.1 €/kWh (European Energy Portal5) 
Waste handling 1 €/m
3 [142] 
Labour 30€/h (Eurostat6) 
Supervision cost and indirect OPEX 100% of the direct labour 
Annual maintenance 10% of the annual capital investment cost. 
Fixed OPEX 15% of the annual capital investment cost 
k - annuity factor; i - capital charge factor (or interest factor); t - the equipment economic lifetime 
 
Evaluation of the costs in the preliminary design stage involves guesses and applications 
of rules-of thumb, therefore the quality and accuracy of these estimations are 
dependent on the skill and experience of the engineer [134]. For the methodology 
proposed the accuracy is considered to be about ±30%. Regardless of the level of detail 
and complexity in an economic study and in the project design, a certain degree of 
uncertainty will always remain [135]. This makes it is necessary to evaluate the effect of 
certain modifications to the original project on the total project cost by performing a 
sensitivity analysis to the cost used to calculate the process economic performance. 
 
4.2.2 Environmental evaluation 
In the last decade, an awareness of the impact that chemical production processes can 
potentially have on the environment has become a rising factor of concern. White 
biotechnology has been developing new processes that can potentially replace many of 
the conventional chemical processes, with a consequent possible reduction of chemical 
effluent and energy demand. Despite the great environmental advantages that 
biotechnology can bring to the chemical industry, being “bio” does not necessarily mean 
that a process is sustainable or more environmentally friendly than a conventional 
synthetic route and often questions regarding the benefits of these new routes against 
the traditional chemical processes are raised. Therefore, a fair comparison between the 
different synthetic routes is required and it is imperative to evaluate different process 
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options using economic assessments and environmental metrics side by side to find the 
most efficient and sustainable process configuration. 
There are two well-established environmental metrics used to assess the environmental 
impact of a process: green chemistry metrics and life cycle assessment impact factors. 
4.2.2.1 Green chemistry metrics (GCM) 
Experts often find it difficult to assess bioprocesses, by virtue of the limited data 
available [143]. Indeed, the published number of complete environmental assessments 
of biocatalytic process is very limited [143]. However, when a comparison between 
synthetic routes is made, there are several simpler approaches to quantify the process 
environmental performance [144-146]. Among those, green chemistry metrics have 
been developed to measure the greenness of a given process according to the Green 
Principles [3-5]. Green chemistry metrics can be divided into reaction-related metrics 
and process-related metrics. 
Reaction-related metrics 
The green chemistry metrics that are included in the reaction-related metrics group 
intend to quantify exclusively the greenness of the reaction chemistry. Some of the 
reaction-related metrics include atom efficiency (AE), reaction mass efficiency (RME) 
and carbon mass efficiency (CME).  
Atom Efficiency (AE) 
Atom efficiency (AE, or atom economy) measures how much of the starting material 
ends in the desired product [147] (Equation 4.3). Hence, this metric assesses the 
reaction chemistry. The driver behind this metric is to fulfil the 12 principles of Green 
Chemistry, aiming at a product synthesis with high reaction yield and low waste 
[22,147]. This principle proposes that the chemists design a reaction where all the atoms 
of the substrates are included in the structure of the final product. This is often observed 
for biocatalytic reactions, with the exception of transferases (EC 3, where a donor is 
required). AE is an easy to use metric, based on the reaction stoichiometry and 
mechanism [148]. However, it does not consider the by-products produced, or co-
substrates used and it is based only on the reaction chemistry, not taking into account 
the overall process. 
Product
Substrate(s)
MW
AE=
MW
 Equation 4.3 
Reaction Mass Efficiency (RME) 
Reaction mass efficiency (RME or just mass efficiency) is a metric developed by 
GlaxoSmithKline (GSK). This metric takes into account the reaction yield, the actual 
molar quantities of reagents and atom economy [144]. RME can be calculated by 
computing the quotient of the mass of the product by the mass of all the reagents in the 
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process (Equation 4.4) [144]. However, this metric does not account for the waste 
generated. 
Product
Reagent
m
RME=
m
i
i
¦
 
Equation 4.4 
Carbon Mass Efficiency (CME) 
Like the mass efficiency, carbon mass efficiency (CME, or just carbon efficiency) is also a 
green chemistry metric developed by GSK to measure the sustainability of the processes 
within the framework of the 12 Principles of Green Chemistry [145]. CME is defined as 
the percentage of carbon in the reagents that remains in the final product (Equation 4.5) 
and takes into account the reaction yield, stoichiometry and the amount of carbon in 
the reagents that is incorporated into the final product [145]. Similarly, this metric takes 
into account not only the reaction chemistry, but also the reaction related issues of the 
process. However, as noted for the previous metric, CME does not account for the waste 
generated during the process. 
C-Product
C-Reagent
m
CME=
m
i
i
¦
 
Equation 4.5 
Process-related metrics 
Process-related metrics intend to quantify the overall process (including the reaction 
chemistry). Some of the reaction-related metrics include process mass intensity (PMI), 
effective mass yield (EMY), E-factor, water and solvent intensity (WI and SI) and C-factor. 
Process Mass Intensity (PMI) 
Process Mass Intensity is the metric chosen by the American Chemical Society Green 
Chemistry Institute’s Pharmaceutical Roundtable as a high-level metric to evaluate the 
sustainable manufacturing of a given process [149]. PMI is defined as the total mass of 
materials used to produce a specified mass of product [149] (Equation 4.6). When 
calculating PMI the starting point is the commonly available materials [149]. Hence, the 
metric accounts for all the steps in the chemical synthesis including the catalyst 
production and all materials (water is also considered), that are used directly in the 
process [150]. Further, PMI also includes the downstream process steps required for 
isolating and purifying the final product at the required quality [150]. However, PMI does 
not include specific concerns regarding the environment, health and safety of the raw 
materials used or the waste produced. 
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i
i
Product
m
PMI=
m
¦
 
Equation 4.6 
Effective Mass Yield (EMY) 
Effective mass yield is defined as the percentage of desired product relative to the mass 
of all non-benign materials used in its synthesis (Equation 4.7) [151]. Unlike the above 
described metrics, this metric highlights the reagent(s) and reaction additive(s) toxicity. 
Despite the fact that this metric has been developed to assess only the reaction step, 
the same concept can be extrapolated to assess the full process (i.e. all steps of a 
synthetic path from commonly available materials to the final purified product). 
However, EMY lacks the definition of non-benign reagents, currently defined as “those 
by-products, reagents or solvents that have no environmental risk associated with 
them” [151]). Nevertheless, this definition cannot specify nor quantify the 
environmental risks. Furthermore, EMY only highlights one potential environmental 
impact (toxicity), disregarding others, such as global warming potential or waste 
generated. For example, when assessing a biofuel production process, this metric would 
give a favourable score to the process, since typically the reagents are renewable 
feedstocks and would be considered benign reagents. 
Product
non-benign Reagent
m
EMY=
m
i
i
¦
 
Equation 4.7 
E-factor 
The E (environmental) factor analyses the amount of waste formed in the synthesis of 
chemical compounds [152], estimating the amount of waste created per kg of product 
produced. Therefore, this green chemistry metric has been recognised as a valuable 
measure to provide information about the environmental performance and waste 
footprint of a given synthetic route [153]. In the E-factor, the waste is defined as 
everything leaving the process boundaries except the desired product. Therefore, E-
factor takes into account the reaction yield, including solvent and reagent losses, 
process aids, etc. [154]. E-factor includes not only the reaction chemistry and the 
process options related with the reaction, but it can also include all the steps in a 
chemical synthesis, upstream or downstream of the reaction step. However, this green 
chemistry metric does not consider what type of by-product or waste is generated.  
E-factor can also be used for multi-step reactions, though the result only provides a 
benchmark guide for different sectors and markets of the chemical industry [155]. In 
Table 4.2 the E-factor of different categories of chemicals are shown [155]. 
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Table 4.2. Typical E-Factor values (without water) in the chemical industry 
Industrial Sector Volume (ton/year) 
E factor 
(kg waste/kg product) 
Bulk chemicals 104-106 <1 – 5 
Fine Chemicals 102-104 5 - >50 
Pharmaceutical Chemicals 10-103 21 - >100 
 
Water is generally excluded from the E-factor as the inclusion of water could lead to 
excessive E-factors for some processes (such as biocatalytic processes), making a 
meaningful comparison of the results difficult [153]. Since water is usually benign, the 
solvent of choice for green chemistry is water, while in the conventional chemical 
synthesis organic solvents are often preferred [21]. There is a historical perception that 
water by itself does not have a significant environmental impact. However, one must 
remember that many chemical processes require highly purified water and there are life 
cycle impacts related to the water purification step. In addition, in many chemical 
synthetic routes, a mixed aqueous-organic waste stream is generated and therefore 
additional units of operation are required to further separate the phases prior to the 
wastewater treatment plant. Furthermore, nowadays assessing the water footprint of a 
given process is also a measure of sustainability, since in many parts of the world 
competition for water is becoming more of a concern and seems certain to become a 
greater issue in the future [156]. Therefore, two types of E factor were considered 
including water (Equation 4.8) and excluding water (Equation 4.9) consumption. 
iwaste
i
Product
m
E factor=
m
¦
 
Equation 4.8 
iwaste water
i
Product
m m
E factor=
m
¦
 
Equation 4.9 
Solvent intensity (SI) and Water intensity (WI) 
From a careful assessment of many of the synthetic routes to chemical products, 
solvents have been found to be one of the biggest mass contributors [157]. This is 
especially true for the pharmaceutical industry where the solvents typically contribute 
80% to 90% of the mass intensity of a process [158]. Hence, solvent intensity (SI) was 
developed to tackle the problems raised when applying the E-factor, by analysing and 
quantifying the amount of all solvents used in the processes for the synthesis of a 
chemical (Equation 4.10). A particular version of solvent intensity is water intensity (WI) 
where the focus is on analysing the amount of water used throughout the whole process 
(Equation 4.11). However, the type of solvent or the quality of the water used is not 
specified and a methodology for measuring the relative greenness of a given solvent is 
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still required. Furthermore, the environmental issues related with the solvent recovery 
are not addressed by this metric. 
isolvent
i
Product
m
SI=
m
¦
 
Equation 4.10 
2 iH O
i
Product
m
WI=
m
¦
 
Equation 4.11 
C-factor 
The C-factor expresses the amount of CO2 produced per mass of product formed [159] 
(Equation 4.12). The innovation in this green chemistry metric is the life cycle thinking, 
as it includes all the CO2 produced from the raw material production, preparation, 
conversion and purification of the chemical. However, this metric focuses only on one 
environmental concern (global warming potential) [160]. Nevertheless, the production 
of chemical products (mainly fine chemicals and pharmaceuticals) entails other 
environmental concerns, such as emission of volatile organic compounds (VOCs), 
toxicity or nutrient enrichment. Thus, the exclusive use of the C-factor for environmental 
assessment leads to a risk of these issues being neglected. Furthermore, C-factor only 
accounts for the emission of CO2, giving a misleading result, especially for renewable 
resources where emissions of methane (CH4) and nitrous oxide (N2O) are equally (if not 
more) worrying in their potential contribution to global warming [161]. 
2emittedi
CO
i
Product
m
C factor=
m
¦
 
Equation 4.12 
4.2.2.2 Simplified Life cycle assessment (LCA) 
The use of simple metrics is an attempt to measure the process chemistry and efficiency 
in a straightforward way. It does not require many process details and is therefore 
attractive for initial process design decisions. However, with simplicity might come 
several drawbacks, such as the fact that most of the metrics do not distinguish between 
waste types and emissions [158]. Moreover, many of these metrics do not consider the 
waste generated upstream or downstream of the investigated process step. At the other 
end of the spectrum, a more elaborate and comprehensive tool to quantify 
environmental effects is Life Cycle Assessment (LCA). Unlike green chemistry metrics, 
LCA is not specific for (bio)chemicals, chemical or bioprocesses. Indeed LCA was 
developed to be a suitable environmental assessment tool for all kinds of products and 
processes and there are LCAs published for different products from food [162] to 
television sets [163]. LCA is a standardized (and regulated) tool (ISO 14040) that provides 
detailed information about the type of emissions and the environmental impact over 
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the life cycle of a product or functional unit. LCA provides a framework for reporting 
applicable green metrics reflecting the whole life cycle of a given product (i.e. from raw 
material to the disposal stage) [164]. LCA metrics can be reported as inventory data 
(energy consumption, raw material consumption or emissions), measure of individual 
potential environmental impacts (such as global warming, acidification and nutrient 
enrichment potential), or as an aggregated score or index (such as EDIP, CML; Eco-
Indicator, etc.) [161]. However, LCA is often a laborious task as it requires a large amount 
of data from a variety of sources [158] and therefore is not yet a widespread practice. 
Further, many of the raw materials common in bioprocesses were not yet correctly 
modelled and assessed in this methodology. 
One of the most relevant steps of the LCA is to calculate the environmental impacts. 
These are classified in impact categories (e.g. global warming, photochemical ozone 
formation, human and eco toxicity potential). The environmental impacts are classified 
according to their radius of action into global, regional or local impacts (Table 4.3). The 
substance’s impact potential is expressed in an equivalency factor (gCO2-eq, gC2H4-eq, 
etc.). The equivalency factor expresses the emission measured relative to a reference 
substance. Substances contributing to more than one type of environmental impact 
require an equivalency factor for each type of impact. For example, emission of methane 
contributes for both global warming potential and photochemical ozone formation. 
Hence, emission of 1 g methane is translated on the impact assessment as 25 gCO2-eq 
and 0.007 gC2H4-eq [161]. Table 4.3 shows the environmental impact potential and the 
equivalent unit (or equivalency factor). 
 
Table 4.3. Environmental impact potentials 
Type of Environmental 
Impact Environmental Impact Abbreviation 
Equivalency 
Factor 
Global Global warming potential GWP gCO2-eq Stratospheric ozone depletion potential SOP gCFC11-eq 
Regional 
Photochemical ozone formation potential POP gC2H4-eq 
Acidification potential AP gSO2-eq 
Nutrient enrichment potential EP gPO43--eq 
Local 
Eco toxicity potential ETP PAF*.m3.day 
Human toxicity potential HTP Cases 
Hazardous waste HWP Kg 
Bulk waste BWP Kg 
*PAF - Potentially affected fraction of species 
 
The importance of a given impact category varies depending on the type of chemical 
assessed [165]. Several companies are reporting the environmental profile of their 
processes and products by describing emission of greenhouse gases or energy savings. 
Nevertheless, when performing an environmental assessment on a given chemical, one 
should choose the most relevant impact potential. For example, solvents are one of the 
biggest mass contributors in the production of fine or pharmaceutical chemicals due to 
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the low water solubility of many substrates and products of interest [158] and thus, 
VOCs emissions are mainly due to solvent use [161]. Hence, when assessing this type of 
chemical processes, it would be more relevant to study the impact assessment of 
regional and local impacts, such as photochemical ozone formation potential (instigated 
by high concentrations of VOCs) and eco and human toxicity potential (due to emission 
of toxic particles during the chemical production process [166]), since a reduction of 
these impacts might represent improvements in the process. On the other hand, when 
fuel production from renewable resources is evaluated, it is would be more beneficial 
to analyse the impact on greenhouse gas emissions, nutrient enrichment potential and 
land use (due to the crop growth). When comparing process options for the 
manufacture of biofuels, large volume (bulk) (bio)chemicals, or in fermentation 
processes (such as for the biocatalyst production), the impact of the cultivation of the 
raw materials (for the carbon-source) on global warming and nutrient enrichment 
potential is influenced mainly by the choice of crop, but also by the process yield. 
Therefore, the yield coefficient of biomass on substrate (Ysx) could be a very useful 
assessment metric. Primary energy demand is also a suitable metric to measure the 
process efficiency, mostly for the fermentation and downstream processing steps. In a 
similar way, acidification potential can also measure the process efficiency, as the most 
significant man-made sources of acidification (e.g. SO2) are combustion processes for 
electricity and heat production [161]. However, this relationship is very dependent on 
the type of fuel used for energy production and its sulphur content. 
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5 Description of a systematic methodology for 
biocatalytic process development 
5.1 Introduction 
In Chapter 3, it was emphasised that the approaches for process synthesis commonly 
applied to classical chemical processes are usually not suitable for biocatalytic 
processes. Furthermore, the current tools for development of bioprocesses (in 
particular for biocatalytic processes) do not incorporate the comprehensive perspective 
required for the process design (i.e. do not consider all the different alternatives). 
Current tools are often focused on only one process step and this relies heavily on 
experimental evaluation and pilot plant tests.  
The significant potential for improvement of biocatalytic processes (in particular 
biocatalyst improvements by protein engineering) and the implications that these might 
have in the selection of process options and in the process performance, hinder the 
successful application of the conventional approaches. Hence, there is a current lack of 
a systematic approach to guide the development and design of biocatalytic processes, 
which can promptly evaluate the feasibility of a large number of alternative processes 
(typical during early development stage), while identifying and targeting improvements 
required for a feasible process. Additionally, a suitable methodology for the 
development of biocatalytic processes should also define beforehand the conditions 
required for a feasible process (i.e. defining the basic lines, operating conditions of the 
full-scale process, rather than providing all the process details) and thus, it provides 
guidelines for experimentation by correlation with the underlying knowledge [167].  
Applying a systematic methodology in the early development stage brings many 
advantages: evaluating the process feasibility; forecasting the major process challenges; 
understanding the trade-offs when applying a given process technology option (i.e. the 
advantages and limitations of a given process consideration) and; identifying and 
ranking the most suitable strategies. 
The methodology developed in this thesis uses several engineering tools, such as widely 
used economic and environmental evaluation (by applying a simplified version of the 
life cycle assessment and calculating green chemistry metrics, see Section 4.2), process 
modelling and bottleneck analysis. Moreover, specific tools used in bioprocesses, such 
as cofactor and interaction matrices analysis and operating windows (see section 4.1.1 
and 4.1.2, respectively). 
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5.2 Methodological framework 
A process development methodology should reflect the considered reaction, biocatalyst 
and process conditions. A methodological approach for process development should be 
an iterative process, as a decision taken in one step will affect the subsequent step and 
consequently the final outcome. Therefore, reformulations of the process are required 
in order to attain the most suitable process design. 
The workflow and the tools included in the methodology are outlined in Figure 5.1. The 
whole evaluation methodology contains five steps. A detailed description of each step 
is given in the following sections. 
 
5.2.1 Step 1: Define threshold values for process metrics 
The integration of the objective function for cost optimisation is incorporated from the 
very first step of the proposed methodology. Based on the industrial sector targeted (i.e. 
bulk chemical, fine chemical or pharmaceutical) the engineer can estimate the annual 
production, the expected market value and revenue. The market value and annual 
production (defining which market segment the product of interest falls into) have a 
great influence on the scale, mass and energy balances. Further, the threshold values 
for the process metrics (biocatalyst yield, reaction yield, space-time yield and final 
product concentration) are also greatly influenced by the market segment (see Section 
5.2.1.1). Additionally, when this information is not available it is necessary to use rules 
of thumb or analogies with other industrial processes. 
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Figure 5.1. An overview of the proposed methodology for process development in 
biocatalysis EHS – Environmental, health and safety 
 
5.2.1.1 Methodological constraints: guidelines for process metrics 
Process scale-up is one of the fundamental steps in process development [168]. Even 
though this stage of the process development is often carried out only in industry, there 
is increasing interest in academia to develop and prove relevant scalable technologies. 
Process scale-up requires not only an increase in volume (of flow rates), but first and 
foremost an increase in the process mass metrics (product concentration, reaction yield, 
biocatalyst yield and space-time yield, Figure 5.2). Within the framework of the 
methodology suggested the establishment of the threshold values for these process 
metrics is of particular relevance since the success of the process development at large-
scale requires a good understanding of the biocatalyst and the physicochemical 
environment at this scale [52]. Many constraints will only be observed under the 
operating conditions at large-scale (biocatalyst inhibition and solubility at operating 
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concentrations, mass transfer limitations, among others) thereby, influencing the 
selection and adoption of different process technologies. This section compiles 
previously suggested guidelines [14,16,24,49] for the process metrics for different 
industrial sectors (Table 5.1 and Table 5.2) . 
 
Figure 5.2. Methodology for process scale-up; A common starting point when 
developing a biocatalytic process (low volume and process mass metrics); B developed 
biocatalytic process (low volume and high process mass metrics); C common ending 
point for an implemented biocatalytic process (high volume and process mass metrics) 
 
Catalyst production 
The biocatalyst cost is dependent on the efficiency of its production. Originally, 
commercial enzymes were recovered from “simple” fermentation broths of their 
naturally occurring microorganisms, with a relatively low enzyme concentration of 
about 10 genzyme/Lfermentation [169]. In the last decade, several methods have been 
developed enabling efficient expression and production of recombinant proteins 
(enhancement of secretion efficiency, prevention of inclusion bodies formation, co-
expression of chaperones among others) [170]. Consequently, nowadays, industrial 
production of enzymes is performed in fungal (yeast) or bacterial hosts exploiting the 
expression of heterologous genes, applying recombinant DNA technology to maximize 
product purity and economy of production, resulting in higher enzyme concentrations 
(often above 30 genzyme/L)  [169]. 
Enzyme concentration (genzyme/L) as a fermentation metric is of particular interest when 
operating with free enzymes and immobilised enzymes. When operating with free 
enzymes the biocatalyst should be preferentially used in its crudest form, since the 
purification steps significantly increase the biocatalyst cost (up to 10-fold [16]). 
Furthermore, these purification steps often affect the enzyme activity negatively. 
Nevertheless, operating with crude lysates might lead to side activities complicating the 
final product recovery. Enzyme concentration is ultimately related to enzyme yield, 
host-cell concentration (g CDW/L) and total protein concentration (gtotal protein/gCDW). 
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When operating with “resting” microbial cells (i.e. whole-cells) where the enzyme of 
interest is (are) overexpressed, it is required to quantify the overexpressed protein(s) 
inside the cell. Hence, it is also required to set a threshold value for the protein 
expression level (grecombinant protein/gtotal protein), measuring how easy it is to express the 
desired enzyme(s). In recent improvements of host expression systems, recombinant 
enzymes reached up to 30% of the total cellular proteins under the control of an 
inducible promoter without the formation of inclusion bodies [171]. When targeting the 
overexpression of more than one enzyme in a whole-cell, it is perhaps more relevant to 
know how much of the total protein corresponds to the overexpressed enzyme(s) 
(grecombinant protein/gtotal protein), so that the relative activities can be balanced (see Section 
7.4.2). 
In recent years, the possibility of obtaining the desired biocatalyst at reasonable cost 
has become a reality, in particular for an increasing number of enzymes (such as lipases). 
However, for other enzymes (such as Z-transaminases and monooxygenases) the 
fermentation development still represents a challenge [172]. Table 5.1 summarises the 
fermentation metrics for different levels of development in the biocatalyst production. 
Unless stated otherwise, the metrics for “average” were used. 
Table 5.1. Guidelines for fermentation metrics [16] 
Note: Higher values might be achieved for secreted enzymes at optimised conditions 
 Units Low Average High 
Cell density g CDW/L 10 50 100 
Total protein concentration g total protein/g CDW 0.40 0.50 0.60 
Protein overexpression level g recombinant protein/g total protein 0.10 0.20 0.30 
Enzyme concentration g enzyme/L 0.40 5 18 
 
Threshold values for process metrics 
When developing a biocatalytic process, the engineer should consider a holistic design 
approach. Hence, the allowable costs for the different steps of a biocatalytic process 
(fermentation, catalyst formulation, reaction and downstream processing) should be 
integrated, setting the boundaries for the design exercise. By setting threshold values to 
the so-called ‘process metrics’ for each industrial sector (Table 5.2), the engineer can 
identify the efforts required and select between the different process alternatives 
available, in order to ensure a feasible process (and thus, generating feasible 
flowsheets). Hence, five process metrics are proposed in order to evaluate the required 
development efforts and to assess the contribution of each individual step towards 
process feasibility: biocatalyst yield (assessing the cost of the biocatalyst); reaction yield 
(as a measure of the raw materials cost); space-time yield (accounting for CAPEX, utilities 
and labour); product concentration and enantiomeric excess (assessing the downstream 
processing contribution).  
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Even enzymes for which the optimisation of the expression system is not fully realised 
can be applied in industrially relevant processes [14], as the catalyst cost does not mean 
much in itself. The relevant question to analyse is how much the cost of the catalyst 
(including fermentation and catalyst formulation) contributes to the final production 
cost (when compared with competing synthetic processes). Furthermore, the 
environmental impact of the biocatalyst should also be included in the overall process 
assessment, since the fermentation step can have a large impact on land use footprint, 
nutrient enrichment potential (due to growing of the carbon source crop) and 
acidification potential (due to energy demand) [173]. Therefore, processes where the 
catalyst contribution is significant lead to a less sustainable process. It is therefore 
necessary to set a threshold value for the efficiency of the biocatalyst (biocatalyst yield, 
gProducts/gBiocatalyst). This metric sets targets for the biocatalyst activity and stability. 
Efficient conversion of the raw material (RM) is also a requirement for the process 
success, since high reaction yield (% molProduct/molSubstrate) simplifies the downstream 
separation and leads to a more cost-effective process, lowering the economic and 
environmental contribution of the raw material to the final process performance. As raw 
materials costs are often in the range of 40% to 90% of the total processing costs [83], 
dependent on the industrial sector (Table 5.2), there are different threshold values for 
the suggested reaction yield for each market. When aiming for the production of a low 
value chemical (bulk chemical), there is a small gap between the cost of the raw 
materials and the profitable product cost. Therefore, the production costs are often 
dominated by the cost of the raw materials and very high reaction yields are required. 
Furthermore, achieving a high conversion of the oil-based raw material leads to lower 
cumulative energy requirements (and consequently lower global warming, acidification 
potentials low human and eco toxicity environmental impacts), while for bio-based raw 
materials a high reaction yield might lead to lower nutrient enrichment potential (due 
to the use of fertilisers during the growing of crops) and land use. For thermodynamically 
challenged reactions, the allowable cost contribution of the raw material determines 
the efforts required for displacing the equilibrium (excess of co-substrate, ISPR, etc.). 
However, for low value chemicals, the reaction thermodynamics might influence the 
process viability, since these types of chemicals have a small allowable cost for 
downstream process (for co-substrate recovery) and often cannot afford the 
implementation of expensive process technologies to shift the equilibrium (e.g. 
membrane technology or resins for ISPR). 
When developing a new process, the business drivers are two-fold: economic (CAPEX 
and OPEX) and environmental (greenhouse gas emissions) and thus, energy requirement 
reductions are often targeted [80]. High space-time yield (STY or volumetric 
productivity, gproduct/Lreactor/h) is required to lower the capital costs, energy requirements 
for stirring and heating during the reaction (lowering utility costs, emissions and 
environmental impacts related with energy production) and labour related costs. This 
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process metric assesses the speed at which the reaction occurs, the equipment 
occupancy time and the maximum annual production. When performing cost evaluation 
there is a trade-off between the STY and biocatalyst yield (Table 5.3), since operating at 
higher biocatalyst loading increases the STY (reducing the time that reaction takes to 
reach completion and consequently CAPEX, utilities and labour related costs) at the 
expense of increasing the biocatalyst cost contribution. 
Recovery of the final product from the reaction phase is a critical step and it is often left 
out when developing and assessing a biocatalytic processes. Clearly the extent (and 
consequently the allowable cost) of the DSP is dependent on the product’s subsequent 
use. Despite being beneficial for biocatalyst activity and stability (Table 5.3), operating 
at low product concentrations (gProducts/Lreactor) might compromise the DSP cost due to 
the high volume of water (or organic solvent) that it is necessary to evaporate. Hence, 
operating at low product concentration increases the energy requirements of the 
process (and consequently the energy costs and the emissions related with energy 
production), the solvent intensity (leading to VOCs emissions), the process water 
footprint and volumetric capacity of the DSP units of operation (with subsequent 
increase of the capital costs). Hence, unless the product is removed during the course 
of the reaction by ISPR, there is a trade-off between the biocatalyst activity and stability 
(and consequently the biocatalyst yield) and the final product concentration, that 
determines the process viability. Furthermore, chirality is often a requirement for many 
products, such as chiral drugs, agrochemicals, food additives and fragrances [174] and 
thus the enantiomeric excess (ee %, enantiomer /
enantiomer enantiomer 
mol
mol mol
S R
S R
) is also an important process 
metric, since further enantio-separations can increase the DSP costs and determine the 
process viability [174]. 
 
Table 5.2. Assumed threshold values for process metrics 
Process Metrics Cost Annual  Production 
Biocatalyst 
yield 
Reaction 
yield 
Space-time 
Yield 
Product 
concentration ee 
Units (€/kg) (ton/year) g product/g biocatalyst % 
g product/L 
reactor/h 
g product/L reactor % 
Bulk  
chemical 0.5 - 10 10
4 - 106 103 - 105 >95 >20 >300 >90% 
Fine  
chemical 10.0 - 50 10
2 - 104 102 - 103 >90 >2.5 >150 >95% 
Pharmaceutical 
chemical >100 10
 - 103 10  - 102 >90 >1 >60 >95% 
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Table 5.3. Trade-offs between process metrics reflecting the process economic and 
environmental performance  
Process  
Metric 
Biocatalyst 
yield 
Reaction 
yield 
Space-time 
Yield 
Product 
concentrati
on 
ee 
Units g product/g biocatalyst % g product/L reactor/h 
g product/L 
reactor 
% 
Process Step Fermentation Raw materials production Equipment Downstream process 
Economic  
performance 
Biocatalyst 
allowable cost 
Raw materials  
allowable cost 
Equipment, labour and  
utilities allowable cost DSP allowable cost 
Environmental  
performance 
Growing crops  
(Land use and EP) 
Energy (ACP) 
PMI, EMY and E-factor 
Oil-based RM: 
Energy, GWP, ACP, Toxicity 
ETP, HTP 
Bio-based RM: 
Land use and EP 
Energy 
(GWP, ACP) 
Water footprint (WI) 
Solvent intensity 
(SI): (POP) 
Energy (GWP, ACP) 
↑ [Substrate] ↓ a) ↓ a) ↑ ↑ n.a. 
↑ [Biocatalyst] ↓ n.a. ↑ n.a. n.a. 
↑ W  
(residence time) 
or batch-time 
↑ ↑ b) ↓ ↑ b) n.a. 
a) If substrate and product inhibition 
b) If not thermodynamically limited 
n.a. not affected 
 
5.2.2 Step 2: Define constraints 
Information about the process is highlighted in this step. The quality of the design is very 
much dependent on the quality of the information gathered at this point. Therefore, a 
deep search in the scientific literature and discussion with experts in the field is required 
in order to avoid proposing solutions that are in reality impractical. Indeed, for someone 
unfamiliar with the process or case study this is probably the most laborious and time-
consuming step of the whole methodology. Hence, resources spent on development 
need to be used in the most efficient manner, collecting relevant information for process 
design. The information required should cover reaction, biocatalyst and process 
constraints. 
Other constraints can also be related with the intellectual property rights, so-called 
‘freedom to operate’ (FTO). FTO is an evaluation of whether the designed process can 
infringe on the patent, design or trademark rights of another entity. Hence, a FTO 
analysis should be always performed in order to avoid developing a process where the 
chosen technologies are covered by intellectual property rights. Nevertheless, it can also 
be possible to develop and design a process that is protected by intellectual property 
rights. Hence, it is required to evaluate the cost of the royalties and licensing fees and 
clear performance benefit by putting in place the technology. 
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5.2.2.1 Reaction constraints 
A graphical identification of the reaction(s) in the process is required. The main, 
secondary, competitive, reversible and undesirable reactions should be included here, 
since these affect the reaction yield and consequently, the process performance. It is 
also important to mention if these reactions occur in cascade, parallel or in a network 
structure [101]. 
Biocatalysts, like organocatalysts, have no impact on the position of the thermodynamic 
equilibrium [175]. The reaction yield in thermodynamically constrained reactions (such 
as reversible reactions) is determined by the reaction thermodynamic constant (Keq). 
Hence, in order to select the appropriate process option to displace the equilibrium, it 
is necessary to characterise the reaction in terms of its Keq under operating conditions 
(pH, temperature and pressure). This information can be obtained either experimentally 
[30] or in Thermodynamics of Enzyme-catalysed Reactions Database (TECRDB, [176]). 
Finally, it is also necessary to compile knowledge about the compound involved in the 
reaction, such as the physical and chemical properties. When developing a process the 
most relevant properties are aqueous solubility (Saq), density (ρ), vapour pressure (Pvap), 
partition coefficient (LogP), boiling point (Tb), melting point (Tm), acid dissociation 
constant (pKa), among others. There are several databases where such information can 
be obtained [178-181]).  
5.2.2.2 Biocatalyst constraints 
Kinetic information describing the effects of the operating conditions on the biocatalyst 
activity and stability is also required. This information should comprise of specific 
biocatalyst activity (molProduct/(gbiocatalyst·min)), substrate and/or product inhibition 
effects (if observed) and biocatalyst stability in half-life time (t½, biocatalyst). This 
information might not always be readily available, but at least basic information on how 
these parameters are affected under operating conditions is required. Furthermore, for 
cofactor dependent enzymes, it is also necessary to report the cofactor specificity (e.g. 
NADP(H)- or NAD(H)-dependent enzymes), as different cofactors imply different a 
different cofactor stability and cost and therefore, threshold values for total turnover 
number (TTN) should also be attained for an economically feasible process. 
5.2.2.3 Process constraints 
Selected process options should be in accordance with the previously defined reaction 
and biocatalyst constraints. The process constraints include the boundaries of the 
process options selected. These can have different natures, depending on the category 
selected: reactor selection, ISPR technique selected, selection of the immobilisation 
technique, among others (Table 5.4). For later stages of the process development (see 
example in Chapter 9), these constraints include operating mode, reactor type (and thus, 
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maximum catalyst loading), product recovery technique (including selectivity and 
capacity), etc. 
 
Table 5.4. Examples of possible process constraints, for three distinct groups of 
process options 
Process option 
group Examples of options Design variable 
Reactor 
Stirred tank reactor (STRs) Catalyst loading 
Packed bed reactor (PBR) Catalyst loading  Mass flow velocity 
Membrane bed reactor (MBR) 
Catalyst loading 
Volumetric flow (depending on the 
membrane) 
Immobilisation  
technique 
Carrier-free 
Enzyme loading 
Stability 
Cofactor leaching 
Carrier-bound Protein loading Cofactor leaching 
Entrapment Catalyst loading Mass transfer limitation 
Membrane entrapment 
Catalyst loading 
Volumetric flow (depending on the 
membrane) 
In-situ product removal 
(including co-product) 
Adsorption Resins Selectivity Capacity 
Membrane Membrane Cut-off 
Bi-phasic System (organic solvent) Selectivity Solubility of the reaction compounds 
Enzyme degradation or recycling Specific activity 
Evaporation Bi-phasic diagram (vapour-liquid diagram) 
 
5.2.3 Step 3. Application of engineering tool 
This thesis proposes three different engineering tools to be applied at different stages 
of the design: cofactor and interaction matrices, windows of operation and bottleneck 
analysis. As the process development progresses to later stages, the reaction, 
biocatalyst and process constraints become delineated with increasing detail. 
Therefore, different tools are required in order to narrow down the development space 
toward a suitable and feasible process design at different levels of process 
understanding.  
Cofactor and interaction matrices (Table 5.5) aim at understanding the major reaction 
and biocatalyst constraints, in order to propose the most suitable process options. 
Normally, at this early stage, there are no major process constraints to take into account, 
as many of the process options are not yet selected. The outcome of this tool is a limited 
number of possible biocatalyst formulations and reactor configurations to operate the 
process (see Chapters 6 and 7). Later in the development procedure, other constraints  
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(at the previously sketched process design) are often brought to light (e.g. 
thermodynamic equilibrium, kinetics and stability at operating conditions, among 
others). To overcome these limitations, there is a number of process options that canbe 
put in place (also with constraints in their applicability). The section of the most suitable 
process options(s) can be assisted by applying windows of operation. Windows of 
operation (Table 5.5) are used as a tool to understand the benefits and limitations of 
applying a given combination of process technologies, ultimately providing an operating 
map indicating areas where different process technologies might be successfully 
applied. Moreover, windows of operation indicate the development areas where efforts 
should be focused on in order to achieve the threshold values for process metrics (see 
also Chapters 6 and 8). The selection of these areas can be ultimately done by applying 
a more detailed process evaluation (such as bottleneck analysis). Bottleneck analysis 
(Table 5.5) provides the final tuning for process optimisation, before proceeding to pilot 
plant tests. The outcome of this tool is a revamped design and the benefits of 
undergoing reaction, biocatalyst and process optimisation are evaluated (see also 
Chapters 6 and 9).  
By applying the proposed methodology, promising strategies to improve the process 
performance are identified and further experimental evaluation and validation is carried 
out (Table 5.5 and Figure 6.1). The rational approach for each applied tool is given in the 
corresponding chapters (Chapter 7, 8 and 9, respectively).  
 
Table 5.5. Tools for process development and required information 
Constraint 
Group 
Engineering tool 
Cofactor and interaction 
matrices Windows of operation Bottleneck analysis 
Reaction Interaction between components 
Interaction between components 
Thermodynamic equilibrium 
Interaction between components 
Thermodynamic equilibrium  
Reaction conditions 
Biocatalyst 
Substrate, intermediates and 
production inhibition 
Cofactor requirements 
Activity (simple kinetics) 
Substrate, intermediates and 
production inhibition 
Cofactor requirements 
Kinetics 
Substrate, intermediates and 
production inhibition 
Catalyst formulation 
Cofactor requirements 
Kinetics 
Process  IS(c)PR removal capacity 
Reactor design 
IS(c)PR removal capacity 
Solubility limit 
 
5.2.4 Step 4: Process development strategy 
The outcome of the aforementioned tools is a development strategy where the most 
promising process configurations are identified. In this step of the methodology, a 
scenario analysis (what-if analysis) to the operating space is performed. Since 
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biocatalytic processes often need a great development effort to meet competitive 
operating conditions, it is necessary to revaluate the effect of modifying soft constraints 
(i.e. resilient parameters in the process design). Nevertheless, even when a feasible 
flowsheet is attained the engineer should revaluate the operating space and understand 
the benefits of relaxing one or more soft constraints by improving the biocatalyst or 
process technology(ies) associated with this constraint. Furthermore, information 
should be acquired at the conditions as close as possible to the defined development 
strategy. 
 
5.2.5 Step 5: Define targets for improvement 
Performance evaluation tools (such as economic and environmental assessment) are 
applied in conventional chemical process design and synthesis as an objective function 
to attain an optimal design. Together with kinetic and process modelling tools, the 
process feasibility can be proven conceptually before entering the laboratory [104,181] 
while experimental resources can be used to collect relevant information for decision-
making and/or improve the process models. This procedure will allow the assessment 
of the impact of modification or improvements in the process metrics, while setting 
targets for the research efforts in the process technology(ies) and/or in improving the 
biocatalytic performance.  
Besides, some knowledge about the development time of each targeted area is 
important. For instance, improving the biocatalyst activity at operating conditions might 
be a laborious task (up to 18 months [65]), while screening for a suitable IS(c)PR 
technology that is able to keep the product concentration below the inhibitory limit 
might be facilitated by high throughput experimentation in micro-reactors. 
 
5.3 Concluding Remarks 
This chapter has presented a general methodology for process development in 
biocatalytic processes, by applying three tools for different stages of process 
development (see also Chapter 6). The correct application of this methodology is highly 
dependent on the information known beforehand. The outcome of this methodology is: 
1) a limited number of experiments for achieving the process development targets; 2) a 
reduced number of experiments for decision-making during the process design stage 
and; 3) defined operating conditions where the process achieves the threshold values 
for the process metrics. In the following chapters, the methodology will be illustrated 
with three different case studies, applying the proposed tools to the diverse industrial 
sectors. 
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6 Introduction to the case studies 
In this thesis, a systematic methodology for early stage development of biocatalytic 
processes is proposed, aiming for more efficient and competitive process design. The 
multidisciplinary nature of biocatalytic processes implies that several considerations 
(reaction, biocatalyst and process) need to be appraised simultaneously, making the 
application of a traditional systematic methodology for conventional chemical processes 
difficult (see Section 3.1), particularly during the early stage of development, when little 
detail about the process is known. In general, for biocatalytic processes, the success of 
the scale-up is based upon on the effort put into developing the process. Improvements 
in biocatalytic processes can be obtained by careful choice and optimisation of the 
reaction conditions, biocatalyst and/or the process technology(ies). Hence, it is crucial 
to identify where the research efforts should be focused in order to attain a viable 
process and/or ascertain when such technology has been sufficiently developed. A 
summary of the procedure is depicted in Figure 6.1. 
 
Figure 6.1. Overview of the proposed methodology for process development during 
early stage; Number 1, 2 and 3 refers to the case studies of the same number 
(Chapters 7, 8 and 9) 
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The synthesis and design of processes is a complex and multidisciplinary problem and 
several operational constraints (market competition, profitability, environmental 
regulations and existing facilities) can set threshold values for process metrics (e.g. 
biocatalyst yield, reaction yield, space-time yield and final product concentration and 
enantiometic excess, Step 1. in Figure 6.1). 
In the following step of the proposed methodology (Step 2. in Figure 6.1), constraints of 
different origins (reaction, biocatalyst and process constraints) are used in order to rule 
out undesired or infeasible solutions. This information will be fed into the tools 
developed in this thesis (windows of operation, cofactor and interaction matrices and/or 
bottleneck analysis). The outcome of these tools is a collection of feasible development 
options assuming further reaction, biocatalyst and process optimisation (Step 3. in 
Figure 6.1). By performing a scenario analysis, targets for development can be set (Step 
4. in Figure 6.1). 
Three case studies have been selected in order to develop the methodology presented 
in this thesis. Valuable contributions were obtained from each case study, not only in 
developing and in demonstrating each tool required in this methodology, but also in 
compiling the information required for process development. The three case studies 
are:  
x Case Study 1: Multi-enzyme system for biocatalytic production of caprolactam 
x Case Study 2: Chiral amine production using Z-transaminase 
x Case Study 3: Chiral aliphatic alcohol production using alcohol dehydrogenase 
The first case study proposes a multi-enzyme system for synthesis of a commodity 
chemical, where the process success is greatly determined by the market and the 
competing technologies. In this case study, cofactor and interaction matrices are used 
as a development tool to guide process design (see Section 5.2.3). This tool assesses the 
reaction constraints, how these can affect the choice of the biocatalyst formulation and 
the process synthesis. In this case study different catalyst formulations (free-enzyme, 
whole-cell, immobilised) and consequently, different flowsheets are compared in terms 
of their impact on the process economic and environmental performance. The outcome 
of this case study is a limited number of flowsheets where the biocatalytic process 
presents a competing alternative to the conventional chemical route. For this purpose, 
guidelines for recombinant DNA technology (both in protein and in genetic engineering) 
are given (see Chapter 7). 
The second case study explains the use of windows of operation (see Section 5.2.3) as 
a tool to assist during process synthesis of high value chemicals (chiral amines) through 
asymmetric synthesis using transaminase, where the speed of process development has 
great impact. Many of the proposed transaminase syntheses do not yet fulfil the 
required economic metrics necessary for process scale-up. Frequently encountered 
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challenges for the biocatalytic synthesis of chiral amines using ω-transaminases include 
potentially unfavourable thermodynamic equilibrium, low biocatalyst activity and 
stability, as well as substrate and product inhibition. To overcome these limitations 
there are several possible process solutions as well as solutions via biocatalyst 
engineering. Potential process solutions include operating with an excess of substrate 
(e.g. addition of an excess of amine donor), application of in-situ product removal and 
in-situ co-product removal (IScPR) or a combination of these. By applying the window of 
operation, a systematic approach is provided for data collection and option selection, 
exploring conceptual scenarios where the process would be feasible and competitive 
and defining an operating space, i.e. a set of operating conditions that define the process 
flowsheet (see Chapter 8).  
In the third case study, flowsheet, mass and energy balances are established based on 
an already running process for the biocatalytic synthesis of long-chain chiral alcohols 
using a bi-enzymatic system. However, the process does not comply with the threshold 
process metrics and the current design is not economically viable. By applying the 
bottleneck analysis (see Section 5.2.3), comprising both economic and environmental 
assessment of the process, the main limitations are identified. The outcome of the 
methodology is a revamped design and evaluation of the benefits of undergoing 
reaction and process optimisation. By applying the proposed methodology, promising 
strategies to improve the process performance are identified and further experimental 
evaluation and validation is carried out. By iteration, this tool is able to identify the 
required process improvements in order to attain a competitive process (see Chapter 
9). 
In order to give a general idea of the third part of this thesis Table 6.1 summarises the 
three case studies including the previously available data in the scientific literature, tools 
applied and the steps that were performed following the described methodology. 
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7 Cofactor and interaction matrices for process 
development of multi-enzyme systems 
7.1 Introduction 
Increasing pressure to operate greener and cheaper processes has stimulated the 
chemical industry into developing alternative routes to fulfil market demands without 
compromising product quality [182], opening new opportunities for the application of 
biocatalysis in organic synthesis [25]. Synthetic routes often require sequential 
reactions in order to obtain the desired product, implying the use of more than one 
enzyme or organocatalyst in consecutive reaction steps. From this perspective, the 
expansion of the enzyme toolbox opens new opportunities for biocatalysis [63], where 
by mimicking the metabolic networks inside the cell, biocatalysis can stand as a 
suitable and greener alternative to the conventional chemical routes. These processes 
are called multi-enzymatic processes. Multi-enzymatic processes are defined by using 
two or more enzymes catalysing a group of reactions in a defined pathway [183,184]. 
In these types of processes, the catalytic activity of all the enzymes involved in the 
synthetic route can be explored. The substrate is converted to the first intermediate, 
which is then converted by the following enzyme and so on, until the desired product 
is obtained. In principle, this procedure can simplify the downstream steps since the 
intermediates are consumed and thus, often eliminated from the reaction medium. 
Hence, several promising applications are envisaged for multi-enzymatic processes, 
making these a promising next-generation of biocatalytic processes [44,184,185]. 
To date, several studies have reported the use of multi-enzyme systems for direct 
fermentation of the carbon source to the product (in so-called de-novo pathways) 
[184,186], in-situ cofactor regeneration [130,187-190], deracemisation of asymmetric 
molecules [191-193] and cascades [45,184,194-196] (Table 7.1), among others. 
Nevertheless, multi-enzymatic processes are often very complex systems, with many 
interactions between enzymes, substrate(s), intermediates and product(s), affecting 
the catalyst activities [45]. Furthermore, as observed for more conventional 
biocatalytic processes (i.e. single enzyme), the required final product concentrations 
for an economically viable process are often much higher than those observed in the 
biocatalyst’s natural environment, often compromising the performance of the 
biocatalyst. 
Despite the increasing interest of the chemical industry in implementing multi-
enzymatic processes, very few cases have been successfully scaled-up. Santacoloma 
[101] and Xue [25] with their co-workers have contributed with an overview of process 
engineering insights to the field of multi-enzyme processes. The first, by developing a  
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Table 7.1. Examples of in-vivo and ex-vivo multi-enzyme systems performed in single 
or multiple reactors 
Catalyst Reactor Examples 
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methodological framework for process modelling and therefore contributing for the 
understanding of multi-enzymatic processes [101]; and the second, by highlighting the 
technology options and tools available for the development of multi-enzymatic 
processes [25]. However, to date process option selection for implementation of these 
processes has been performed on a case-by-case basis. Hence, a methodology that 
integrates the chemistry, biological and process engineering challenges is required for 
the full implementation of multi-enzymatic processes. In this chapter, the 
methodology developed in this thesis is proposed to assist in the selection of possible 
process options (such as biocatalyst formulation) aiming for the development of a 
sustainable process. For this purpose, cofactor and interaction matrices (see Section 
4.1.1) were employed as a tool to identify feasible process configurations. The 
outcome of the proposed tool is a list of possible flowsheets where the reaction, 
biocatalyst and process constraints are overcome. These flowsheets are then 
evaluated in terms of their economic and environmental performance. In doing so, the 
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most favourable flowsheets and operating conditions can be identified. Consequently, 
the conditions for biocatalyst screening and development as well as the main process 
bottlenecks can be identified. Furthermore, research resources can be directed to 
collect relevant data for decision-making (e.g. biocatalyst specific activity, enzyme 
expression level and required co-substrate excess). 
 
7.2 Process considerations for development of multi-enzymatic 
process and tools 
The establishment of a multi-enzyme cascade process is still a major challenge in white 
biotechnology [25,44] as these processes are characterised by a high degree of 
complexity due to the combination of several catalytic activities [101], often with a 
mismatch of operating conditions. There are a wide range of process options that must 
be considered simultaneously, such as biocatalyst formulation options (whole-cell or 
isolated enzyme in their free or immobilised form) and reactor design (e.g. STR or PBR) 
(see Section 2.2.1). The correct choice of each of these process options constitutes a 
major challenge in multi-enzymatic processes and it has a strong influence on the 
process performance and viability. 
 
7.2.1 Reaction constraints 
When developing a multi-enzyme system there are three main chemistry constraints 
that the process engineer should have in mind during process design: 1) the cofactor 
balance (i.e. a cofactor consumed in one step must be regenerated in a later or parallel 
step of the multi-enzyme reaction), since a viable process requires an in-situ 
regeneration of the electron transporting cofactors, such as NAD(P)H; 2) interactions 
between the different compounds involved in the multi-enzyme system (e.g. inhibitory 
effects or side reactions), so the concentration of inhibitory substrate(s), 
intermediate(s), or product(s) are controlled by balancing the catalytic activity of the 
enzymes involved in the reaction system and/or by implementing process technologies 
(in-situ substrate supply, product removal, etc.) and; 3) reaction thermodynamics, 
since this often determines the reaction yield and the required efforts in process 
engineering (e.g. by applying selective IS(c)PR) to displace the reaction yield to values 
where the process is competitive.  
In order to guide the reader through the following sections, consider the following 
reaction system (Figure 7.1), including 5 sequential enzyme-catalysed reactions 
transforming a substrate A to a product F, where components B to E are reaction 
intermediates and CF is an electron transfer cofactor required in the first and third 
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reaction steps (catalysed by E1 and E3). For simplicity, the presented general reaction 
scheme is similar to the multi-enzyme reaction for the synthesis of H-caprolactam (see 
Section 7.4). 
 
Figure 7.1. General reaction scheme for a multi-enzyme cascade process from 
substrate A to product F involving enzymes E1 to E5, cofactor CF and intermediates B 
to E. 
 
7.2.1.1 Cofactor matrix 
Many of the enzymes of interest for organic synthesis, such as those that catalyse 
oxidative and reductive reactions, require the presence of the so-called “free 
coenzymes” (e.g. NADP(H), NAD(H), and FAD(H2)) [130]. These play a role as hydrogen, 
oxygen or electron transporters between coexisting reactions (either sequential, 
parallel or network reactions). An efficient cofactor regeneration system to balance 
the cofactor use is indispensable for the multi-enzyme reactions involving oxidative 
and/or reductive reactions, since cofactors are complex, unstable [131] and quite 
expensive [130] and thus, for process success cannot be provided in stoichiometric 
amounts.  
The cofactor matrix is a tool to gather information about the cofactor shuffling 
between its oxidized and reduced forms across the different reaction steps of a multi-
enzymatic process (see Section4.1.1). In order to build a cofactor matrix, the different 
cofactors in their oxidized and reduced form are arranged in rows and the enzymes 
involved in the multi-enzyme system are arranged in columns. The matrix is then filled 
by defining the relationship between each cofactor form and each enzyme, i.e. 
substrate (S), product (P), or x when no interaction is observed. Table 7.2 shows the 
cofactor matrix of the cascade reaction displayed in Figure 7.1. 
 
Table 7.2. Cofactor matrix for the general enzymatic cascade; 
S substrate; P product; x no reaction 
Cofactor Enzyme E1 Enzyme E2 Enzyme E3 Enzyme E4 Enzyme E5 
ox: CFox S x P x x 
red: CFred P x S x x 
 
The process must be designed in such way that it includes the cofactor regeneration. 
The first and third catalytic steps (E1 and E3) require the use of cofactors as electron 
donor and acceptor respectively (i.e. they consumed the oxidized and the reduced 
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forms of the cofactor, respectively). Since the cofactor consumed by enzyme E1 is 
regenerated in the third step of the enzymatic cascade, the logical process design, for 
economic reasons, is that these two reactions exist in the same reactor. 
When using whole-cells, cofactors are synthesised and regenerated as a part of cellular 
metabolism [130] (see also Section 7.2.2). The pyridine nucleotide cofactors NAD(H) 
and NADP(H) are indispensable cofactors of the cell, since they are the main electron 
carriers in reduction and oxidation reactions [189]. Hence, the selection of a whole-cell 
as the biocatalyst can offer a continuous source of cofactors, which could, in some 
cases, simplify the reaction structure, since no extra enzymes would be required for 
cofactor recycling [130]. Despite the fact that whole-cells have some reserves of 
cofactors, cofactor depletion can be a problem in particular when the enzyme using 
these cofactors is overexpressed on the host cell. Therefore, it is often necessary to co-
express the enzyme(s) involved in the cofactor regenerating systems, in order to 
promote a continuous source of cofactor, avoiding that the cofactor supply becomes 
reaction rate-limiting. 
7.2.1.2 Reaction thermodynamics 
The design of natural pathways in living organisms typically implies that the first and 
the last reactions of a given pathway are thermodynamically favourable (i.e. have a 
large and negative value for the Gibbs free energy, 'Gr) [140]. The reaction design in 
native pathways allows feasible metabolic pathways at low substrate and/or high 
product concentration, respectively [140], so the reaction can, theoretically, achieve 
full conversion. 
However, for organic synthesis (i.e. non-natural pathways) in most of the cases this 
does not always hold true. Several enzyme catalysed reactions of interest are 
reversible [197] and the maximum reaction yield is thus determined by the 
thermodynamic equilibrium constant. The knowledge of the reaction thermodynamics 
is crucial during process design since it will determine which process solution(s) are 
feasible at industrial scale and where the process performance requirements (such as 
reaction yield and product concentration) are achieved [36]. The different strategies 
adopted for displacing the reaction equilibrium towards the product(s) side have 
different cost structures and different implications for the process design. In general, 
the easiest option for shifting the equilibrium towards a high yield of the product 
would be, in principle, to use an excess of co-substrate. However, the use of this 
strategy is restricted to limited number of cases where the equilibrium is only slightly 
unfavourable, since at industrial scale the substrate concentration needs to be kept at 
high levels and there will be an upper limitation of how large an excess of co-substrate 
can be used, due to the solubility of the co-substrate (see Chapter 8). Perhaps a 
straightforward strategy in multi-enzyme process is to couple thermodynamically 
favourable steps with more challenging reactions in order to drive the overall reaction 
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to completion. Other methods to shift the equilibrium towards the synthesis of the 
desired product include to selectively remove the product or co-product from the 
reaction phase during course of the reaction (i.e. apply ISPR [49-51,198]). Another 
alternative to overcome the challenging thermodynamic reaction equilibrium is to 
couple the challenged reaction with one side reaction (i.e. a parallel reaction) that 
convert the co-product into a nonreactive species or back to the original substrate 
[38,199]. 
7.2.1.3 Interaction Matrix 
An interaction matrix identifies the different interactions (or relationships, e.g. 
inhibitory effects) that might happen between the different compounds (substrate(s), 
products, by-product(s), intermediate(s), cofactors, etc.) and the enzymes catalysing a 
specific biocatalytic step.  
In order to build an interaction matrix, the different components are arranged in rows 
and the enzymes are arranged in columns [44]. The matrix is then filled by defining the 
relationship between each compound and each enzyme, i.e. substrate (S), product (P), 
inhibitor (I), activator (A), or non-interactive (x). Some of this information can be 
drawn directly from the reaction structure and complemented through experimental 
procedures (or reported results in scientific literature). During kinetic modelling, an 
interaction matrix can be used to identify an inhibitory compound indicating that a 
new parameter (inhibition constant) should be added to the reaction rate kinetic 
modelling formulation [101]. However, in the context of process design, the 
interaction matrix indicates the key process considerations that will affect or modify 
the flowsheet, mass and energy balances. Hence, this tool indicates a limited number 
of viable (and preliminary) process options to be later evaluated using economic and 
environmental analysis. 
This is a particularly important evaluation tool when dealing with multi-enzyme 
systems, as it provides a visual understanding of the overall system. Table 7.3 shows an 
example of the interactions that exist between the compounds in the cascade reaction 
displayed in Figure 7.1.  
In this example, the substrate A is inhibiting the enzyme catalysing the third reaction 
step (E3). The cofactor matrix determined that for the process viability the reactions 
catalysed by E1 and E3 need to occur in the same place. Hence, a substrate feed 
strategy (in-situ substrate supply or fed-batch) needs to be put in place, in order to 
maintain the concentration of substrate below the inhibitory levels.  
The intermediate E, produced in the reaction catalysed by E4, is also an inhibitory 
compound to this enzyme. Thus, it is required to keep the concentration of this 
intermediate at a low level. This can be attained by levelling (i.e. balancing) the 
enzyme activity of E4 and E5, in such way that the rate of production of the 
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intermediate E (rE4) is balanced with the rate of consumption of this intermediate (rE5), 
keeping the intermediate E concentration below E4 inhibitory level. 
 
Table 7.3. Interaction matrix for the general enzymatic cascade; S substrate; P product; 
I inhibitor; A activator; x non-interacting compound (no reaction) 
  Enzymes 
Compounds E1 E2 E3 E4 E5 
Compound A S x I x x 
Compound B P S x x x 
Compound C x P  S x x 
Compound D x x P S x 
Compound E x x x P I S 
Compound F x x x x P I 
Cofactors 
CFox S x P x x 
CFred P x S x x 
 
Furthermore, the interaction matrix also shows that product inhibition in E5 is 
observed. ISPR techniques can be a suitable strategy to reduce the product (F) 
concentration below its inhibitory level without compromising the process 
performance metrics (namely the final product concentration).  
In summary, the analysis of the reaction constraints tell the process designer that the 
first three reactions (catalysed by E1, E2 and E3) need to take place in the same 
reactor, independently of the type of catalyst formulation adopted. Moreover, a 
strategy for product recovery in order to operate at high specific biocatalyst activity is 
also required. 
 
7.2.2 Biocatalyst options 
7.2.2.1 Whole-cell and isolated enzyme options 
Multi-enzymatic processes can be carried out in intracellular (i.e. in-vivo) processes, 
where the enzymatic reactions are carried out inside the cell (resting or growing), or 
extracellular (i.e. ex-vivo) processes, where the reactions are taking place outside the 
cell using free-enzymes (either isolated, in crude extract, or immobilised) [44]. The 
choice of the biocatalyst can largely determine the design of biocatalytic processes 
[200].  
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Despite the several advantages of operating with in-vivo (such as the natural recycling 
systems of the cofactors and lower production costs [201]), the use of cells (growing or 
resting) in organic synthesis is not a simple task, as it requires the manipulation of 
metabolic pathways and gene regulation in order to control the sequential enzymatic 
reactions inside the cell (for resting whole-cells). While for growing cells (i.e. 
fermentation processes), the control of the metabolic flux is even more challenging. 
Aside from shifting the carbon flow to the desired synthetic pathway, the cells must 
also keep their metabolic functions for growth, with consequent production of 
metabolites (leading to higher DSP efforts) [186]. Moreover, the transport of the 
substrate over the cell membrane is often limited [202]. In addition, the regulation of 
the catalytic activity of the different enzymes involved in the enzyme cascade is 
dependent on the concentration of each individual enzyme inside the cell. In other 
words, when a tight regulation of the concentration of each enzyme involved in the 
cascade is not achieved, the reaction rate for the target reaction is as fast as the speed 
of the slowest enzyme. Hence, it is necessary to control the protein overexpression 
level in the host. For resting cells (whole-cell biocatalysts) maintenance, replication 
and function of the recombinant DNA in a host organism requires energy [203,204]. 
The maintenance energy of a recombinant organism increases due to promoter 
induction causing high-level expression of the target gene cloned in the host bacteria 
[205]. 
Many of the aforementioned drawbacks encountered for whole-cell processes can be 
overcome by putting in place a multi-enzymatic system of isolated enzymes or cell-free 
systems (generally based on crude extracts [206]). For isolated enzymes, when the 
process requires cofactor regeneration, it is necessary to dose the cofactor, which can 
drastically raise the production cost, even when a cofactor recycling system is put in 
place, as these compounds are unstable and thus hinder their reuse and recyclability 
[187]. Moreover, there are a limited number of enzymes and enzyme functions 
commercially available [207,208]. Further, the cost of isolated enzymes and their 
operational stability at industrially relevant conditions is still a major challenge for the 
successful implementation of biocatalytic processes. However, this later issue can be 
potentially overcome by enzyme immobilisation (see Section 7.2.2.2).  
Recent studies of cell-free systems suggested that many of the drawbacks of operating 
with whole-cells or isolated enzymes have been overcome, expanding the capabilities 
of natural biological systems [206,209]. In this approach, inspired by the in-vivo 
options (fermentation and resting whole-cells), the complex biological system is 
released by cell lysis [209]. The main advantage in relation to in-vivo processes is that 
there is no mass transfer barrier (such as cell membrane) allowing a direct access of 
the substrate to the enzymes [209]. Further, the multi-enzyme components (natural 
and unnatural) can be added or synthesised and can be maintained at precise ratios 
[206]. Thereby, the chemical environment can be controlled and sampled [206]. The 
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activity of the different enzymes involved in the cascade reaction might be controlled 
by inducing overexpression of the desired pathway during cell growth, whilst side or 
competing pathways can be knocked-out by the action of cell-native proteases [209]. 
The application of cell-free biology in organic synthesis also allows the combination of 
pathways and enzymes from different hosts [209]. However, to put in place this 
technology, a comprehensive understanding of the regulatory mechanisms for the 
metabolic networks is required.  
The characteristics related to the different types of catalyst that can be used in a multi-
enzymatic process are listed in Table 7.4. 
 
Table 7.4. Comparison of intra and extracellular catalyst for multi-enzymatic process 
Intracellular (in-vivo) catalysis Extracellular (ex-vivo) catalysis 
 
Growing whole-cell 
(Fermentation) 
Resting 
whole-cell 
Isolated 
enzyme 
Cell-free  
system 
Complexity Very complex Complex Less complex Complex 
Process control (T, pH) Online monitoring Possible Possible Possible 
Process control  
(substrate, intermediates and products concentrations) 
Unlikely Difficult Easy Possible 
Metabolic control  
(regulation of enzyme activity) 
Difficult Possible Easy Possible 
Process robustness  
(reaction reproducibility) 
Variable Reproducible Reproducible Reproducible 
Reaction yield  
(substrate utilisation for product formation) 
Low High High High 
Toxic intermediates or substrates Problematic Relevant Less relevant Less relevant 
Formation of by-product Very possible Possible Less possible Possible 
Cofactor regeneration Easy Easy Possible Possible 
Stability Low High 
(if immobilised) 
High 
(if immobilised) 
Depending on the 
cell state when 
harvested 
Mass transfer of substrates and products Limiting Limiting Not relevant Not relevant 
Biocatalyst cost Low Low High Low 
Downstream cost High High 
Low 
(depends on 
inhibitory effects) 
High 
Research required for development High High Lower High 
 
7.2.2.2 Soluble and immobilised options 
Many of the reported multi-enzymatic reactions are carried out at laboratory scale 
using soluble enzymes. Nevertheless, this approach is perfectly adequate to achieve a 
good understanding of the reaction mechanism and the interaction between the 
different compounds in the reaction media. The use of soluble enzymes when scaling-
up constitutes a problem for the economic viability of the process, due to the difficulty 
in separating the enzymes at the end of the reaction and the low operational stability 
of these. Since the cost of the biocatalyst can constitute a considerable portion of the 
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process operational costs [16], it is necessary to reuse the enzymes, in order to attain 
an economically competitive biocatalyst allowable cost. 
The separation of soluble enzymes from solution requires ultrafiltration membranes 
[209]. Nevertheless, the use of these membranes implies an increase in utilities costs 
(due to the high energy requirements) and the operating costs (due to membrane 
fouling and thus reduction in lifetime). However, there are a few examples where the 
use of this technology has proven to be an economically competitive process option 
[209,210]. Hence, a comparative evaluation of the applicability of membrane 
technology is required. 
Enzyme immobilisation can constitute a suitable alternative, since this strategy is able 
to improve the enzyme stability, enabling the use of alternative reactors, simplifying 
the downstream process and preventing carry-through of protein activity to the 
subsequent operating unit [57,211]. Enzymes can be immobilised on different types of 
supports, such as polymeric matrices (including resins, cellulose or hydrogel) [55], 
magnetic particles [212], encapsulation (e.g. polyethylenimine microspheres) [213], 
carrier materials (e.g. dendrispheres) [57], or through methods of enzyme self-
immobilisation (e.g. CLEC, CLEA, Spherezyme) [57]. For many of the aforementioned 
enzyme immobilisation techniques, co-immobilisation of two or more enzymes (co-
localization) has been reported [25,57]. Impressively, some of these studies have 
successfully co-immobilised systems requiring cofactor regeneration [214,215]. 
However, it has been reported that cofactor leaching might occur [216]. The 
immobilisation procedure is still a rather costly process and the immobilisation of the 
enzyme and cofactor may only be cost effective if there is a significant increase of their 
operational stability. In addition, during the immobilisation process, the enzyme may 
lose its activity, some of the optimal operational conditions might be affected, the 
apparent Michaelis constant might change [217] (due to the partition effect inside and 
outside the carrier [217]) and new mass transfer limitations might arise, negatively 
affecting the reaction rate. 
For the aforementioned reasons the use of immobilised catalyst(s) in multi-enzyme 
systems might not be so simple, especially when cofactors are involved in the reaction 
(such as the reactions catalysed by E1 and E3 at the cascade reaction displayed in 
Figure 7.1). 
 
7.2.3 Process technology options 
The process considerations are essential to formulate mass and energy balances and to 
achieve a feasible process. Therefore, these should be consistent with the reaction and 
biocatalyst considerations listed above. Moreover, it is necessary to document with a 
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certain level of detail and accuracy the process considerations envisaged here, as they 
can be submitted to a scenario analysis during process debottlenecking. Process 
options include multi-step or one-pot processes, reactor design, operating mode, 
process control, process intensification options, among others. Considerations about 
operating mode, process control and process intensification options have been 
summarised in Chapter 2, and more detailed information can be found in the scientific 
literature (e.g. [25,101]). 
7.2.3.1 Multi-step and one-pot processes  
Multi-enzymatic processes can be operated either in a single reactor or in a battery of 
reactors. In theory, for an n-step multi-enzymatic reaction, the number of possible 
processes is 2n-1. For the 5-step cascade (Figure 7.1), there are 16 possible flowsheets. 
However, by putting in place a cofactor matrix and interaction matrix (summarising 
reaction constraints) and the information gathered about the reaction 
thermodynamics, the number of flowsheets is narrowed down to 4 possibilities (Figure 
7.2). 
Enzymes 
E1 E2 E3 E4 E5 
Option 1 
Reactor 1 
A                              D 
(Controlled feeding) 
Reactor 2 
D                              E 
(ISPR) 
Reactor 3 
E                              F 
(ISPR) 
Option 2 
Reactor 1 
A                              D 
(Controlled feeding) 
Reactor 2 
D                              F 
(ISPR) 
Option 3 
Reactor 1 
A                              E 
(Controlled feeding and ISPR) 
Reactor 2 
E                              F 
(ISPR) 
Option 4 
Reactor 1 
A                              F 
(Controlled feeding and ISPR) 
Figure 7.2. Scheme of the possible flowsheets and required process technologies to 
operate a 5-step cascade for production of product F (see Figure 7.1) 
 
Multi-enzymatic processes often require combinations of enzymes from different hosts 
[25]. In such cases, the enzymes involved in the cascade may not share the same 
optimal operational conditions (pH, temperature, etc.) and the biocatalysts’ reaction 
rate may be difficult to balance at the process conditions (substrate, product and 
intermediate concentrations, among others). In this case, it might be preferable to 
compartmentalise the different catalysts in different vessels, with a consequent 
increase of the capital cost (Option 1 to 3 in Figure 7.2). 
When the conditions of each individual enzyme catalysed reaction are well matched, 
the process can be carried out by dosing the multi-enzyme system into a single reactor, 
in a so-called ‘one-pot process’ (Option 4 in Figure 7.2). In one-pot processes, the 
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intermediates can be consumed immediately by the subsequent enzyme, leading to 
low concentrations of intermediate and decreasing its inhibitory effects on the 
enzymes involved in the cascade. Additionally, in principle, operating in an one-pot 
reactor can decrease the capital costs of the process, while eliminating the separation 
and purification steps required to remove intermediates, leading to lower downstream 
processing costs [44]. Moreover, operating in a one-pot reactor allows the regulation 
of the catalytic activity of individual enzymes by changing the operation conditions, 
such as pH or temperature. 
7.2.3.2 Reactor design 
Great process improvement can be achieved by applying a suitable reactor design and 
therefore, other reactor types should be considered when proposing a new process 
design [218]. To date, mainly stirred tank reactors (STR, [1,219]) are used in multi-step 
biocatalytic reactions. However membrane reactors [215] and packed bed reactors 
(PBR, [220]) have also been reported. The selection of the biocatalyst can also have 
major implications in the reactor selection, enabling some options (e.g. packed bed 
reactor for immobilised enzymes), while process requirements such as oxygen supply 
might enable the use of other reactors, such as bubble column reactor. Process 
considerations for selection of the reactor design were addressed in Chapter 2 (Section 
2.2.1.4). 
 
7.3 Evaluation tools: economic and environmental assessment 
Economic and environmental assessment can be used as an evaluation and decision-
making tool to quantitatively estimate the expected cost structure and environmental 
impact of the process, respectively. Despite the uncertainty inherent to this type of 
evaluation at early development stage, performing such analysis can be of benefit in 
ranking and selecting the most promising option(s) to be further explored and to 
indicate the conditions for further development where research efforts should be 
focused. Details about the routine for simplified economic assessment of the process 
and environmental evaluation are given in Section 4.2.  
 
7.4 Case study 1: Multi-enzyme system for biocatalytic 
production of H-caprolactam  
Polycaprolactam (6-aminohexanoic acid homopolymer) is a versatile chemical material 
used in several different applications (e.g. coating agents, textile fibres, engineering 
plastics, electronic components and food packaging) [221].  
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The demand and production of H-caprolactam (the current starting material for the 
polymerisation to polycaprolactam) is dependent on the demand for polycaprolactam 
and the monomer world production is expected to be 500 000 tons/year by 20151 
[221]. 
The conventional chemical synthesis by Beckmann rearrangement is a well-established 
industrial process for the production of H-caprolactam worldwide [221] (Figure 7.3). 
However, the industrial production route results in a large quantities of (low value) 
ammonium sulphate [222] (4.4 kg of (NH4)2SO4 produced per kg of H-caprolactam 
[223]). Furthermore, this synthetic route takes place in very acid (pH 2 [224]) 
conditions and the cyclohexanone (i.e. the starting material) is toxic. 
 
Figure 7.3. Reaction scheme for chemical synthesis of polycaprolactam 
 
There are other alternative synthetic routes to the synthesis of H-caprolactam using 
chemocatalysis [221,224,225]. However, most of these reactions have cyclohexanone 
as the starting material. Further, these synthetic routes still need to be improved since 
they produce a large amount of co-products, leading to a less effective process [221].  
Since polycaprolactam is easily recyclable if a greener synthetic route could be 
developed, then polycaprolactam would be a potentially environmentally friendly 
product. Evonik Industries AG in collaboration with University of Graz has proposed a 
synthetic route from cyclohexanol to the polycaprolactam-monomer (6-aminohexanoic 
acid, 6AHA) (Jan Pfeffer, personal communication, 2012). The use of a biocatalytic 
route might overcome such limitations observed for the chemical synthetic routes. 
This biocatalytic route provides an opportunity to improve the EHS process profile 
since the process runs under milder conditions when compared with the conventional 
chemical routes, which, ideally, will allow the process to be carried out with much 
reduced energy and under acid- and solvent- free conditions. Furthermore, the 
proposed route (Figure 7.4) starts from cyclohexanol (1), which can be obtained from a 
renewable feedstock (by pyrolysis and hydrodeoxygenation of lignin) [226] and 
constitutes a safer starting material than cyclohexanone. Aside from a better 
environmental profile, the bioprocess should also be economically competitive. 
However, for the synthesis of polycaprolactam, it is necessary to convert 6AHA into H-
caprolactam. At BASF, this reaction is taking place in the liquid phase without any 
                                                                
1 www.icis.com 
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catalyst, just containing a mixture of an organic solvent and water at temperatures of 
around 250°C and pressures of around 10 MPa [227,228]. Hence, when comparing the 
conventional chemical route and the biocatalytic route it is necessary to include the 
cyclisation of 6AHA into H-caprolactam (Figure 7.4). 
 
Figure 7.4. General reaction scheme for production of H-caprolactam;  
Enzymes involved in the cascade: E1 alcohol dehydrogenase (ADH, EC 1.1.1.X);  
E2 cyclohexanone monooxygenase (CHMO, EC 1.14.13.22); E3 Lipase (EC 3.1.1.X);  
E4 alcohol dehydrogenase (ADH, EC 1.1.1.X); E5 Z-transaminase (TAm, EC 2.6.1.X). 
Compounds in the enzymatic cascade: 1) cyclohexanol 2) cyclohexanone  
3) 6-hexanolactone 4) 6-hydroxyhexanoic acid 5) 6-oxohexanoic acid 6) 6AHA  
7) H-caprolactam 
 
7.4.1 Reaction constraints 
The methodology proposed in the previous section will be applied to guide process 
development of the biocatalytic synthesis of H-caprolactam using the cascade 
proposed in Figure 7.4. 
7.4.1.1 Cofactor matrix 
The reaction structure is useful to fill in the cofactor matrix. Further, it is also necessary 
to know which type of cofactor can be accepted for each specific enzyme. Table 7.5 
shows the cofactor matrix of the cascade reaction in Figure 7.4. The enzyme involved 
in the second catalytic step of the cascade reaction for synthesis of caprolactam is the 
cyclohexanone monooxygenase (CHMO). CHMO is a Baeyer-Villiger monooxygenases 
(BVMOs) belonging to Type I [229] requiring NADPH as source for electrons [229]. 
Since CHMO is strictly NADPH-dependent, the use of this enzyme requires an efficient 
coenzyme recycling system. This cofactor recycling can be carried out by an alcohol 
dehydrogenase (ADH) belonging to the group of NADP(H)-dependent ADH (EC 1.1.1.2, 
such as ADH from Lactobacillus brevis, see Chapter 9). For simplicity of the reaction 
design, this enzyme should catalyse an oxidation reaction within the cascade (i.e. E1 or 
E4 in Figure 7.4).  
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Table 7.5. Cofactor matrix for the enzymatic cascade for production of caprolactam; 
S substrate; P product; x no reaction 
Cofactor E1 ADH 
E2 
CHMO 
E3 
Lipase 
E4 
ADH 
E5 
Tam 
ox: NAD+ S x x S x 
red: NADH P x x P x 
ox: NADP+ S P x S x 
red: NADPH P S x P x 
 
Further, on the fourth cascade step a second oxidation reaction is taking place, 
requiring a cofactor system for regeneration of the redox power. Since this reaction 
can be carried out using either NAD(H)-or NADP(H)-dependent ADH, and given that no 
other chemistry constraints are found, the cofactor selection must be done based on 
the process economics. Hence, an NAD-dependent alcohol dehydrogenase was chosen 
due to the cost of the nicotinamide adenine dinucleotide phosphate (NADP(H)) is 
about 5-fold more expensive than NAD(H) [130]). In general, NAD(H) also has an 
increased stability at operating conditions when compared with NADP(H) [230]. 
7.4.1.2 Thermodynamics of the transaminase-catalysed reaction 
The second reaction consideration is related to the thermodynamic equilibrium of the 
Z-transaminase-catalysed reaction. Z-Transaminase is a suitable catalyst for producing 
chiral amines by direct asymmetric synthesis from ketones. Transaminases catalyse the 
transfer of an amine (-NH2) group from an amine donor (e.g. alanine and propan-2-
amine) to a ketone acceptor, yielding an amine and a co-product ketone (pyruvate or 
acetone, respectively). This reaction requires the cofactor pyridoxal phosphate (PLP) to 
act as a shuttle to transfer the amine group [231]. Despite the many appealing features 
of the Z-transaminase-catalysed reactions, thermodynamic equilibrium is a major 
challenge for the success of the process implementation [36]. 
The thermodynamic limitations encountered in transaminase-catalysed reactions can 
be addressed in several different ways, such as addition of excess of amine donor or 
application of ISPR. 
Co-substrate (amine donor) excess 
One of the easiest options for shifting the reaction thermodynamic equilibrium 
towards a high product yield is to operate with an excess of the amine donor [36]. 
However, this strategy is quite limited for two main reasons. First, when the 
production of a commodity chemical (such as H-caprolactam) is desired, the final 
product concentration required is quite high (often >300 g/L). At this concentration, 
there will be an upper limitation of how large the excess of amine donor can be until 
its aqueous solubility limit is reached (for instance, aqueous solubility of alanine in 1.9 
M and aqueous solubility of propan-2-amine in 16.9 M, see also Section 8.2.2.2). 
Secondly, the narrow margin between substrate purchasing cost and product selling 
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price, often observed in commodities and bulk chemical production processes (as the 
case with H-caprolactam), implies a very effective amine donor recovery which can 
raise the overall production cost.  
Additionally, for Z-transaminases the choice of the amine donor can also be discussed, 
since this can strongly affect the reaction equilibrium position [30]. An ideal process 
would use ammonium as the amine donor [232], since this is a cheap amine donor 
[38]. However, few reports can be found for such a reductive amination of ketones 
[233]. To date two main amine donors are preferred in transaminase-catalysed 
reactions: alanine (Ala) and propan-2-amine (IPA) [234]. The choice of the amine donor 
is not trivial and depends on the strategies adopted to displace the reaction 
equilibrium (e.g. co-product removal via conversion to nonreactive specie or recycling 
back to the original amine donor). 
In-situ product or co-product removal 
A second strategy to shift the equilibrium position towards a high reaction yield is to 
remove the product or co-product from the medium during the reaction itself 
(IS(c)PR). The most suitable strategy for ISPR is dependent on the properties of the 
product and the other components in the reaction mixture. Regarding the product 
removal (IS(c)PR), this is an appealing process technology, which ideally enables the 
displacement of the reaction equilibrium while reducing product inhibition. However, 
there are some limitations for the application of IS(c)PR. A common limiting factor is 
related to the selectivity of the separation. Non-selective ISPR can reduce the product 
concentration to levels lower than its inhibitory concentration, but cannot displace the 
thermodynamic equilibrium. The separation selectivity becomes more challenging in 
multi-enzymatic systems, where the number of compounds is greater. Furthermore, 
the application of IS(c)PR does not solve the problem related with the regeneration (or 
recycling) of the amine donor and therefore it might hamper an otherwise 
economically feasible process if an expensive amine donor needs to be provided in (at 
least) stoichiometric concentrations. 
Therefore, a suitable strategy is to combine the Z-transamination reaction with other 
enzymatic steps that convert the co-product into a nonreactive species or back to the 
original amine donor [36]. There is a wide range of suitable enzyme cascades that have 
been proven capable of converting the co-product [232,234-237]. Of particular interest 
is the in-situ recycling of the co-product back to the original amine donor. This strategy 
can be applied when alanine is used as amine donor, employing an amino acid 
dehydrogenase and ammonia [234]. Hence, when choosing this strategy, the ultimate 
amine donor is ammonia, which makes the process potentially more economically 
attractive [38]. In this system pyruvate (i.e. co-product) can then be recycled back to 
alanine using an alanine dehydrogenase (AlaDH, EC 1.4.1.1), which consumes ammonia 
and NADH [238,239]. By putting in place this strategy not only can the thermodynamic 
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equilibrium of the transaminase-catalysed reaction be shifted, but also the cofactor 
balance of the overall cascade can be closed (Figure 7.5). Table 7.6 shows the revised 
cofactor matrix of the cascade reaction in Figure 7.5.  
 
Figure 7.5. Revised enzymatic cascade for production of 6AHA; Enzymes involved in 
the cascade: E1 NADP+-dependent alcohol dehydrogenase (ADH, EC 1.1.1.2);  
E2 cyclohexanone monooxygenases (CHMO, EC 1.14.13.22); E3 lipase (EC 3.1.1.X); E4 
NAD+-dependent alcohol dehydrogenase (ADH, EC 1.1.1.X); E5 transaminase (TAm,  
EC 2.6.1.X); E6 alanine dehydrogenase (AlaDH, EC 1.4.1.5). 1) cyclohexanol 2) 
cyclohexanone 3) 6-hexanolactone 4) 6-hydroxyhexanoic acid 5) 6-oxohexanoic acid  
6) 6AHA 
 
Table 7.6. Cofactor matrix for the revised enzymatic cascade for production of 
caprolactam; S substrate; P product; x no reaction 
Cofactor E1 ADH/NADP(H) 
E2 
CHMO 
E3 
Lipase 
E4 
ADH/NAD(H) 
E5 
Tam 
E6 
AlaDH 
ox: NAD+ x x x S x P 
red: NADH x x x P x S 
ox: NADP+ S P x x x x 
red: NADPH P S x x x x 
 
From Figure 7.5 and Table 7.6, it can be concluded that, for a feasible process and 
independent of the catalyst formulation chosen the first two reaction steps need to be 
carried out together in the same vessel (one-pot) and the last three catalyst steps also 
need to be carried out in a one-pot reactor. 
7.4.1.3 Interaction Matrix 
Table 7.7 shows the interactions that exist between compounds involved in the 
biocatalytic synthesis of 6AHA. 
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Table 7.7. Interaction matrix of the enzymatic cascade for production of caprolactam; 
S substrate; P product; I inhibitor; A activator; x no reaction, no effect;  
c competing reaction (Jan Pfeffer, personal communication 2011) 
Compounds 
Enzymes 
E1 
ADH/NADP(H) 
E2 
CHMO 
E3 
Lipase 
E4 
ADH/NAD(H) 
E5 
TAm 
E6 
AlaDH 
1) cyclohexanol  S x x x x x 
2) cyclohexanone  P S I x x x x 
3) 6-hexanolactone  x P S x x x 
4) 6-hydroxyhexanoic acid  x x P S x x 
5) 6-oxohexanoic acid  x x x P, Sc S x 
6) 6AHA  x x x x P x 
7) H-caprolactam x x x I x x 
O2 x S x x, Sc x x 
H2O x P x x x P 
Alanine x x x x S P 
Pyruvate x x x x P S 
NH4+ (as NH4Cl) x x x x x S 
Cofactors 
NAD+ x x x S, Sc x P 
NADH x x x P, Pc x S 
NADP+ S P x x, Sc x P 
NADH P S x x, Pc x S 
PLP x x x x A x 
By-products 
Adipic acid (Figure 7.6) x x x Pc I I x 
 
Table 7.7 cyclohexanone (2) has an inhibitory effect on Baeyer-Villiger monooxygenase 
(cyclohexanone monooxygenase, CHMO). Hence, this compound must be kept at very 
low concentrations. This can be achieved by balancing the relative activity of the first 
and the second enzyme of the multi-enzyme system (ADH and CHMO, respectively). 
Further, it is clear that the cyclisation of the 6AHA to H-caprolactam cannot take place 
in the reaction medium, since apart from the extreme reaction conditions (250 oC 
which would per se hinder the biocatalytic synthesis) this last compound was observed 
to be inhibitory to the enzyme activity of the second alcohol dehydrogenase (E4). 
Finally, the synthesis of an undesired by-product (adipic acid) was observed (Figure 
7.6). One of the possible reasons for the synthesis of adipic acid is the promiscuity of 
the alcohol dehydrogenase, which can transform the 6-oxohexanoic acid into adipic 
acid. Hence, it is necessary to search for a selective enzyme, while operating under an 
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inert atmosphere [240,241]. This last constraint implies that the second enzyme 
catalysed step, which requires oxygen, must be carried out in a separate vessel from 
the last three enzymatic steps. Further, in order to avoid the synthesis of adipic acid, 
the ADH/TAm can be adjusted in order that 6-oxohexanoic acid is promptly consumed 
in the transaminase-catalysed reaction. 
 
Figure 7.6. Competing side-reaction to the design H-caprolactam, with conversion of 5) 
6-oxohexanoic acid in to adipic acid [240] 
 
7.4.2 Biocatalyst considerations 
7.4.2.1 Whole-cell and isolated enzyme options 
In the biocatalytic route for production of 6AHA, the choice of the biocatalyst 
formulation might determine in part the process design and feasibility. In general, 
processes running with isolated enzymes require an investment upstream of the 
reaction (for enzyme purification and formulation), while operating with whole-cells 
implies higher downstream costs [200]. Operating with whole-cell generally implies 
working at lower concentration and likewise side reactions may occur. Table 7.8 
summarises the advantages and disadvantages of isolated enzyme or whole-cell 
catalyst form with respect to the limitations of 6AHA biocatalytic production. 
 
Table 7.8. Advantages and disadvantages of whole-cell and isolated enzymes for 
production of 6AHA 
Limitation Enzymes  affected Whole-cell Isolated enzyme 
Enzyme activity 
and stability 
E1 & E2 
E3 
E4, E5 & E6 
+ Engineered cells can have improved stability at 
industrial conditions [200]; 
- Requires great effort to manipulate the 
expression level of each protein inside the cell. 
+ Easy control of the enzyme activity; 
- Enzyme stability if not immobilised. 
Cofactor E1 & E2 E4, E5 & E6 
+ Use of the cell-native cofactors; 
- Carbon source to enhance cofactor recycle. 
+ Reaction control; 
- Requires to dose expensive unstable 
cofactors. 
O2 supply E1 & E2 
+ Enzymes are shielded inside the cell; 
- O2 supply for reaction and maintenance [242]. 
+ Stoichiometric amount; 
- Enzyme stability due to oxidative 
damage of the interfacial effects [243] 
 
When operating with whole-cells (resting cells) the host growth rate is insignificant and 
close to zero [140]. However, at this cell stage it is expected that there is consumption 
of the carbon source for cell maintenance (for ATP generation) [140], even if the 
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observed uptake rate is low. There are two main ATP-generating processes: respiration 
and fermentation [244]. Respiration is the process in which the electrons released by 
the electron carriers (such as NADH and NADPH) are transferred sequentially through 
the electron transport chain (a series of membrane-bound protein carriers) reducing a 
terminal electron acceptor, such as oxygen in aerobic hosts [244]. In the specific case 
of the biocatalytic cascade for production of 6AHA, in the cyclohexanone 
monooxygenase (CHMO, E2) there is a trade-off between the cell density and space-
time yield due to oxygen demand, as the oxygen-transfer rate must cover both the 
CHMO activity and the endogenous respiration [242]. If at the operating conditions the 
oxygen transfer rate becomes limited, the process might be operated by applying 
isolated enzymes. In the absence of oxygen (such as in the case of the last three 
reactions of the enzymatic cascade), the host can undergo ATP-generating processes 
by fermentation, in which the final electron acceptor is an organic compound [244]. 
However, in this situation operating the process using whole-cells implies that there is 
synthesis of by-products, with consequent increase of the downstream process cost, 
which could be avoided by operating with isolated enzymes. 
Perhaps the main biocatalyst challenge in multi-enzyme reactions is to regulate the 
activity of the enzymes involved in the cascade reaction. Operating with purified 
enzymes this task becomes easier to accomplish by changing the concentration of the 
enzymes and/or varying the reaction conditions [111]. Nevertheless, recent advances 
in system biology and cell engineering have led to an increased understanding of the 
cellular metabolic networks and cell physiology, supporting the identification of 
genetic targets for improved gene expression regulation, membrane stability, etc., 
enabling the implementation of whole-cell biocatalysts [245]. Likewise, it is important 
that whole-cell biocatalysts can take in substrates effectively. For many of the 
industrially relevant substrates there is no active transport system and diffusion across 
the cell membrane determines the rate of reaction [202]. Yet, permeabilisation 
techniques may prove useful in overcoming mass transfer limitations through the cell 
membrane [246]. 
The first step is to collect information about the enzyme activity catalysing each 
reaction in the cascade in order to determine the correct dosing/overexpression level 
of each enzyme. Ideally, the specific activities should be measured for the expected 
operating conditions (i.e. in the presence of the other components of the cascade 
reaction and according to the interaction matrix defined above). However, at an early 
development stage, this information might not be easily available. Furthermore, since 
biocatalyst specific activity is often one of the parameters subjected to development 
before full-scale implementation [65,247], the process engineer can use the published 
information in order to get a preliminary idea of the required enzyme ratio in the 
reactor(s). Table 7.9 compiles the published specific activities for the reactions 
involved in the enzymatic cascade for production of 6AHA. 
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Table 7.9. Specific enzyme activity for the reactions in the multi-enzyme production of 
6AHA 
Enzyme Specific Activity [mmolProduct/min/gEnzyme] 
Reference 
E1 ADH/NADP(H) 32 [248] 
E2 CHMO 25 [249] 
E3 Lipase 100 Assumed 
E4 ADH/NAD(H) 43 [250] 
E5 TAm 9.9 [196] 
E6 AlaDH 50 [251] 
 
Based on the specific activity of each individual enzyme it is necessary to determine 
the relative amount of each enzyme that needs to be dosed to the reactor. This issue 
will be raised in Section 7.5, where the different reactor configurations will be 
identified.  
7.4.2.2 Soluble and immobilised enzyme options 
The use of an immobilised catalyst in the production of 6AHA might not be a simple 
task, since cofactors are involved in the reaction (Section 2.2.1.2 and 7.2.2.2). Thus, the 
only enzymatic step that can be carried out by an immobilised catalyst is the third 
reaction catalysed by lipase. There are several commercial formulations of this 
enzyme, such as Lipozyme RM IM, Lipozyme TL IM and Novozym 435 (commercially 
available from Novozymes A/S). Furthermore as observed for the activity, when 
moving from bench-scale to an industrial scale, an increase of the biocatalyst stability 
is one of the parameters subject to improvement [65] by either protein engineering or 
immobilisation. 
 
7.4.3 Process technology options 
For the enzymatic cascade reaction for production of 6AHA, there are 16 theoretical 
possible flowsheets if the process is carried out in single or several reactors (see 
Section 7.2.3.1, 25-1=16). However, when taking into account the reaction constraints, 
the number of flowsheets is narrowed down to three, showing that the biocatalytic 
synthesis of 6-aminohexanoic needs to be carried out in a series of reactors as shown 
in Figure 7.7. 
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 Enzymes 
E1 
ADH/NADP(H) 
E2 
CHMO 
E3 
Lipase 
E4 
ADH/NAD(H) 
E5 
TAm 
E6 
AlaDH 
Option 1 
Reactor 1 
soluble enzyme 
whole-cell 
Reactor 2 
soluble enzyme 
immobilised enzyme 
whole-cell 
Reactor 3 
soluble enzyme 
whole-cell 
Option 2 
Reactor 1 
soluble enzyme 
whole-cell 
Reactor 2 
soluble enzyme 
whole-cell 
Option 3 
Reactor 1 
soluble enzyme 
whole-cell 
Reactor 2 
soluble enzyme 
whole-cell 
Figure 7.7. Scheme of the possible flowsheets available for the biocatalytic synthesis of 
6AHA 
 
The choice of operating in batch or continuous mode in multi-step biocatalytic 
reactions is related to the biocatalyst formulation adopted and the required reaction 
yield. Operating in a continuous mode requires that the biocatalyst and cofactors can 
be retained inside the reactor, which might not be retained inside the reactor, which 
might not be economically feasible when operating with isolated free enzymes (see 
Section 2.2.1). Furthermore, when operating in a continuous mode a complete 
conversion is not achievable (unless operating in a plug-flow reactor). This last 
drawback of continuous operation is particularly relevant when dealing with bulk or 
low value fine chemicals (such as the case of H-caprolactam), since the cost of the raw 
materials dominates the overall production costs, implying that high reaction yields are 
required for the economic viability of the process [252]. Therefore, it is assumed that 
the biocatalytic route for production of 6-aminhexanoic acid is carried out in a batch 
mode. 
Regarding the reactor selection, the choice is related to the biocatalyst formulation 
chosen and the need to supply oxygen. Table 7.10 shows the available reactor options 
for the present case study.  
 
Table 7.10. Reactor options for the biosynthesis of 6AHA 
  Whole-cells 
Isolated 
free enzyme 
Immobilised 
enzyme 
Oxygen supply required E1 & E2 STR, BCR STR, BCR N/A 
Oxygen supply not required 
E3 STR STR PBR, FBR, EBR 
E4, E5 & E6 STR STR N/A 
N/A – not applicable 
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It is assumed that, when operating with whole-cells and isolated enzymes, the reactor 
chosen is a stirred tank reactor (STR), while reactions catalysed by immobilised 
enzymes are carried out in a fluidised bed reactor (FBR). 
Initial concentrations for all the components are reported in Section 7.6 and in 
Appendix 3. During the process, pH and temperature would need to be controlled and 
maintained.  
 
7.5 Possible flowsheets 
Selecting the most suitable process flowsheet is a central issue in process design, 
particularly at the initial process development stage, as the information available is 
often scarce. Experimental evaluation of all the different process technology options 
might be expensive and time-consuming due to the large number of possible 
combinations, resulting in an enormous number of different process designs. Reaction 
and biocatalyst considerations have been used to narrow down the number of 
alternative process flowsheets. However, apart from the arrangement of the different 
synthetic steps into the reactor(s) (i.e. dosing of the different biocatalysts in the 
reactor), there are other alternative technologies that need to be considered 
simultaneously (such as catalyst formulation). Hence, just by considering the different 
types of catalyst formulation possible in each reactor the number of flowsheets 
increases to 20 (Figure 7.7, Table 7.11).  
The remaining challenge for the process engineer is to rank these possible alternative 
process technologies in terms of their economic and environmental profile. In doing 
so, the most environmentally friendly and economic processes at full-scale 
implementation would be identified. The goal of generating the flowsheets (and mass 
and energy balance) is not to get to a detailed design and dimensioning of the process, 
but instead to be able to identify the most promising solution(s) and research areas 
where further development is required, when limited information about the process is 
available. Figure 7.8 shows a possible flowsheet for biocatalytic production of 6AHA. 
Based on the specific activity of each individual enzyme (Table 7.9), the relative 
amount of each enzyme (i.e. enzyme concentration) that needs to be dosed to the 
reactor can be calculated in order to adjust the overall reaction rate (Table 7.12). For 
this purpose, the enzyme activity of each individual enzyme is the product of enzyme 
concentration and its specific activity. The motivation for matching the different 
enzyme activities when operating with multi-enzyme systems is two-fold: to optimise 
the biocatalyst(s) allowable costs and; when cofactor recycling is required, to ensure 
that the rate of reaction is not limited by the cofactor regeneration. Table 7.12 shows 
the relative amount of each enzyme dosed in the biocatalytic reactors, when operating 
with isolated enzymes.  
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Table 7.11. Summary of the 20 possible flowsheets for biocatalytic production of 6AHA 
Option Reactor 1 Reactor 2 Reactor 3 
Option 1 
1 Isolated enzyme Isolated enzyme Isolated enzyme 
2 Isolated enzyme Isolated enzyme Whole-cell 
3 Isolated enzyme Whole-cell Isolated enzyme 
4 Isolated enzyme Whole-cell Whole-cell 
5 Isolated enzyme Immobilised enzyme Isolated enzyme 
6 Isolated enzyme Immobilised enzyme Whole-cell 
7 Whole-cell Isolated enzyme Isolated enzyme 
8 Whole-cell Isolated enzyme Whole-cell 
9 Whole-cell Whole-cell Isolated enzyme 
10 Whole-cell Whole-cell Whole-cell 
11 Whole-cell Immobilised enzyme Isolated enzyme 
12 Whole-cell Immobilised enzyme Whole-cell 
Option 2 
1 Isolated enzyme Isolated enzyme 
2 Isolated enzyme Whole-cell 
3 Whole-cell Isolated enzyme 
4 Whole-cell Whole-cell 
Option 3 
1 Isolated enzyme Isolated enzyme 
2 Isolated enzyme Whole-cell 
3 Whole-cell Isolated enzyme 
4 Whole-cell Whole-cell 
 
 
Figure 7.8. Example of a possible flowsheet for biocatalytic production of 6AHA 
(Option 2 or Option 3), including biocatalyst production (fermentation and biocatalyst 
formulation), biocatalysis (reaction) and downstream processing (recovery and 
purification). Note: The biocatalyst is normally produced independently from the 
reaction step and then stored until use [16]. 
 
The same principle can be applied to set threshold values for the overexpression level 
in the host cell of each individual enzyme, assuming that the relative specific activity 
does not change drastically. For example, the NAD(H)-dependent alcohol 
dehydrogenase (E4) still shows higher activity (with the same approximated activity 
ratio) than the transaminase (E5) inside the cell. Therefore, it is necessary to match the 
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overexpressed enzyme level (i.e. enzyme concentration inside the cell) assuming that 
20% of the total protein content in the cell is the overexpressed enzymes [209] and the 
total protein content in the recombinant host is 50% of the total cell dry weight (CDW). 
Further, when operating with whole-cell as the biocatalyst, the overall reaction rate 
(and henceforth the process space-time yield) is determined by the whole-cell 
concentration in the reactor. Table 7.13 shows the required content of recombinant 
enzyme in the whole-cell (in grams of recombinant enzyme per grams of cell-dried 
weight) (option 2). 
 
7.6 Process mass and energy balances 
For identified process flowsheets, simulations and documented results are used to 
obtain the necessary process data for a process evaluation. Mass and energy balances 
are performed based on the candidate flowsheets generated. In the mass and energy 
balances, the amount of the raw materials (reagents, catalysts and reaction additives), 
intermediates, (co-)products and energy are calculated for each candidate flowsheet. 
 
7.6.1 Assumptions 
In order to achieve a competitive design, the process performance should (at least) 
match the performance of the competing technology. Therefore, a set of process 
performance metrics need to be defined in order to reflect the different allowable 
production costs (see Section 5.2.1). In this case study, the performance metrics are: 
reaction yield (defining the raw material allowable cost [253]); final product 
concentration (as an indication of the downstream process cost [254]); and space-time 
yield (defining labour and utilities operation costs and capital cost by the equipment 
occupancy [255]). Table 7.14 summarises the base case assumptions for this case 
study. These assumptions will define the reactor volume and reaction conditions. 
Aspects of current good manufacturing practice (cGMP), such as validation and 
qualification protocols and aseptic downstream processing have not been included in 
the calculations although these could be requirements at production scale. The full 
details of the base case are given in Appendix 3.  
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Table 7.14. Base case process assumptions for biocatalytic production of 6AHA 
Annual Production (ton/year) 10000 
Annual operating hours (h/year) 8000 
Final product concentration (g/L) 250 
Batch time (h) 8 
Reaction Yield (molProduct/molStarting material) 95% 
Reactor Overhead (%) 20% 
Glucose (% wt. of CDW) 10% 
Total Turnover Number for NAD(H) (TTNNAD(H)) 100000 [187] 
TTN NADP(H) 10000 [187] 
TTN PLP 90 [37] 
TTN Alanine 1 
 
Despite the fact that these performance metrics are not often easily achieved during 
the early stage of process development, it is necessary to assume that these 
performance threshold values will be achieved when the time for implementing the 
process comes (i.e. before the pilot-plant tests). As the goal of the performance 
evaluation is to assess the potential benefits of the selected process options (put 
together in a flowsheet) at full-scale, these not yet achieved (but likely) assumptions 
will be presumed for the economic and environmental evaluation. By adopting this 
strategy, underdeveloped synthetic routes (such as the proposed biocatalytic route) 
can be compared with implemented processes (such as the synthesis of H-caprolactam 
by Beckmann rearrangement). In addition, these assumptions (in line with the 
threshold values for the process metrics, see Section 5.2.1) define the initial operating 
conditions at which data and further development efforts should be focused. Hence, 
the true potential of further developing the proposed biocatalytic route can be 
assessed. However, it holds true that at the first instance with the state-of-the-art for 
the biocatalyst, the flowsheet chosen will not perform as defined here. The 
achievement of these performance metrics are thus the target for biologist, chemists 
and process engineers. 
 
7.7 Process evaluation 
7.7.1 Economic assessment 
Economic evaluation can be used as a decision-making tool to quantitatively estimate 
the expected profitability of a process [16]. However, at the early development stage, 
this evaluation tool can select the most promising process design options, while 
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identifying the current process bottlenecks preventing the process commercial 
success. As shown in Figure 7.9 none of the evaluated processes can compete 
economically with the current industrial process (in which the H-caprolactam current 
selling price is 2.70 €/kg).  
 
Figure 7.9. Production cost for the different process design option for production of 
6AHA; Legend:  cyclohexanol,  biocatalyst,  alanine,  cofactors,  glucose,  
NH4Cl,  utilities,  labour,  CAPEX and  current H-caprolactam selling price 
 
Figure 7.9 shows clearly that there are two main process bottlenecks preventing an 
economically successful industrial implementation: the biocatalyst formulation 
(including the cofactor costs) and the efficient recycling of alanine.  
Most of the reported industrial biocatalytic processes use whole-cells as catalysts [14], 
affecting the process economics in two ways: the possibility to use the cell’s native 
cofactors (preventing the dosing of expensive cofactors) and the biocatalyst cost (in 
€/kgbiocatalyst).  
From the evaluated process options, when operating with isolated enzymes (in either 
free or immobilised form) the cost of the biocatalyst and the cofactor can account for 
up to 80% of the total production costs (Figure 7.9). However, when operating with 
whole-cells (or partially with whole-cells) the costs are reduced by 8% (when operating 
partially with whole-cells, i.e. when only of the reactors is operating with whole-cells) 
and by 20% (when operated fully with whole-cells, i.e. when all the reactors are 
operating with whole-cells) when compared with the fully isolated catalyst options 
(options 1.1, 2.1 and 3.1). Further, it is also noticeable that the benefits of operating 
with whole-cells are more relevant when the last three reaction steps (E4 to E6) are 
performed in whole-cells, since these reactions require dosing two types of expensive 
cofactor (PLP and NAD(H)). The most favourable scenarios are found when both parts 
of the reaction that are cofactor dependent (i.e. the first two and the last three 
reaction steps, E1-E2 and E4-E5-E6, respectively) are performed using a whole-cell 
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(options 1.8, 1.10 and 1.12, option 2.4 and option 3.4). Furthermore, the assumed 
values for TTNNAD(H) and TTNNADP(H) are already significantly favourable for initial design 
stages and TTN values above the assumed are very seldom attained [187], which 
eliminates the option of operating with isolated enzymes. 
However, for all the evaluated scenarios (including the most favourable options, i.e. 
options 1.8, 1.10 and 1.12, option 2.4 and option 3.4), the economic viability of the 
process is compromised, as the production cost is still higher than the current selling 
price of H-caprolactam, since the alanine cost is the main identified bottleneck.  
 
7.7.2 Environmental assessment 
There are two sets of environmental metrics mainly used to assess the environmental 
profile of a production process: the green chemistry metrics and the Life Cycle 
Assessment (LCA) impact factors. 
Green chemistry metrics can be divided into reaction-related metrics and process-
related metrics. Reaction-related metrics include atom efficiency (AE) [147], reaction 
mass efficiency (RME) [144] and carbon efficiency (CE) [144]. These metrics are 
intended to quantify exclusively the greenness of the reaction chemistry and therefore 
are constant across the all the evaluated scenarios. Process-related metrics include 
water intensity (WI) [157], process mass intensity (PMI) [149] and E-factor [152]. These 
metrics aim at quantifying the overall process (including the reaction chemistry).  
Water intensity is of special interest in biocatalysis and fermentation processes, since 
one of the most attractive features of bioprocesses in organic synthesis is the 
possibility of operating with an environmentally compatible solvent (water) [21]. 
However, water has become a scarce and overexploited natural resource. In addition, 
these processes usually lead to a large amount of wastewater that needs to be 
properly cleaned and this is usually very energy intensive [256]. Therefore operating 
with high concentrations is not only a matter of ensuring lower downstream process 
costs, but also an environmental issue. Despite the relevance of this green chemistry 
metric, it is only related to the final product concentration and consequently constant 
across the all the evaluated scenarios (4 kgwater/kgproduct), due to the assumed operating 
conditions used to build the mass and energy balances (Table 7.14). 
Process mass intensity (see Section 4.2.2.1), was also used to compare the 
environmental performance for the 20 different scenarios (Figure 7.10). For these 
flowsheets and mass balances, the reaction performance (final product concentration, 
space-time yield and reaction yield) are assumed constant according with Table 7.14. 
Hence, the variations of PMI across the evaluated scenarios (Figure 7.10) come only 
from the biocatalyst selected and consequently, the cofactor requirements for each 
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option. Since PMI is a mass-based metric (kg reagents and biocatalyst/kg Product), bigger mass 
contributors (starting material, alanine and NH4Cl) have a bigger contribution on the 
PMI of the process step (reaction). Since the impact on the mass contribution of the 
biocatalyst is less than 2% of the total process mass (excluding water), there are no 
major variation in the PMI of the reaction when evaluating different catalyst options. 
Nevertheless, when integrating a holistic viewpoint of the overall process to the PMI 
calculation (i.e. including the production of the biocatalyst), the impact of the catalyst 
formulation has a higher impact in the PMI and leads to an increase of nearly 10% in 
the calculated PMI value (Figure 7.10) when compared with the calculated PMI 
considering only the reaction step. A further increase is expected when integrating the 
production of the cofactors used during the multi-enzymatic synthesis of 6AHA. 
However, due to the lack of inventory data regarding industrial production of 
cofactors, this calculation was not performed. Nevertheless, these will only accentuate 
the benefits of operating in a whole-cell, as shown in Figure 7.10. 
 
Figure 7.10. Process mass intensity (PMI, kgraw materials/kgProduct) for production of 6AHA; 
Legend:  PMI of the reaction step;  PMI of the reaction step considering the 
fermentation and catalyst formulation for production of the catalyst 
 
A similar trend can be observed for the E-factor. Due to the lower enzyme stability 
often observed when operating with isolated enzymes [16] and cost intensive enzyme-
retaining techniques, biocatalyst reuse is not possible when this type of catalyst 
formulation is selected. Therefore, the process options that include whole-cell and/or 
immobilised enzymes display a more favourable E-factor. When operating with whole-
cells (at least partially) resulting in a 3% decrease of the E-factor. However, as 
observed previously for PMI, the mass contribution of the biocatalyst is lower than the 
mass contribution of other waste streams containing alanine, cofactors and unreacted 
starting material (cyclohexanol). Pyruvate is the biggest waste contributor, since the 
turnover number of alanine is too low. Therefore, improving the alanine turnover 
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number is not only a matter of enabling an economically feasible process, but also 
improves its environmental profile. 
The use of the aforementioned metrics is an attempt to measure the process 
chemistry and efficiency in a straightforward and easy to use way. Furthermore, these 
metrics do not require process details and are therefore attractive for initial process 
design decisions. However, these metrics do not distinguish between waste types and 
emissions [158]. Further, these metrics also do not consider the emissions, waste 
generated or resources used upstream or downstream of the investigated process 
step, nor the life cycle of the used raw materials. Life Cycle Assessment (LCA) is a more 
elaborate and comprehensive tool to quantify environmental effects [22], and 
provides detailed information about the type of emissions and the potential 
environmental impact over the whole life cycle of the product. Figure 7.11 displays the 
potential environmental impacts for the enzymatic cascade for production of 6AHA.  
LCA results for the 20 evaluated process options revealed that the starting material 
(i.e. cyclohexanol), alanine and the catalyst are the major contributors to the process 
environmental impact, by contributing more than 80% of the impacts evaluated and 
depicted in Figure 7.11. In particular, the starting material and alanine were the 
biggest contributors to the environmental impacts.  
Despite that the biocatalyst accounts for less than 10% of all the depicted 
environmental impacts, it is clear that operating with whole-cells implies savings in all 
the reported emissions and energy requirements. These savings are more relevant 
when the second half of the reaction (catalysed by E4, E5 and E6) is performed in a 
whole-cell by comparing the performance of option 1.2 and 1.7, option 2.2 and 2.3 or 
option 3.2 and 3.3, corresponding to the scenarios where the reaction catalysed by E4, 
E5 and E6 is conducted using a whole-cell catalyst or E1 and E2 is conducted in a 
whole-cell, respectively. Further, the most favourable scenarios for the environmental 
profile are found when both parts of the reaction that are cofactor dependent (i.e. the 
first two and the last three reaction steps) are performed using a whole-cell (options 
1.8, 1.10 and 1.12, option 2.4 and option 3.4). 
Nevertheless, more than 70% of all the reported emissions are allocated to alanine and 
cyclohexanol. As concluded from the process economic assessment, the low alanine 
turnover number leads to a high mass requirement of this amino acid, which 
compromises not only the economic viability, but also the environmental profile of the 
process. The production of cyclohexanol is currently based on the cobalt- catalysed 
oxidation of cyclohexane [257]. Currently this process exhibits several disadvantages: 
apart from numerous operational safety issues, the synthesis of cyclohexanol requires 
a high consumption of hydrogen for the hydrogenation step, high energy demands of 
the process, the oxidizing step has the disadvantage of producing multiple by-
products. The aforementioned disadvantages are reflected on the cyclohexanol 
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environmental profile, which in turn are reflected on the studied biocatalytic process. 
Nevertheless, recent studies proposing new greener routes for production of 
cyclohexanol have been reported, opening the opportunity for improved 
environmental profile [257]. Further, the environmental profile of the biocatalytic 
process proposed can also be improved by operating at higher reaction yield, as it will 
be discussed later.  
A B 
C D 
E 
Figure 7.11. Potential environmental impacts from production of H-caprolactam, 
including biocatalytic production of 6AHA and subsequent cyclisation to H-caprolactam; 
A Primary energy demand; B photochemical ozone formation potential; C Global 
warming potential; D Eutrophication Potential; E Acidification potential Legend:  
Biocatalyst (including cofactors),  Alanine,  Cyclohexanol,  Others and  
 H-caprolactam production environmental impact with the Beckmann 
rearrangement 
 
However, even for the identified favourable scenarios, the environmental profile for 
the base case is still not particularly favourable when compared to the current 
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chemical synthesis of H-caprolactam. The biocatalytic route only shows savings in the 
primary energy demand and the greenhouse gas emissions, while for the rest of the 
evaluated environmental impacts (photochemical ozone creation, eutrophication and 
acidification potential) the performance of the biocatalytic synthetic route is worse 
than the environmental performance of the conventional chemical route. Contributing 
to the not outstanding environmental profile is the alanine and cyclohexanol 
production processes and the consequently the assumed values for TTNAla and reaction 
yield (see Table 7.14). 
The above section, dedicated to process evaluation, was able to identify two main 
bottlenecks preventing the successful implementation of the biocatalyst process 
(alanine requirement and efficient conversion of the starting material). In particular, an 
efficient in-situ alanine recycle is required, in order to ensure an economically viable 
process. Further, the most promising solutions were identified (options 1.8, 1.10 and 
1.12, option 2.4 and option 3.4) and it was shown that operating in whole-cell brings 
economic and environmental advantages when compared with the isolated enzyme 
system. From the five most promising design options, option 1.12 might result in 
better process design.  
Option 1.12 is a three-pot process, where the catalyst used is a whole-cell for the first 
and the last reactor and in the second reactor, an immobilised lipase is used as the 
catalyst. Despite the greater capital cost of this option when compared to the 
scenarios operating in a two-pot process (option 2.4 and option 3.4), operating in a 
three reactor process can bring advantages in control as well as matching the 
operating conditions and overexpression level of a reduced number of enzymes might 
be an easier task [241]. Moreover, option 1.12 allows a greater flexibility for adapting 
to process modifications and/or fitting an already existing process. In addition, 
economic evaluation revealed that only a small percentage of the production costs 
arose from the process capital costs. Nevertheless, when operating with lower space-
time yield (i.e. higher batch times and higher reactor occupancy and lower biocatalyst 
concentration) the allocated capital costs will increase and therefore operating in a 
battery of three reactors might not be the most economic situation. Further, when 
comparing scenario 1.8, 1.10 and 1.12, the economic and environmental evaluation 
did not identify major drawbacks to operating with an immobilised biocatalyst, as the 
amount of biocatalyst used is small. Hence, selecting to operate with an immobilised 
lipase (E3) results in higher biocatalyst stability, when compared with isolated or 
whole-cell (option 1.8 and 1.10, respectively), while conveying simplicity to the 
process. 
 
121
Part III Case studies 
 
104 
7.8 Scenario analysis  
Assuming that biocatalyst production and enzyme overexpression is not limiting the 
process performance, in the evaluated scenario the low efficiency of in-situ alanine 
recycling prevents the economic viability of the process.  
The alanine total turnover number (TTNAla, defined as ‘mole of product formed per 
mole of alanine’) assumed is too low, leading to high alanine concentration 
requirements in the reactor. Previous studies using AlaDH, for alanine recycling in 
amination of primary alcohols [196] or asymmetric amination of ketones [258] have 
reported a 5-fold excess of alanine, which hinders the possibility of an economically 
successful scale-up. Nevertheless, the regeneration of alanine from pyruvate was 
reported to be a thermodynamically favourable reaction [197]. Hence, it might be 
possible to achieve higher TTNAla by improving the activity of alanine dehydrogenase, 
either by engineering its specific reaction activity via protein and/or reaction 
engineering (e.g. optimise pH, buffer, temperature) or by process engineering to 
optimise the enzyme ratio and compound concentrations in the reactor. Improving the 
TTNAla to 5 molproduct/molAla leads to 50% reduction of the production costs, enabling a 
profitability margin for the biocatalytic production of 6AHA, while further 
improvements to TTNAla to 10 molproduct/molAla result in 60% decrease of production 
costs, with a further increase of the profitability margin. Figure 7.12 displays the 
savings in the process production cost and in the environmental impacts of operating 
with higher TTNAla. 
From Figure 7.12, it can be concluded that improving in-situ alanine recycle in order to 
obtain higher TTNAla than 20 molproduct/molAla ceases to be of any benefit to the process 
economics, as the production costs become dominated by cost of the starting material. 
Regarding the process environmental impact, there are also major benefits of 
operating with higher TTNAla (as shown in Figure 7.12 B), with great savings in the 
process energy demands and therefore, in many of energy-related environmental 
potentials (such as acidification potential and global warming potential). 
  
122
7 Cofactor and interaction matrices for process development of multi-enzyme systems 
 
105 
A B 
Figure 7.12. Effect of the alanine total turnover number in overall production cost (A) 
and in the process environmental impact (B) Legend for B:  acidification potential; 
 eutrophication potential;  global warming potential;  photochemical ozone 
creation potential;  primary energy demand from renewable and non-renewable 
resources. Assumptions: process is performed according with option 1.12 (3-pot 
reactor); 95% reaction yield; 250 g/L of final product concentration; 8 hours of batch 
time 
 
The second process bottleneck identified that the reaction conversion has a great 
impact to the process environmental impact in all of the evaluated scenarios due to 
the present production process of cyclohexanol, as compound is the major cost driver 
when using whole-cells. Therefore, it is necessary to ensure an efficient conversion of 
the cyclohexanol to H-caprolactam in order to attain an economically competitive and 
environmentally friendly biocatalytic process. When operating with whole-cells, even 
at high reaction yield (99%), the cyclohexanol contributes with 50% of the total 
production costs (Figure 7.13 A, as commonly observed for many other bulk chemical 
production processes [252]). When considering the environmental impact of the 
process, the cyclohexanol contribution to the overall process environmental 
assessment is remarkable and it strongly affects the overall environmental 
performance (Figure 7.13 B). From the impact categories evaluated, photochemical 
ozone formation potential, global warming potential and primary energy demand are 
particularly relevant, due to the current production process of cyclohexanol, which 
demands intensive solvent use and large energy demands. The environmental impact 
for the biocatalytic production of H-caprolactam could be greatly reduced by 
considering other synthetic routes for production of cyclohexanol [257]. 
123
Part III Case studies 
 
106 
A B 
Figure 7.13. Effect of the reaction in overall production cost (A) and in the process 
environmental impact (B) Legend for B:  acidification potential;  eutrophication 
potential;  global warming potential;  photochemical ozone creation potential; 
 primary energy demand from renewable and non-renewable resources. 
Assumptions: process is performed according with option 1.12 (3-pot reactor); TTNAla 
10 molProduct/molAla; 250 g/L of final product concentration; 8 hours of batch time 
 
In the scenario analysis, other than the identified bottleneck scenarios should be 
considered, in order to avoid pitfalls and sub-optimised processes. Often there is a 
trade-off between the amount of biocatalyst dosed and the process utilities and capital 
costs. For instance, operating a process for a long batch time (i.e. obtaining a small 
space-time yield and operating at low reaction rate) implies higher equipment 
occupancy and higher reactor volumes, with consequent increase of the process 
capital and utilities costs. However, the process reaction rates can be increased (and 
the batch time reduced) by dosing more biocatalyst into the reactor (i.e. increasing the 
biocatalyst concentration), with subsequent increase of the biocatalyst allowable cost. 
Hence, there is an optimal space-time yield that needs to be identified, in order to 
obtain the minimum production costs (Figure 7.14). 
 
Figure 7.14. Effect of the batch time and consequent space-time yield in the reaction 
in  overall production cost  biocatalyst cost and  capital costs. Assumptions: 
process is performed according with option 1.12 (3-pot reactor); 95% reaction yield; 
TTNAla 10 molProduct/molAla; 250 g/L of final product concentration; 8 hours of batch 
time 
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7.9 Concluding remarks 
Multi-enzymatic processes can arise as a suitable and greener alternative to the 
conventional chemical routes. However, these processes are often very complex 
systems, with many interactions between enzymes, substrate(s), intermediates and 
product(s), affecting the catalyst(s) activities, which prevents many multi-enzymatic 
processes from being successfully scaled-up. Indeed, current process option selection 
for implementation of these processes has been performed on a case-by-case basis.  
In this chapter, a rational approach for defining a development strategy for multi-
enzymatic processes was presented. The proposed methodology requires a profound 
and structured knowledge of multi-enzyme systems, integrating chemistry, biological 
and process engineering. Hence, the information required (compound interaction, 
enzyme activity, etc.) has been listed in order to evaluate and propose a reduced 
number of feasible process design options, where the identified challenges are 
addressed. Here, this approach was used to set the mass and energy balances. This 
approach can also be useful in determining the biggest cost drivers and thus, proposes 
and guides further experimental evaluation of the process. This would lead to a 
reduction in expensive and time-consuming research as only the most promising need 
to be considered, reducing the number of experimental work. 
The number of options can be further reduced, by evaluating the process economic 
and environmental performance. This assessment is not only able to identify the most 
promising process based on its economic and/or environmental performance, but it is 
also able to identify the current process bottlenecks and, by performing a scenario 
analysis, the effects of overcoming these bottlenecks can be identified. 
By applying this methodology a priori to experimental evaluation (even at early 
research stage, during screening), the laboratory experts (either chemists or biologists) 
are able to understand the most probable operating conditions at full-scale and thus, 
they are able to collect information at these relevant conditions (for example, enzyme 
specific activity in the presence of other compounds and substrate selectivity) but also 
during biocatalyst development, by setting threshold values for the biocatalyst activity 
at relevant concentrations.  
Whole-cells provide a more promising scenario for multi-enzyme systems, namely 
when the use of cofactors is required. Great advances have been made in 
understanding the complex mechanisms in protein overexpression, substrate transfer 
across the membrane and in knocking-out competing pathways inside the cell, in order 
to obtain suitable whole-cell biocatalysts for industrial processes. However, the 
success of whole-cell biocatalysis for multi-enzymatic processes is ultimately 
dependent on how enzyme activity and protein overexpression can be controlled 
inside the cell. Therefore, cell-free systems and artificial cells are promising alternative 
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to the whole-cell. However, these solutions might translate to a biocatalyst cost 
increase (in particular for the artificial cells).  
For the specific case study presented in this chapter, some considerations were not yet 
taken into account that will reflect in some adjustments into the process (e.g. ISPR 
requirements). 
For instance, the final product of the biocatalyst synthetic route (6AHA, compound 6) 
has two functional groups that will probably form salts, not only with other molecules 
from the same compound, but also with other components present in the last reactor 
(alanine, pyruvate and compound 5). This will not only affect the reaction yield, but 
also the downstream process. Furthermore, compound 6 is an analogue of the amino 
acid lysine and therefore, it may act as an enzyme inhibitor for enzymes that have this 
residue on their binding site. However, this effect was not observed in the interaction 
matrix. 
Further, the values for the specific activity gathered for this example, are merely 
illustrative and ideally would have been collected according with the methodology at 
the operating conditions. However, the information used was obtained from scientific 
literature, where the reported enzyme-catalysed reactions were performed at 
different pH and temperature. Hence, when applying a second round of this 
methodology, the process engineer should reconsider the enzyme activities for the 
recombinant hosts selected and as close as possible with the defined operating 
conditions. 
When applied to the multi-enzyme system for biocatalytic production of H-caprolactam 
the proposed methodology was able: 
1. To select the most favourable reactor configuration (multi-pot) in order to avoid 
cross interference between the different compounds in the enzymatic cascade; 
2. To select the most favourable biocatalyst formulation (whole-cell) based on the 
economic and environmental evaluation of the process flowsheets generated; 
3. To identify two main process bottlenecks that are preventing a competitive 
process, while indicating targets for further development: 
x Process evaluation showed that alanine has a great impact in attaining a 
successful process scale-up, while scenario analysis has proven the benefits of 
improving alanine in-situ regenerating system in the process viability. 
Therefore, it is necessary to develop process solutions to decrease the alanine 
requirement, increasing the TTNAla to a minimum of 10 molproduct/molAla by 
implementing an efficient regeneration system of pyruvate back to alanine. 
x Finally, the starting material (cyclohexanol) was proven to have a great 
impact on the environmental and economic profile of the process. Therefore, 
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the biocatalytic production of H-caprolactam is stymied until greener and 
cheaper production routes for cyclohexanol are commercially available. 
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8 Windows of operation for selection of technology 
options 
8.1 Introduction 
The attractive features of biocatalytic processes (such as, exquisite selectivity, 
biodegradability of the biocatalyst and mild reaction conditions) have led to an 
increased number of processes running at a commercial scale [14,219]. Although 
biocatalysis has many potentially attractive features, an analysis of emerging and 
interesting enzyme-catalysed reactions indicates that in many cases biocatalyst yield 
and process intensity are frequently too low for successful industrial implementation. 
In fact, when a biocatalytic route is first considered, often it does not meet the 
required process metrics for an economically feasible scale-up (i.e. high product 
concentration, high enantiomeric excess, high reaction yield, high biocatalyst yield and 
high space-time yield) [13]. Further, for the majority of scaled biocatalytic processes, 
the conditions at which the enzymes are operating in the industrial reactor (e.g. 
substrate and product concentrations) are far different from those found in their 
natural environment. This incongruity can be addressed in a number of different ways 
(ISPR, enzyme engineering, immobilisation, etc.). A crucial step in process design is 
therefore to select between alternative technologies and routes to overcome this 
incongruity. For instance, Table 8.1 shows a list of potential process solutions that are 
likely to improve the process performance in biocatalytic reactions where the 
thermodynamic equilibrium is unfavourable. 
Biocatalytic processes are still in their infancy, as many of the suitable biocatalysts are 
still under development and therefore, most of the reactions are neither well 
developed nor optimised. Furthermore, the process technologies are not yet fixed and 
many alternative process configurations are possible. To carry out experiments in 
order to evaluate all the possible set-up combinations is a costly and laborious task. 
Hence, it is necessary to develop a methodology to identify where the most promising 
process solutions lie, integrating improvements that come not only from process 
engineering but also from molecular biology (to improve the biocatalyst) and 
chemistry (to improve reaction chemistry). 
The use of a conceptual process design methodology (see Chapter 3) for the 
development of biocatalytic processes can bring a number of advantages [69]. 
Nevertheless, there is still not a rational approach to option selection and 
development for biocatalytic processes (e.g. ISPR, IScPR, operate with co-substrate 
excess and catalyst formulation) where the process bottlenecks are analysed and 
resolved in a systematic manner. The methodology proposed in this chapter utilises  
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Table 8.1. Overview of potential process solutions to improve the productivity of 
thermodynamically challenged biocatalytic reactions 
Challenge Solution Flowsheet 
Equilibrium shifting 
Co-substrate excess 
 
In-situ product removal 
(ISPR) 
 
In-situ co-product removal 
(IScPR) 
 
 
Equilibrium shifting 
Product inhibition 
Co-substrate excess 
In-situ product removal 
 
 
Equilibrium shifting 
Co-Product 
inhibition 
Co-substrate Excess 
In-situ co-product removal 
 
Equilibrium shifting 
Product and co- 
-product inhibition 
In-situ product removal 
In-situ co-product removal 
 
 
Equilibrium shifting 
Product and co- 
-product inhibition 
Co-substrate excess 
In-situ product removal 
In-situ co-product removal 
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the principles behind windows of operation (see Section 3.2.4) as a tool to identify 
suitable process conditions and assess feasible process configurations. The proposed 
methodology aims at facilitating the development of a biocatalytic process at an early 
stage. The outcome of this methodology is three-fold: 1) to channel resources to 
collect the relevant data for process development; 2) to identify the main process 
technologies that will ensure a feasible process; 3) to identify further development 
efforts, helping to direct research and thereby, setting R&D targets that are imperative 
for process success. 
 
8.2 Methodological framework 
The workflow, tools and data required in the methodology for developing windows of 
operation are outlined in Figure 8.1. The procedure contains 7 steps and includes 
literature research, data collection, process modelling, data generation (through 
process modelling) and comparison of different scenarios, aiming to identify and set 
targets for improvement in the different research areas of the process design (e.g. 
reaction design, catalyst design, catalyst selection and ISPR, IScPR and ISSS selection). 
 
8.2.1 Step 1. Determine reaction thermodynamic equilibrium (Keq) 
Rationale: The reaction thermodynamic equilibrium plays a crucial role in predicting 
the extent of a reaction (i.e. reaction yield) and the equilibrium position for the desired 
process [197]. Hence, the thermodynamic equilibrium constant is a critical parameter 
for a rational process development strategy in reversible reactions. The 
thermodynamic equilibrium constant determines the substrate(s) and product(s) 
concentrations at equilibrium, the thermodynamic reaction yield at the equilibrium 
position and which process options are feasible [30]. Therefore, an early determination 
of the equilibrium constant (Keq) is essential for a truly systematic approach for process 
development.  
Method: Estimation tools (e.g. group contribution methods) are commonly used in the 
chemical process industry to predict thermodynamic properties [259]. However, to 
date, these have been found to be unsuitable for aqueous based biocatalytic reactions 
due to the poor match between the experimental and the predicted data [30]. A 
simple experimental methodology to accurately determine reaction thermodynamic 
equilibrium constant in biocatalytic reactions was proposed by Tufvesson and his co-
authors [30]. Further, the Thermodynamics of Enzyme-catalysed Reactions Database 
(TECRDB, [176]) compiles apparent equilibrium constants and molar enthalpies of 
reaction on 400 different biocatalytic reactions. The output of this step is a value for 
the thermodynamic equilibrium constant. 
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Figure 8.1. An overview of the proposed methodology to identify potential favourable 
scenarios 
 
8.2.2 Step 2. Determine required co-substrate excess 
Rationale: The easiest and most common strategy for shifting equilibrium is to use an 
excess of one of the substrates (usually the less expensive one) pulling the equilibrium 
towards the product side and thereby, increasing the thermodynamic reaction yield 
(see first entry in Table 8.1). However, operating with substrate excess increases the 
downstream process (DSP) costs, as the non-reacted substrate must be removed from 
the reactor effluent stream. Further, for a truly sustainable process, the non-reacted 
substrate must be recycled into the new batch, which might further increase the DSP 
costs.  
Method: The methodology to determine the required co-substrate concentration for 
displacing the thermodynamic reaction equilibrium is given in Section 8.2.2.1 and 
8.2.2.2. 
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8.2.2.1 Step 2.1. Plot required substrate excess against thermodynamic yield 
For a generic reaction A B C Do m  given Keq and initial limiting substrate 
concentration ( 0A ), the required co-substrate excess (Xs) to obtain the desired 
thermodynamic reaction yield (Yreaction) by solving a system of equations (Equation 8.1). 
0
0
0
0
(1 )
(1 )
eq eq
eq
eq eq
eq reaction
eq reaction
eq reaction
eq reaction
C D
K
A B
C A Y
D A Y
A A Y
B A Y Xs
­  ° °°  °°®°  °°   °    °¯
Equation 8.1 
Where eqA , eqB , eqC  and eqD  represent the concentration in equilibrium (reaction 
phase) of the reaction components and B is the co-substrate dosed in excess. Plotting 
the required co-substrate excess against the desired reaction yield allows a graphical 
visualisation of the trade-off between the desired reaction yield and the effort 
required to shift the equilibrium by use of co-substrate excess. 
8.2.2.2 Step 2.2. Determine substrate excess limits 
At industrially relevant concentrations, there is an upper constraint for the applicability 
of this strategy to displace the reaction equilibrium due to the water-solubility of the 
co-substrate dosed in excess, as well as the stability and inhibition of the biocatalyst at 
high co-substrate concentrations. Hence, it is necessary to determine the maximum 
allowable excess based on the co-substrate solubility limit and its inhibitory 
concentration. The physical properties of the substrates, products and reaction can be 
found experimentally, in the scientific literature or determined by computer aided 
(CAPE) software, such as ThermoData Engine software from NIST [260] and ProPred 
from ICAS [261]. 
 
8.2.3 Step 3. Determine product or co-product concentration 
required 
Rationale: Many of the thermodynamically challenged reactions would require an 
enormous amount of substrate excess to shift the equilibrium towards the product 
side, which would lead to an unfeasible process. Hence, a suitable strategy is to apply 
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in-situ removal of product or co-product, increasing the driving force to displace the 
reaction equilibrium.  
The potential benefits of putting in place an ISPR strategy are 4-fold: 1) it can remove 
the product from the reaction medium, decreasing the necessity of a substrate excess; 
2) it can minimise product inhibition or stability effects on the biocatalyst [51]; 3) it can 
reduce product losses either by product degradation, or uncontrolled product removal 
from the system (e.g. by evaporation) [198] and; 4) it can decrease the DSP efforts 
[49]. 
Method: The methodology to determine the required product or co-product 
concentration for displacing the thermodynamic reaction equilibrium is given in 
Section 8.2.3.1. 
8.2.3.1 Step 3.1. Plot substrate excess against (co-)product concentration in the 
aqueous phase 
Integrating an ISPR strategy for equilibrium shift would result in a trade-off between 
the required (co-)product concentration in the reaction phase and the co-substrate 
excess. Hence, for the same generic reaction, given Keq, thermodynamic reaction yield 
(Yreaction) and initial limiting substrate concentration ( 0A ),the trade-offs where the 
process performance is achieved can be computed by solving a system of equations 
(Equation 8.2). 
0
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eq reaction
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C C C
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Equation 8.2 
Where tC  is the overall (co-)product production of the component C achieved for the 
reaction yield threshold value and rC  is the amount of (co-)product C removed from 
the reaction phase by ISPR (or IScPR).  
The graphical representation of the required product concentration in the reaction 
phase and co-substrate concentration provides a preliminary indication how effective 
the ISPR technology put in place needs to be. However, the selection of the suitable 
ISPR technology will be further discussed in section 8.2.3, when in-situ co-product 
removal (IScPR) is evaluated simultaneously. 
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8.2.4 Step 4. Determine operating curve for simultaneous ISPR and 
IScPR 
Rationale: For particularly thermodynamically challenged reactions, the above 
strategy(ies) might not yet result in a feasible process, as the concentration of the (co-
)product required in the reaction phase will probably be too low to be achievable even 
with a very effective and selective ISPR technique. Furthermore, even at more 
reasonable requirements for product removal in the aqueous phase it is sensible to 
investigate the ease of simultaneously removing the co-product in order to alleviate 
the burden on one of the technologies. 
Method: Hence, the trade-off between simultaneous removal of product and co-
product needs to be plotted, in order to obtain a better selection of product and co- 
product removal technology (see Sections 8.2.4.1 - 8.2.4.3). 
8.2.4.1 Step 4.1. Plot product against co-product concentration in the aqueous 
phase 
Integrating an ISPR strategy with a simultaneous IScPR in order to shift the equilibrium 
would result in a trade-off between the required product and co-product 
concentration in the reaction phase. Therefore, for a given equilibrium constant (Keq), 
thermodynamic reaction yield (Yreaction), initial limiting substrate concentration ( 0A ) 
and co-substrate excess (Xs) the trade-offs where the process performance is achieved 
can be computed by solving a system of equations (Equation 8.3). 
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Equation 8.3 
Where tD  is the overall co-product production of the component D achieved for the 
reaction yield threshold value and rD  is the amount of co-product D removed from 
the reaction phase by IScPR.  
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8.2.4.2 Step 4.2. Mark in Step 4.1. the limits for ISPR and IScPR 
Rationale: During the ISPR and IScPR selection, the physicochemical properties 
commonly investigated for separation are: volatility, water-solubility, charge, 
hydrophobicity and molecular size [49,50]. The sequence for selecting an appropriate 
separation is often determined by the separation driving force (i.e. the IS(c)PR 
technology chosen is that where the difference in physicochemical properties between 
the targeted compound to be separated and the other components in the reaction 
mixture is greatest) [50]. 
In particular, for the in-situ removal of the co-product, the use of enzymatic cascades 
to selectively remove the co-product from the reaction phase represents as a suitable 
solution. This IScPR technology takes advantage of the exquisite selectivity of enzymes 
to degrade (or recycle) the co-product. Theoretically, the co-product concentration 
obtained employing this process option can be as low as desired, since the rate of co-
product conversion is only dependent on the amount of catalyst used for the 
conversion reaction(s) dosed in the reactor (due to the typically low Km value of 
enzyme-catalysed reactions). However, the use of further enzymatic steps might 
increase the overall process cost (depending on the type of catalyst formulation 
adopted), as well as the complexity of the reaction system. 
In most of the reported ISPR and IScPR techniques, the target molecule for selective 
(co-)product removal is at a higher concentration than the unreacted substrate [50]. 
However, these operating conditions are seldom observed in thermodynamically 
challenged reactions, since these processes often run under greater substrate 
concentration than the targeted molecule. Hence, the ISPR and IScPR techniques used 
in these circumstances must show high selectivity towards the product and low 
selectivity towards the substrates. The ideal ISPR (or IScPR) technique should show 
high selectivity for the target product without compromising its capacity in the 
presence of the other reaction compounds (reagents, co-product(s), reaction additives, 
etc.). However, high capacity ISPR techniques are generally associated with low 
selectivity towards the product [51].  
Method: The adopted ISPR strategy is very much dependent on the molecules’ 
properties and ideally should be tailor-made for the target molecule. Unless the 
IS(c)PR technique(s) chosen is(are) highly selective, the substrate(s) will be 
simultaneously removed from the reaction system, which will also affect the 
thermodynamic equilibrium and the reaction yield and kinetics. However, tailored-
solutions are not often easy to find. To date there is no systematic approach for ISPR 
selection and the majority of the solutions put in place are done on a case-by-case 
basis. 
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8.2.4.3 Step 4.3. Plot product against co-product concentration in the aqueous 
phase for the selectivity of the selected ISPR and IScPR technique  
Rationale: As mentioned earlier, one of the most important requirements for ISPR and 
IScPR is the selectivity of the separation technique selected (i.e. the ability to separate 
more effectively between the product and other compounds in the reaction phase) 
[50]. Operating with a non-selective IS(c)PR technology implies that other compounds 
in the reaction media are also removed together with the targeted molecule. 
Regardless the effect on the raw materials cost, applying a non-selective IS(c)PR is 
especially critical in thermodynamically challenged reactions as the thermodynamic 
equilibrium is affected. 
Method: Hence, it is necessary to rectify the calculated relationship between the 
required product and co-product concentration in the reaction phase for the selectivity 
of the ISPR and IScPR methods adopted. Therefore, knowing the selectivity of the 
chosen ISPR and IScPR method (SC and SD, respectively), the equilibrium constant (Keq), 
thermodynamic reaction yield (Yreaction), initial limiting substrate concentration ( 0A ) 
and co-substrate excess (Xs) we can calculate the trade-off where the process 
performance is achieved by solving a system of equations (Equation 8.4).  
Where ,i CPC  and ,i DPC  are the partition coefficient of component i for the ISPR and 
IScPR method selected, respectively ; tA  and tB  is the overall substrate and co-
substrate consumed for the reaction yield threshold value; ,r CA  and ,r DA are the 
amount of substrate A removed from the reaction phase when ISPR and IScPR are put 
in place, respectively; ,r CB  and ,r DB are the amount of co-substrate B removed by the 
ISPR and IScPR, respectively; ,r CC  and ,r DC are the amount of product C removed from 
the reaction phase when ISPR and IScPR are put in place, respectively; and ,r CD  and 
,r DD are the amount of substrate D removed by ISPR and IScPR, respectively. For 
instance, a highly selective ISPR method implies an infinite value for SC, as the partition 
coefficient for the other compounds is zero. 
 
8.2.5 Step 5. Determine reaction kinetics 
Rationale: Process mathematical models provide a good process insight. Developing a 
kinetic model allows a rapid understanding and evaluation of the type of options 
required for process optimisation.  
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Often biocatalytic reactions are not only thermodynamically challenged but also 
kinetically challenged. Therefore, strategies to shift the equilibrium should be 
considered alongside with strategies to overcome substrate and product inhibition of 
the biocatalyst. A validated kinetic model is useful for predicting process performance 
under different operating conditions (e.g. concentration of the reaction components), 
in order to define an operating space, where the required biocatalyst specific activity 
can be achieved. 
The performance of the biocatalyst can be affected mainly by stability and/or 
inhibition, which is ultimately reflected in the reaction rate (and biocatalyst specific 
activity). Moreover, the process kinetic model should ideally integrate not only the 
reaction kinetic model, but also dynamic models describing the mass transfer 
phenomena occurring in ISPR, IScPR and/or ISSS strategies adopted. 
Method: The methodology is given in Section 8.2.5.1. 
 
Step 5.1. Plot product against co-product concentration in the aqueous phase 
The kinetic model can be plotted as a 3D-surface depicting the biocatalyst 
performance (i.e. biocatalyst specific activity) against a range of suitable operating 
variables (i.e. concentration of product, co-product and substrate in the aqueous 
phase). The biocatalyst performance metric can be determined for the assumed 
biocatalyst yield and process space-time yield (see Section 5.2.1). The 3D-surface is cut 
at the defined threshold value for the biocatalyst specific activity, creating a region 
where the reaction achieves the desired performance. 
 
8.2.6 Step 6. Generate an window of operation 
Rationale: All the threshold values for the process metrics and technology constraints 
(e.g. for ISPR and IScPR) are now plotted on common axes (operating variables, 
product and co-product concentration in the reaction phase) and the area where the 
process fulfils all the requirements (defined by the constraints and/or threshold values 
for process metrics) is the window of operation for the process. This methodology 
provides a proper visualisation: either the process is feasible (if there is a window 
bounded by all the aforementioned constraints and process metrics threshold values) 
or not (if there is no window). Moreover, by adopting this graphical methodology, the 
sensitivity of different metrics and constraints used as inputs to the window can be 
discerned. 
Method: The window of operation can be obtained by superimposing the plots 
representing the hard constraints, i.e. the concentration of product, co-product and 
co-substrate to shift the equilibrium to the desired thermodynamic reaction yields, 
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with the limitations of the possible ISPR and IScPR techniques adopted and the kinetic 
plot, resulting from cutting the 3D-surface generated in Step 5. at the defined 
threshold performance metric for the biocatalyst specific activity). 
 
8.2.7 Step 7. Perform scenario analysis 
Rationale: In this final step, a scenario analysis (what-if analysis) is carried out. A 
scenario analysis is one of the most simple and straightforward forms of evaluating 
alternative process options not considered in the above methodological flow. This 
methodology allows a rapid and effective way to study the effects of potential 
improvements process and biocatalyst by setting threshold values for the process 
metrics at relevant process conditions (see Section 5.2.1).  
Method: Relaxing the threshold values for the process metrics (i.e. biocatalyst yield, 
reaction yield, space-time yield and final product concentration) is expected to affect 
greatly the cost of the process. In addition, modifying these parameters will also affect 
the size, position and shape of the window of operation. Hence, this methodology 
allows a quick evaluation of the trade-offs between the production cost (in the form 
performance metrics) and the development cost (implicit in the size and position of 
the window of operation). Hence, by coupling this methodology to the development of 
the biocatalyst, targets for the biocatalyst development can be set, avoiding over-
development, i.e. a situation where the process is no longer limited by the reaction 
kinetics, but instead by the thermodynamics. 
Finally, the scenario analysis also provides a quick evaluation of different ISPR and 
IScPR technologies available at the current state-of-the-art. The methodology is able to 
set targets for the ISPR, IScPR and/or ISSS technique, by pinpointing the minimum 
required product, co-product and/or substrate concentrations in the aqueous phase. 
Hence, this methodology could be coupled to a rational approach for in-situ product 
removal selection. 
 
8.3 Case study 2: Chiral amine production using Z-transaminase 
8.3.1 Introduction 
Biocatalytic synthesis of optically pure compounds has emerged as an attractive 
complement to heterogeneous and homogeneous catalysis, due to the high selectivity 
[38] and mild conditions, avoiding the need for protection and deprotection strategies, 
resulting in processes with fewer steps and potentially increasing the overall process 
yield whilst reducing downstream process costs [1,219,262]. Together with the 
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possibility to tailor the biocatalyst properties using molecular biology tools [48,65] and 
a potentially green profile [24], biocatalysis is a particularly attractive technology to 
assist in the synthesis of industrially relevant compounds, such as optically pure chiral 
amines.  
Chiral amines are key building blocks for many pharmaceuticals (NCEs and APIs). Chiral 
amines can be produced both by chemical and biocatalytic synthesis [263]. In recent 
years, ω-transaminase-catalysed reactions have proven to be an attractive 
complement to the existing routes for the synthesis of optically pure chiral amines.  
ω-transaminases (EC 2.6.1.X, also known as aminotransferases) catalyse the transfer of 
an amine group from a donor molecule to a prochiral ketone (Figure 8.2) using 
pyridoxal-phosphate (PLP) as a cofactor [231]. Regarding the reaction step, there are 
two main strategies to produce chiral amines: direct asymmetric synthesis or kinetic 
resolution of a racemic mixture of amines. The kinetic resolution approach is a 
potentially industrial attractive route for the production of enantiopure chiral amines 
due to its favourable thermodynamic equilibrium. However, these reactions are 
hampered by a theoretical 50% reaction yield [36]. The alternative route, asymmetric 
synthesis, is the focus of this chapter. Asymmetric synthesis is generally the preferred 
reaction configuration due to the higher theoretical reaction yields and facilitated 
separation steps.  
 
Figure 8.2. Model transaminase-catalysed reaction; * chiral centre 
 
Nevertheless, as a relatively new technology, many of the proposed transaminase-
catalysed syntheses do not yet fulfil the required economic metrics necessary for 
process scale-up [16]. Frequently encountered challenges for the biocatalytic synthesis 
of chiral amines using ω-transaminases include potentially unfavourable 
thermodynamic equilibrium, low biocatalyst activity and stability, as well as substrate 
and product inhibition (Table 8.2). To overcome these limitations there are several 
possible process solutions, as well as alternative solutions via biocatalyst engineering 
and chemistry (i.e. reaction engineering) related solutions (Table 8.2). Potential 
process solutions include operating at substrate excess (i.e. addition of an excess of 
amine donor), application of in-situ product removal (ISPR) and in-situ co-product 
removal (IScPR) or combination of these (Table 8.2). 
Of recently published studies, only four successfully attained the process metrics 
suitable for a sustainable and viable process, all of them by applying the 
aforementioned process solutions [37,264-266] (Figure 8.3). In the studies by Savile 
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and co-workers [37] and Martin and co–workers [264], process feasibility was achieved 
by operating with an amine donor excess and using protein engineering techniques to 
improve biocatalyst yield and tolerance to higher concentrations of the substrate 
[37,264]. Interestingly, Truppo and co-workers [265] achieved process feasibility by 
only applying process solutions (use of enzymatic cascades and in-situ product 
removal) [265]. While in the latest successful study, Truppo and his co-workers [266] 
attained process feasibility following the previous work performed by Savile and co-
workers [37] by applying protein engineering techniques and enzyme immobilisation 
while employing a greener solvent to increase substrate solubility in the reaction 
medium [266]. Despite the successful results, all of these studies were developed on a 
case-by-case basis and probably the true optimal process is yet to be designed. 
Ultimately, the ideal strategy would be a joint effort for process and biocatalyst 
improvement that should be carried out side-by-side and guided by a rational 
methodology in order to decrease development resources and time. 
 
Figure 8.3. State-of-the-art of development strategies for biocatalytic processes; 
Legend:  Improvements in (S)-aminotetralin production by protein engineering 
[264] using whole-cell (biocatalyst yield in gProduct/gCDW);  Improvements in 
sitagliptin production by protein engineering and 50% DMSO [37];  
Improvements in PEA production by ion-exchange resin for ISPR and enzymatic 
cascade for IScPR [265];  Improvements in sitagliptin production by enzyme 
immobilisation and water saturated with isopropyl acetate [266] (biocatalyst yield in 
gProduct/gimmobilised enzyme). 
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8.3.2 Methodology application 
In order to guide development efforts and process design at an early stage of process 
development a methodological approach is required. The methodology put forward in 
section 8.2 identifies potential windows of operation, defines guidelines for process 
and biocatalyst development and assists in the choice of the most suitable process 
option (i.e. suitable ISPR and IScPR technologies). 
The proposed methodology is demonstrated for the synthesis of (S)-1-phenyl-
ethylamine (PEA) using propan-2-amine (or isopropylamine, IPA) as the amine donor 
and ω-transaminase (ATA-40, c-Lecta, Leipzig, Germany) as the biocatalyst (full 
experimental details are given at [267]). In this system, acetophenone (APH) is the 
prochiral ketone (or acceptor) and acetone is the co-product (Figure 8.4).  
 
Figure 8.4. Biocatalytic production of PEA using IPA as amine donor by Z–transaminase 
(ATA-40) 
 
Regardless the selection of the substrate (that is only determined by the desired 
product), when employing transaminases the choice of amine donor (co-substrate) is a 
very important issue. Different amine donors can strongly affect the thermodynamic 
equilibrium constant [30], the biocatalyst specific activity and may imply a different 
process technology(ies) and downstream operating units. Nevertheless, the use of 
alternative amine donors for the synthesis of PEA will not be discussed is this chapter. 
8.3.2.1 Step 1. Determine reaction thermodynamic equilibrium (Keq) 
The thermodynamic equilibrium constant for the adopted system was experimentally 
determined by Tufvesson and co-workers according with Equation 8.5 [30]. The 
thermodynamic equilibrium was found to be as 0.033 [30], i.e. strongly in favour of the 
reagents over the products (see also Section 8.2.1). 
> @ > @
> @ > @eq eqeq eq eq
PEA Ace
K
APH IPA
 
 
Equation 8.5 
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8.3.2.2 Step 2. Determine required co-substrate excess 
In order to evaluate which substrate should be dosed in excess, the process engineer 
must consider the cost of the substrate and the ease of recovery. In the presented case 
study propan-2-amine (IPA) was the substrate dosed in excess (while acetophenone 
(APH) is the limiting substrate), because IPA is a cheaper substrate and its recovery is 
potentially facilitated by applying ion-exchange chromatography, exploiting the 
differences of the isoelectric point of the different compounds at different pH values.  
Step 2.1. Plot required substrate excess against thermodynamic yield 
Based on assumed threshold values for the reaction yield (see Section 5.2.1) and in the 
reaction thermodynamic equilibrium (see Section 8.3.2.1), the co-substrate excess is 
required (Figure 8.5). 
A
B 
Figure 8.5. Required IPA excess to shift the thermodynamic equilibrium A at fixed 
reaction equilibrium constant aiming different reaction yield B at fixed reaction yield 
for different reaction equilibrium constants  
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Figure 8.5 shows that in order to obtain reaction yield of 90%, IPA should be dosed at 
280-fold excess, for the determined reaction kinetic equilibrium constant. However, 
when relaxing the performance constraint for the reaction yield, the required IPA 
excess for shifting the reaction equilibrium drops according with Figure 8.5 A (see also 
8.3.2.7). Furthermore, when considering other amine donors for the synthesis of  
1-phenylethylamine (PEA) the reaction thermodynamic equilibrium constant differs 
and the co-substrate excess required will vary according with Figure 8.5 B. 
Step 2.2. Determine substrate excess limits 
It is necessary to evaluate to what extent co-substrate dosing is feasible, bearing in 
mind the co-substrate solubility limits and the effect in the reaction kinetics. The co-
substrate excess is a function of the final product concentration and yield threshold 
values, as shown in Equation 8.6 and Equation 8.7. 
0
[ ]
[ ] f
PEA
APH
Yield
 Equation 8.6 
 0 0[ ] [ ] 1 IPAIPA APH Xs    Equation 8.7 
The initial co-substrate concentration (in the case study 0[ ]IPA ) must be lower than 
the solubility limit (16.9 M, [36]) and it should be lower than the inhibitory 
concentration observed (5 M, [268]). Figure 8.6 shows the allowable co-substrate 
excess for the case study. 
 
Figure 8.6. Maximum IPA excess for varying final amount of product produced per litre 
of reactor (assuming 90% of reaction yield) based on the solubility of the IPA ( ) and 
inhibitory concentrations of IPA ( ) 
 
Figure 8.6 shows that the maximum co-substrate excess is a function of the 
performance constraint defined for the final product concentration (see also 8.3.2.7). 
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When a lower final product concentration is required the maximum allowable co- 
substrate excess increases, as shown in Figure 8.6. While at higher final product 
concentrations (closer to those required for bulk chemicals) the maximum allowable 
excess decreases and operating with very low or no co-substrate excess (i.e. at 
stoichiometric concentration of co-product) becomes virtually compulsory in order to 
avoid operating above the co-substrate solubility limit and to decrease downstream 
costs (particularly crucial in bulk chemicals). 
Figure 8.6 shows that, for the final product concentration of 100 g/L, the maximum co-
substrate excess that the reaction can be operated is 17-fold, above this value the co-
substrate is not soluble and forms a second phase. Further, it is also necessary to 
consider the inhibitory effects of IPA concentration on the reaction kinetic 
performance. Hence, for a non-engineered catalyst the maximum co-substrate excess 
in which the reaction can be operated is 4.5-fold. However, this value can increase (up 
to a maximum of 17-fold, solubility limit) if the inhibition profile of the catalyst towards 
IPA is improved (see also 8.3.2.7). 
Finally, Figure 8.6 proves that for the presented case study, the performance level 
defined in Step 2 (see Section 5.2.1) cannot be reached by exclusively applying co-
substrate excess as a strategy for shifting the reaction equilibrium. 
8.3.2.3 Step 3. Determine product or co-product concentration required 
Hence, other ways to shift the reaction thermodynamic equilibrium towards the 
product (PEA) must be explored. Another strategy to displace the thermodynamic 
equilibrium towards the product side is by selectively and continuously removing the 
product or co-product from the reaction phase as it is formed by applying in-situ 
product removal (ISPR) or in-situ co-product removal (IScPR), respectively.  
Step 3.1. Plot substrate excess against (co-)product concentration in the aqueous 
phase 
The reaction equilibrium is then defined according with Equation 8.8 and Equation 8.9 
for ISPR or Equation 8.10 when IScPR is applied. 
> @ > @
> @ > @aq aqeq aq aq
PEA Ace
K
APH IPA
 
 
Equation 8.8 
> @ > @ > @T aq removedPEA PEA PEA   Equation 8.9 
> @ > @ > @T aq removedAce Ace Ace   Equation 8.10 
Figure 8.7 shows the trade-off between the IPA excess and the concentration of 
product or co-product in the aqueous (reaction) phase. 
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A
B 
Figure 8.7. Required IPA excess at varying concentrations of A product and B co-
product  in the aqueous phase applying ISPR and IScPR, respectively; Assumptions: 100 
g of product produced per litre of reactor; reaction yield 90%. Legend:  IPA 
solubility limit;  isopropylamine kinetic limit;  PEA solubility limit (42 g/L, [36]) 
 
In Figure 8.7 the operating area (in white) shows the region where the performance 
metrics are achieved for final product concentration and reaction yield. The black 
curves show the operating curves of substrate excess and product or co-product 
removal (Figure 8.7 A or Figure 8.7 B, respectively). Below this curve, the performance 
metrics are not achieved (light red area). The grey area in Figure 8.7 A represents the 
area when the product reaches the solubility limit (42 g/L, [36]), forming a second 
phase in the reactor. The darker red area represents the unfeasible area for the co-
substrate excess, where the co-substrate concentration is higher than its solubility 
limit. Finally, the orange area represents where the concentration of IPA is higher than 
its inhibitory limit and the reaction kinetics would be affected if operating at this co-
substrate concentration. However, the feasible space for the predefined performance 
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metrics (Section 5.2.1) in this strategy can be enlarged if protein engineering is 
considered. Figure 8.7 shows the target product or co-product concentrations in the 
reaction phase to effectively displace the thermodynamic equilibrium and reach the 
threshold value for the reaction yield.  
8.3.2.4 Step 4. Determine operating curve for simultaneous ISPR and IScPR 
For reactions where the thermodynamic equilibrium is particularly challenged, 
operating with a co-substrate excess together with simultaneous removal of the 
product (PEA) and co-product (acetone) might constitute a suitable strategy to shift 
the reaction equilibrium in order to attain the defined performance metrics. The 
reaction equilibrium is then defined according with Equations 8.8 – 8.10. 
Step 4.1. Plot product against co-product concentration in the aqueous phase 
Figure 8.8 shows the trade-off between the concentration of product and co-product 
in the reaction phase at different IPA excess. 
 
Figure 8.8. Required concentrations of product and co-product in the aqueous phase 
applying ISPR and IScPR, respectively; Assumptions: 100 g of product produced per 
litre of reactor; reaction yield 90%. Legend: without IPA excess  IPA solubility 
limit;  IPA kinetic limit;  PEA solubility limit 
 
Figure 8.8 shows how a combined strategy with simultaneous removal of product and 
co-product as well as an excess of amine donor can shift the equilibrium towards the 
product side. As expected, the requirements for ISPR and IScPR are higher when a 
lower excess of amine donor is used (black line, represents no IPA excess). The lines 
(black, orange and red) show the operating curves of PEA and acetone removal at 
different substrate excess (stoichiometric concentration, limit for inhibitory co-
substrate excess, co-substrate excess at solubility limit, respectively). Above this curve, 
the performance metrics are not reached. The grey area in Figure 8.8 represents the 
area where the product reaches the solubility limit (42 g/L, [36]), forming a second 
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phase in the reactor. The red area represents the unfeasible area for the co-substrate 
excess, where the co-substrate concentration is higher than its solubility limit. The 
orange area represents the area where the concentration of IPA is higher than its 
inhibitory limit and the reaction kinetics would be affected if operating at this co-
substrate concentration. Finally, the yellow area represents a possible operating 
space(s) for co-substrate excess between the stoichiometric concentration (i.e. no 
excess) and the excess at the kinetic limit (4.5-fold excess). 
Step 4.2. Mark in Step 4.1. the limits for ISPR and IScPR 
It is now necessary to define the minimum concentration that each potential process 
technology for ISPR or IScPR can achieve (as well as the capacity for removal). However 
it is very hard to generalize for a given technology because the performance (and thus, 
the limits) of in-situ (co-)product removal technology put in place is highly dependent 
on the physical properties of the compounds targeted for separation and the 
compounds present in the reaction phase.  
Tufvesson and co-workers have summarised the applied ISPR strategies for the 
synthesis of chiral amines using transaminase [36]. Table 8.3 lists the current state-of-
the-art for the process technologies available for ISSS, ISPR and IScPR for the synthesis 
of PEA, using IPA as amine donor. 
 
Table 8.3. Process technologies available for the production of (S)-PEA by Z-
transaminase using IPA as amine donor 
Process 
technology Motivation Options Disadvantages 
ISSS 
APH feed 
Avoid inhibition of the 
biocatalyst 
Fed-batch 
Limited by the concentration 
in the feed; 
Mixing 
Resins Neutral polymeric resin Competition with PEA 
Organic solvents 
Decrease of the enzyme 
stability; 
Competition with PEA 
ISPR 
PEA 
removal 
Avoid inhibition of the 
biocatalyst; 
Shift the thermodynamic 
equilibrium 
Resins 
Neutral polymeric resin Competition with APH 
Ion-exchange resin Competition with IPA 
Organic solvents 
Decrease of the enzyme 
stability; 
Competition with APH 
IScPR 
Acetone 
removal 
Shift the thermodynamic 
equilibrium 
Cascade Enzymes: ADH and GDH/FDH* 
DSP;  
Cost of the enzymes and 
cofactor 
Stripping Simultaneous removal of APH (at high [APH]) 
* This enzymatic cascade converts acetone into isopropyl alcohol. It requires the use of cofactor (NAD(P)H) 
and a final electron acceptor (glucose or formate, respectively) for cofactor regeneration; ADH – alcohol 
dehydrogenase; GDH – glucose dehydrogenase; FDH - formate dehydrogenase  
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Regarding acetone removal (IScPR), the usually applied technologies explore the 
difference in the vapour pressure (gas swiping or operating in vacuum), enzymatic 
cascade for conversion of acetone into isopropyl alcohol (Figure 8.9) and/or membrane 
technology. Acetone stripping or evaporation can be used to reduce acetone 
concentration in the reactor [269,270]. However, to achieve a low acetone 
concentration in the reaction phase, the amount of water that needs to be evaporated 
will ultimately be too high for a feasible process. Moreover, the required gas flow 
required for stripping will be enormous, which makes the scale-up uneconomical due 
to the costs of the gas compression. Other IScPR strategies such as enzymatic cascade 
reactions are potentially suitable when it is necessary to remove the co-product to 
very low concentrations [271]. For instance, ketoreductases used for co-product 
reduction to a secondary alcohol are active even at low co-product concentrations 
[237]. The relative biocatalytic activity of all the enzymes in the cascade can be 
adapted to the process needs by adjusting the biocatalyst amounts in the system. On 
the other hand, enzyme cascades will add to the process cost and need to be 
compatible with the process conditions for ω-transaminase reaction.  
 
Figure 8.9. Z-Transaminase-catalysed synthesis of (S)-1-phenylethylamine with IPA as 
donor. The equilibrium displacement is attained by applying yeast alcohol 
dehydrogenase (YADH) and formate dehydrogenase (FDH), degrading the acetone to 
isopropyl alcohol and consequent cofactors regeneration 
 
Reported ISPR and IScPR strategies and their limitations were summarised in Table 8.4. 
By combining the thermodynamic and biocatalyst constraints, it was possible to define 
the minimum requirements for ISPR and/or IScPR.  
Figure 8.10 arises from marking the limits from Table 8.4 on Figure 8.8. 
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Table 8.4. Examples found in scientific literature for process limitations for ISPR and 
IScPR. 
Process Limitation Min. concentration in the reactor (g/L) Reference 
ISPR using ion-exchange resins 3.64 [265] 
IScPR using acetone enzyme cascade 1x10-3 [269] 
IScPR using acetone stripping 5.81 x10-1 [269] 
 
 
Figure 8.10. Required concentrations of product and co-product in the aqueous phase 
applying ISPR and IScPR, respectively; Assumptions: 100 g of product produced per 
litre of reactor; reaction yield 90%. without IPA excess; Legend:  IPA solubility 
limit;  IPA kinetic limit;  PEA solubility limit;  ISPR limit (ion-exchange resin); 
 IScPR limit (acetone stripping) 
 
Figure 8.10 shows that the operating region to displace the reaction thermodynamic 
equilibrium where the process assumptions (regarding reaction yield and 
concentration) are satisfied is very dependent on the amine donor excess used. 
Operating with stoichiometric amount of prochiral ketone and amine donor is often 
preferred at large-scale production (black line in Figure 8.10). However, Figure 8.10 
shows that operating at this condition implies a small operating region where the 
assumed requirements for the performance metrics are achieved. Nevertheless, the 
operating region can be slightly enlarged if, instead of using acetone stripping to 
remove the co-product (light blue region), an enzymatic cascade is put in place. 
Further, operating with a value of co-substrate excess between the stoichiometric 
concentration and 4.5-fold excess (yellow area) can also be a suitable strategy to 
enlarge the feasibility region. Whereas operating at higher co-substrate excess will 
compromise the biocatalyst performance.  
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Step 4.3. Plot product against co-product concentration in the aqueous phase for the 
selectivity of the selected ISPR and IScPR technique  
For simplicity, so far in the presented case study the ISPR and IScPR requirements 
plotted in Figure 8.7 and Figure 8.8 are assumed highly selective. The selectivity of the 
process technology adopted can highly influence its performance. However, to date 
not many studies have explored this drawback and there is a lack of consensus in 
defining the selectivity of a given ISPR or IScPR technology. 
In this work, IS(c)PR selectivity towards product and co-product selectivity is defined 
according to Equation 8.11 and Equation 8.12, respectively. 
PEA
PEA
APH IPA Ace
PCS
PC PC PC
    
Equation 8.11 
Ace
Ace
APH IPA PEA
PCS
PC PC PC
  
Equation 8.12 
Where iPC  is the partition coefficient of the compound i and is defined according with 
Equation 8.13 to Equation 8.16. 
ܲܥ஺௉ு ൌ
ܥ஺௉ுೝ೐೘೚ೡ೐೏
ܥ஺௉ுೌ೜
 Equation 8.13 
ܲܥூ௉஺ ൌ
ܥூ௉஺ೝ೐೘೚ೡ೐೏
ܥூ௉஺ೌ೜
 Equation 8.14 
ܲܥ௉ா஺ ൌ
ܥ௉ா஺ೝ೐೘೚ೡ೐೏
ܥ௉ா஺ೌ೜
 Equation 8.15 
ܲܥ௉ா஺ ൌ
ܥ௉ா஺ೝ೐೘೚ೡ೐೏
ܥ௉ா஺ೌ೜
 Equation 8.16 
Further, the expression for selectivity (shown in Equation 8.11) can be simplified 
according to the type of ISPR used. For instance, when applying neutral polymeric 
resins or liquid-liquid extraction to remove PEA, the ISPR technology can also remove 
the substrate (APH) as these ISPR technologies exploit the hydrophobicity properties of 
the components. Hence, a negligible amount of co-product (acetone) and co-substrate 
(IPA) are removed and therefore Equation 8.11 becomes: 
PEA
PEA
APH
PCS
PC
  Equation 8.17 
In a similar way, when applying ion-exchange resins to remove the product [265], the 
property explored is the isoelectric point (i.e. the protonation level) of the aminated 
compounds (i.e. PEA and IPA). However, this technology might imply that there is 
simultaneous removal of the product and the co-substrate (amine donor) and 
therefore Equation 8.11 becomes: 
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PEA
PEA
IPA
PCS
PC
 
 
Equation 8.18 
 
Figure 8.11 shows the ISPR and IScPR requirements for different ISPR selectivity (for a 
neutral polymeric resin). In Figure 8.11 it is assumed that the co-product removal is 
performed by using a highly effective enzymatic cascade for the conversion of acetone 
to isopropyl alcohol (S=f). 
 
Figure 8.11. Required concentrations of product and co-product in the aqueous phase 
applying ISPR and IScPR, respectively with stoichiometric amounts of substrate (APH) 
and co-substrate (IPA); Assumptions: 100 g of product produced per litre of reactor; 
reaction yield 90%. Legend: highly selective ISPR S=f;  ISPR selectivity S=50; 
 ISPR selectivity S=25;  ISPR selectivity S=12.5; 
 
As expected, the use of a less selective product removal method implies a bigger effort 
to displace the thermodynamic equilibrium, which is put on the co-product removal 
side. Hence, a lower co-product concentration in the reaction phase is required in 
order to achieve the performance threshold value for the reaction yield. 
However, many of the studies reporting ISPR and IScPR efficiency for Z-transaminase-
catalysed reactions do not give a complete characterisation of the method applied and 
often only capacity or concentration in the reaction phase have been reported. For 
simplicity in the following steps we will assume highly selective methods for PEA or 
acetone removal (i.e. S=f). 
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8.3.2.5 Step 5. Determine reaction kinetics  
The previous steps are put in place to determine suitable strategies for the 
displacement of the reaction equilibrium. However, it essentially considers an optimal 
and infinitely improved biocatalyst, as the impact of the concentration of the different 
reaction compounds in the biocatalyst performance is not explored. Therefore, 
developing a process model that can describe not only the enzyme-catalysed reaction 
but also the mass transfer is of great importance in enabling evaluation of the different 
process technologies and the catalyst formulation adopted. 
Step 5.1. Plot product against co-product concentration in the aqueous phase 
The model established by Al-Haque and co-workers [267] for this reaction catalysed by 
the ω-transaminase (ATA-40 from c-Lecta) was used to set up a window of operation. 
The modelled reaction system is strongly inhibited even at low substrate 
concentrations [267]. Therefore, a substrate feeding strategy is required to keep the 
substrate concentration lower than the inhibitory limits (Table 8.3). Throughout this 
work, the concentration of APH was kept at its solubility limit (i.e. 50 mM) by applying 
a substrate feeding strategy. 
Furthermore, transaminase-catalysed reactions are often strongly inhibited by the 
product of the reaction, even at low concentrations. In order to overcome this 
challenge several different strategies can be applied such as using a multiphasic 
reaction (e.g. using a water-immiscible organic solvent or an insoluble porous resin as 
a second phase reservoir). Alternatively, this could also be addressed by modification 
to the biocatalyst itself (this option will be explored in Section 8.3.2.7). Figure 8.12 
shows the kinetic profile for an Z-transaminase-catalysed reaction for the defined 
performance conditions. 
Figure 8.12 shows the reaction specific activity for different amine donor excess at 
different concentrations of product and co-product in the reaction (aqueous phase). 
The reaction was inhibited at very low product concentrations (above 1 mM) as 
reflected by the kinetic parameters, namely in the Michaelis constant and product 
inhibition constant for PEA [267]. Therefore, a successful process requires removal of 
PEA, not only to shift equilibrium (as shown in the previous sections), but also to avoid 
product inhibition and thus achieve a higher biocatalyst yield. Further, the biocatalyst 
specific reaction rate was also affected by the concentration of acetone in solution and 
therefore IScPR should be put in place, not only to ensure a shift of equilibrium, but 
also to increase biocatalyst specific activity. 
Figure 8.12 B and Figure 8.12 C analyse the effect of co-substrate excess on the 
reaction kinetics. The kinetic model used does not consider biocatalyst inhibition at 
high IPA concentrations (higher than 5 M, [268]). Hence, catalyst specific reaction rate 
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depicted in Figure 8.12 B and Figure 8.12 C was not shown to be negatively affected at 
high concentrations of co-substrate. This is also shown in Figure 8.13. 
A 
B 
C 
Figure 8.12. Biocatalyst specific reaction rate (expressed as g product/(g biocatalyst. h)) in the 
synthesis of PEA using IPA as amine donor A using stoichiometric amount of substrate 
and co-substrate, B using 4.5-fold excess of IPA (kinetic limit), C using 17-fold excess of 
amine donor (solubility limit) 
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The contour plots shown in Figure 8.12 can be cut at a single defined value of 
biocatalytic specific activity, giving a region where the threshold value for the specific 
activity is achieved bounded by a curve at constant specific activity  
(0.03 g product/(g biocatalyst. h), black curves in Figure 8.12). Figure 8.13 is obtained by 
overlapping the three black lines from Figure 8.12 A to C. 
 
Figure 8.13. Product and co-product concentration in the reaction phase operation 
curve for constant biocatalyst specific reaction rate 0.03 expressed as  
g product/(g biocatalyst. h) in the synthesis of PEA using IPA as amine donor. Legend:  
without IPA excess;  IPA concentration at solubility limit;  IPA 
concentration at kinetic limit 
 
In Figure 8.13, the red shaded area represents the operating space of different 
combinations of product and co-product concentrations where the biocatalyst specific 
activity is lower than the threshold value defined by the performance metrics (see 
Section 5.2.1) and thus, not a feasible region. The white area represents the range of 
combination of product and co-product concentration that satisfies the threshold 
value for the specific reaction activity (i.e. the operating area where the specific 
reaction activity is higher than 0.03 g product/(g biocatalyst. h)). The yellow area represents 
the enlargement of the feasible space when operating with a value of co-substrate 
excess between the stoichiometric concentration (no excess) and 4.5-fold excess 
(yellow area). 
 
8.3.2.6 Step 6. Generate an window of operation 
A window of operation can be obtained by superimposing Figure 8.10 and Figure 8.13, 
resulting in a window of operation (Figure 8.14) bounded by the different technology 
constraints and process threshold values. Windows of operation can graphically show 
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the operating conditions where the process can be operated to meet the defined 
metrics.  
 
Figure 8.14. Operating space for the synthesis of PEA using soluble ω-transaminase (no 
window of operation can be found); Assumptions: 100 g of product produced per litre 
of reactor; 90% reaction yield; 0.03 g product/(g biocatalyst. h) of required biocatalyst 
activity. no IPA excess  IPA solubility limit; Legend:  IPA kinetic limit;  
PEA solubility limit;  ISPR limit (ion-exchange resin);  IScPR limit (acetone 
stripping);  constant specific activity at no IPA excess (0.03 g product/(g biocatalyst. h)) 
 constant specific activity at IPA solubility limit;  constant specific activity at IPA 
kinetic limit; 
 
When acetone stripping is used to remove the co-product (Figure 8.14), no window of 
operation can be found, since the required concentration of acetone in the reaction 
phase is lower than the reported concentration obtained by applying this IScPR [269]. 
However, when enzymatic conversion of acetone is put in place (Figure 8.15), the 
concentration of acetone in the aqueous media can theoretically be maintained at a 
much lower level by adjusting the amount of the enzymes involved in the acetone-
conversion cascade, matching their activity with the transaminase-catalysed reaction. 
Changing the IScPR technique enables a window of operation (white area in Figure 
8.15) for the studied reaction.  
However, the specific reaction rate considered in Figure 8.14 and Figure 8.15 does not 
meet the assumed requirements for an economically viable process, as the specific 
activity is far too low (0.03 instead of 1 g product/(g biocatalyst. h)). In other words, at the 
current biocatalyst development stage the cost contribution of the biocatalyst to the 
production costs is preventing an economically successful process. Hence, in order to 
attain an economically viable process it is necessary to improve the biocatalyst specific 
activity to successfully operate under more demanding operating conditions. The 
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benefits of altering the biocatalyst, as well as other process options, will be explored in 
the next section. 
 
Figure 8.15. Window of operation for the synthesis of PEA using soluble  
ω-transaminase; Assumptions: 100 g of product produced per litre of reactor; 90% 
reaction yield; 0.03 g product/(g biocatalyst. h) of required biocatalyst activity. Legend:  
no IPA excess  IPA solubility limit;  IPA kinetic limit;  PEA solubility limit; 
 ISPR limit (ion-exchange resin);  IScPR limit (enzymatic cascade);  constant 
specific activity at no IPA excess (0.03 g product/(g biocatalyst. h))  constant specific 
activity at IPA solubility limit;  constant specific activity at IPA kinetic limit; 
 
8.3.2.7 Step 7. Perform scenario analysis 
In this step, a scenario analysis (i.e. what-if analysis) including a study of the effects of 
operating with a different catalyst formulation, improvement of the biocatalyst by 
genetic engineering, the improvement of the ISPR and IScPR technologies and 
modifying thresholds for performance metrics, is carried out. 
Catalyst formulation 
In the previous step, it is stated that the current specific activity of the catalyst is two 
orders of magnitude lower than desired for an economically viable process. Hence, 
with the present state-of-the-art it is not possible to obtain an operating space where 
the process is feasible and economically competitive when soluble-enzyme (ATA-40,  
C-Lecta, Germany) is used as the biocatalyst. One option to obtain an economically 
competitive process is to replace the used soluble-enzyme, by another more stable 
biocatalyst formulation of the same enzyme, e.g. whole-cell or immobilised enzyme.  
The required catalyst specific reaction rate would then be 0.01 and 0.007  
g product/(g biocatalyst. h), assuming a biocatalyst yield of 10 and 200 g product/g biocatalyst [16], 
respectively and that the catalyst could be recovered and recycled 10 and 300 times, 
respectively (see Section 5.2.1). Mass transfer limitations, biocatalyst interface 
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limitation and possible adjustments of the biocatalyst kinetics have not been 
considered here, since the aim is to provide a quick evaluation of other process 
strategies. 
By applying enzymatic cascades for conversion of the co-product and shifting the 
equilibrium, the window of operation becomes limited on the left-hand side by ISPR, 
on the right hand side by the product (PEA) solubility and on the top by the reaction 
kinetics (Figure 8.16). 
A
B 
Figure 8.16. Window of operation for the synthesis of PEA using soluble  
ω-transaminase; Assumptions: 100 g of product produced per litre of reactor; 90% 
reaction yield A using whole-cell (biocatalyst specific activity 0.01 g PEA/(g biocatalyst. h)); B 
using immobilised (biocatalyst specific activity 0.007 g PEA/(g biocatalyst. h)) Legend: no 
IPA excess  IPA solubility limit;  IPA kinetic limit;  PEA solubility limit;  
ISPR limit (ion-exchange resin);  
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Engineered Catalyst 
Improved mutants are likely to provide a larger window of operation, allowing higher 
substrate and product concentrations and improving the process economy since 
higher biocatalyst specific activities can be attained (and consequently operating at 
higher space-time yield). In particular, for the base case analysed here, it could ensure 
the technical feasibility of the process. Figure 8.17 shows the effect of enzyme 
engineering on the process feasibility. 
A
B 
Figure 8.17. Window of operation for the synthesis of PEA using soluble improved ω-
transaminase; Assumptions: 100 g of product produced per litre of reactor; 90% 
reaction yield; with stoichiometric amount of substrate and co-substrate;  
1 g PEA/(g biocatalyst. h)) A 30-fold specific activity improvement; B 40-fold specific activity 
improvement. Legend: no IPA excess  IPA solubility limit;  PEA solubility 
limit;  ISPR limit (ion-exchange resin);  
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When considering developing the catalyst, the goals should be as defined as possible in 
order to screen effectively. In the situation presented in Figure 8.17, apart from 
overcoming low specific activity and inhibition patterns at final product concentration, 
one should also consider the effect of other components in the reaction phase, such as 
the reaction components interfering in the acetone conversion cascade (Figure 8.9). 
Further, the project developer (both process and the biocatalyst engineer) should not 
only consider the biocatalyst specific activity at the relevant reaction conditions (e.g. 
neutral pH), but also other scenarios should be evaluated. For instance, when 
operating the process at a higher pH, the differences in isoelectric point between the 
aminated compounds (i.e. co-substrate and product) are notable, enabling a more 
effective and selective separation of the compounds. Hence, other operating 
conditions not natural to the biocatalyst (but that might improve the process 
performance) must be considered at this stage alongside the biocatalyst development 
at these new operating conditions. 
Hence, engineering the biocatalyst for a scalable and industrially successful process 
starts by defining the goal, such as increasing stability, selectivity or (often) both [65]. 
However, for a more cost-efficient development, the operating conditions should be 
defined simultaneously with the enzyme engineering goal. In other words, the goal 
cannot be simply “achieve 1 g PEA/(g biocatalyst. h))”, but instead “achieve  
1 g PEA/(g biocatalyst. h)) at 100 g/L of final product concentration, with the required 
concentration of substrate and co-substrate to achieve 90% reaction yield, at given pH 
and in the presence of acetone conversion  cascade (i.e. isopropyl alcohol, formic acid 
and NAD(H), see Figure 8.9). In addition, trade-offs between the threshold values for 
the process metrics (setting the threshold value for the biocatalyst activity and the 
reaction conditions) and the biocatalyst engineering efforts should also be studied in 
order to set realistic targets for development that can be achieved in a reasonable 
timespan. 
Modify ISPR 
Operating the process with a highly effective and selective in-situ co-product removal 
technique enlarges the operating space, as shown in Figure 8.15, Figure 8.16 and 
Figure 8.17. The same can be applied to the ISPR technique used. For instance, the use 
of charged membranes constitutes a promising technology to selectively remove the 
chiral amine from the reaction medium, as the properties explored by this particular 
technology are the molecule size and the isoelectric point of the compounds present in 
the reaction medium [272]. Figure 8.18 shows how the operating space can be 
enlarged when operating with an improved ISPR (10-fold improvement) and an 
enzymatic cascade for acetone conversion. 
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The window of operation is still only limited by the biocatalyst kinetics and by the 
minimum concentration of product in the aqueous phase by ISPR (black and blue lines, 
respectively). However, there is a significant enlargement of the window, making the 
process operation easier to implement. 
 
Figure 8.18. Window of operation for the synthesis of PEA using engineered  
ω-transaminase (40-fold improvement) with simultaneous removal of product and co-
product using improved ISPR (10-fold improvement) and acetone removal for 
displacement of the reaction equilibrium and overcome product inhibition 
 
Threshold for performance metrics 
Naturally, the assumptions made (see Section 5.2.1) in defining the threshold for the 
performance metrics have a great influence on the window of operation. In this 
section, the effect of operating at different reaction yields, reaction times (i.e. space-
time yield) and final product concentrations will be evaluated in turn. By doing so, the 
process engineer can assess the trade-off between operating at higher process 
performance and the required development. 
Reaction yield 
Operating at a higher reaction yield decreases the production costs associated with the 
raw materials and simplifies the downstream process. However, for 
thermodynamically challenged reactions, operating at a higher reaction yield implies a 
higher effort to displace the equilibrium towards the product side. 
Figure 8.19 shows the substrate excess required when the reaction yield desired for 
the process increases from 90% to 95%. 
Figure 8.19 clearly indicates that operating at a higher reaction yield is substantially 
more challenging, as an increase in 5% of the reaction yield implies the use of double 
the amount of co-substrate in excess to displace the reaction equilibrium. The same 
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trend is observed when other strategies for equilibrium shifting, such as selective 
removal of product or co-product, are considered (Figure 8.20). 
 
Figure 8.19. Required IPA excess to shift the thermodynamic equilibrium at fixed 
reaction equilibrium constant (Keq=0.033) aiming different reaction yield 
A
B 
Figure 8.20. Required IPA excess at varying concentrations of A product and B co-
product in the aqueous phase applying ISPR and IScPR, respectively; Assumptions: 100 
g of product produced per litre of reactor; reaction yield 90% and 95% yield. Legend: 
 IPA solubility limit;  IPA kinetic limit;  PEA solubility limit (42 g/L, [36]) 
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When simultaneous removal of product and co-product is considered as a strategy to 
shift the equilibrium, the choice of IScPR technique put in place and the co-substrate 
excess used is crucial to ensure process feasibility (Figure 8.21). 
 
Figure 8.21. Required concentrations of product and co-product in the aqueous phase 
applying ISPR and IScPR, respectively; Assumptions: 100 g of product produced per 
litre of reactor; reaction yield 90%. Legend: without IPA excess  IPA solubility 
limit;  IPA kinetic limit;  PEA solubility limit;  ISPR limit (ion-exchange resin); 
 IScPR limit (acetone stripping) 
 
Figure 8.21 shows that operating at a stoichiometric amount of both substrates implies 
that more effective technologies to remove the co-product must be put in place in 
order to allow an operating region. Further, when the IScPR technology chosen for the 
removal of co-product cannot achieve the required concentration, it is necessary to 
operate with co-substrate excess, leading to a more challenging downstream process, 
and a negative impact in the overall production costs (due to an increase in cost 
contribution for the raw materials). 
Figure 8.22 shows the operating region for the engineered catalyst (considered 
previously) and assumes that a low concentration of acetone can be achieved in the 
reaction phase, by employing the use of selective enzymatic cascades. Figure 8.22 also 
shows that operating at higher yield implies a size reduction of the window of 
operation, when compared with the situation evaluated previously in Figure 8.17. The 
window is limited on the right by kinetic limitations, on the left by the effectiveness of 
the method for the product (PEA) removal, from above by the thermodynamic 
equilibrium (unless the use of product excess is considered) and from beneath by the 
IScPR method employed and its effectiveness in removing the co-product (acetone) 
from the reaction phase. 
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Figure 8.22. Window of operation for the synthesis of PEA using soluble improved ω-
transaminase; Assumptions: 100 g of product produced per litre of reactor; 90% 
reaction yield; with stoichiometric amount of substrate and co-substrate; 1 g PEA/(g 
biocatalyst. h)) 40-fold specific activity improvement. Legend: no IPA excess  
IPA solubility limit;  PEA solubility limit;  ISPR limit (ion-exchange resin); 
 
In the present case, further improvement of the biocatalyst specific activity can only be 
justified if the use of a stoichiometric concentration of the co-substrate (IPA) is 
considered, alongside with the use of a more effective PEA removal method. 
Reaction time 
The reaction time is an important constraint for an industrially viable process as it 
reflects directly on the capital costs and utilities costs. Regarding the operation itself, 
the reaction time determines how effective the catalyst needs to be, i.e. it determines 
the threshold value for the biocatalyst specific activity throughout the whole batch 
time, assuming a constant biocatalyst yield. 
In this scenario, it is considered that the reaction time was reduced 4-fold when 
compared with the base case (24-hour batch time). This situation implies a 4-fold 
higher space-time yield and a specific activity of 4 g PEA/(g biocatalyst. h)). It is obvious that 
the catalyst activity needs to be developed more than 40-fold as considered in the 
previous scenario. Figure 8.23 shows the operating space for a 100-fold improved 
biocatalyst activity. Figure 8.23 shows that the operating region is mainly limited by 
the reaction kinetics. The expansion of the operating region is dependent on the 
activity improvement of the catalyst and on a later development strategy for the ISPR 
technique in order to reach lower concentration of product in the reaction phase. 
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Figure 8.23. Window of operation for the synthesis of PEA using soluble improved ω-
transaminase; Assumptions: 100 g of product produced per litre of reactor; 90% 
reaction yield; biocatalyst specific activity of 4 g PEA/(g biocatalyst. h)) for 100-fold specific 
activity improvement. Legend: no IPA excess  IPA solubility limit;  PEA 
solubility limit;  ISPR limit (ion-exchange resin); 
 
Final product concentration 
Finally, the last process performance metric that has strong influence on the process 
costs is the final product concentration, i.e. the amount of product produced per litre 
of reactor over a batch time. The reason for defining final product concentration in 
such a way is, that when applying ISPR, it is desired that the final product 
concentration in the reaction phase is low. However, when this technique is put in 
place, the downstream process is often facilitated and often resulting in no overall 
increase of operating costs.  
As mentioned earlier (see Step 2., Section 8.3.2.2), the maximum IPA excess used is a 
function of the final product concentration defined as performance threshold (Figure 
8.6). Aiming at lower final product concentration implies that the maximum allowable 
co-substrate excess increases. Based on the cost of the substrate and the effort 
required to recycle it, the process engineer can decide to operate at a larger IPA 
excess, in order to decrease the effort on the ISPR and IScPR side to displace the 
equilibrium (Figure 8.6). Figure 8.24 shows the operating space for a 40-fold improved 
biocatalyst activity and applying ISPR and IScPR. 
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Figure 8.24. Window of operation for the synthesis of PEA using soluble improved ω-
transaminase; Assumptions: 50 g of product produced per litre of reactor; 90% 
reaction yield; biocatalyst specific activity of 1 g PEA/(g biocatalyst. h)) for 40-fold specific 
activity improvement. Legend: no IPA excess 50 g/L no IPA excess 100 g/L  
IPA solubility limit;  PEA solubility limit;  ISPR limit (ion-exchange resin); 
 
From Figure 8.24 it can be concluded that there are no major benefits in operating at 
lower final product concentrations, since at the current state-of-the-art, the 
biocatalyst is equally inhibited at both concentrations, resulting in a similar kinetic 
profile. Regarding the effort for equilibrium shifting it is clear that operating with lower 
final product concentrations implies that more effective ISPR and IScPR methods are 
necessary, since a lower product and co-product concentration is required in the 
reaction phase. Hence, the window of operation is limited by the kinetic profile of the 
catalyst used (right-hand side), the effectiveness of the ISPR and IScPR technologies 
applied (left-hand side and beneath) and thermodynamics and the co-substrate excess 
used for displacing the equilibrium (above). 
From the scenario analysis, it is clear that independently of the strategy chosen, for an 
economically viable process, the biocatalyst must be engineered, i.e. the specific 
activity must be enhanced at least 40-fold. Further efforts in engineering the 
biocatalyst, must be carefully considered alongside the improvements in process 
technologies used (e.g. ISPR and IScPR techniques), as these become new constraints 
bounding the window of operation together with the thermodynamic limitations. 
Finally, a last step of this methodology should include a sensitivity and uncertainty 
analysis in order to identify the optimal operating space within the window, where the 
output variable (e.g. process performance metric for costing or environmental impact) 
is minimised. 
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8.4 Concluding remarks 
The windows of operation tool presented in this chapter proved to be a valuable and 
convenient tool to quantify and visualise process performance and feasibility where 
interactions between process technologies and biocatalyst performance (or reaction) 
are significant. In principle, this methodology is generic. The scenario analysis in this 
methodology identifies the need for biocatalyst and process development (ISPR and 
IScPR). Furthermore, this tool can be extended to evaluate the sensitivity of each 
constraint in turn, pinpointing those that have the greatest impact on process 
feasibility as well as providing an initial estimate of the process costs. 
A true integration of process modelling (i.e. kinetic modelling with dynamic models for 
ISSS, ISPR and IScPR) would also be beneficial for a more correct assessment of the 
process, since at the current stage the mass transfer phenomena were considered 
independently from the reaction kinetics. Furthermore, the kinetic model used in this 
case study only takes into account the biocatalyst specific activity, whilst stability was 
disregarded. Hence, it would be of great value to understand the effect of the 
operating conditions on the stability of the catalyst, in order to better predict the 
process performance. 
Despite an increasing number of studies reporting improvements in the process 
performance by applying ISPR [68,273-278], a systematic (or short-cut methodology) 
to select the appropriate separation method is not yet in place. A systematic 
procedure that is able to select suitable separation methods confidently and rapidly 
would reduce the development time and help to focus on a given separation 
technology [49]. In addition, it will be greatly valuable that for each separation 
method, we could assign with a certain degree of confidence in the achievable (co-
)product concentration in the reaction phase and thus, using the required (co-)product 
concentration as input to ISPR technology selection. 
The structured approach presented in this chapter requires a profound knowledge of 
the process and it is based on a deep characterisation of the reaction, biocatalyst and 
process technologies put in place. Such characterisation requires obtaining data by 
reference to past information (i.e. scientific literature research) regarding suitable 
reaction systems (i.e. amine donors); experimental data collection to characterise the 
reaction (both in terms of the thermodynamic equilibrium and in the reaction kinetics); 
and data collection regarding the IS(c)PR technologies available. Hence, it is necessary 
to expand the information reported in the scientific literature and in the databases. In 
addition, it is essential to develop short-cut methodologies in order to select quickly 
between different process technologies, e.g. selection of ISPR technique based on the 
required product concentrations in the reaction phase. 
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This methodology allows the process engineer to identify the main process bottlenecks 
for an economically viable process implementation and provides a simple and 
straightforward way to analyse the outcome of the potential (but likely) improvements 
in the biocatalyst and process design. Furthermore, the methodological approach 
presented can be regarded as a feasibility analysis of different available process 
technologies, while assisting during data collection. Hence, the methodology 
constitutes a useful tool that provides interpretable results to enable rational design 
choices. Furthermore, this tool can be used to direct future research and assist in the 
evaluation of different process options on the process performance. However, 
integrating the cost of development of a given technology would be of great value in 
this tool. For example, the development of in-situ separation technologies does not 
have the same cost as developing an improved catalyst. 
For innovative compounds (such as new pharmaceutical compounds) where the speed 
of development leads to process success, this methodology is able to detect in a 
straightforward and prompt manner unfeasible routes, where either the process 
requirements are too demanding (e.g. high demand for product removal from the 
aqueous phase for displacing the thermodynamic equilibrium), or the biocatalyst still 
requires a substantial development (low specific activity). 
Moreover, the use of ‘windows of operation’ methodology can also assist in 
implementing a quality by design (QbD) in the production process as this methodology 
integrate the impact of raw materials and process parameters on product quality and 
process performance, as well as provide guidelines for a continuous monitoring of the 
process to assure consistent quality and a constant performance over time. 
When applied to the chiral amine synthesis using ω-transaminase, two major 
bottlenecks were identified:  
1. The biocatalyst needs to be engineered, since its specific activity needs to be 
improved at least 30-fold in line with the defined process metrics in order to obtain 
a window of operation and; 
2. The feasibility of the window of operation is dependent on the minimum 
concentration achievable by employing suitable ISPR and IScPR technologies. 
Hence, highly selective ISPR and IScPR techniques must be explored (S>50, as 
defined in the Equations 8.11 – 8.16), as the size of the window of operation is 
defined by the effectiveness of ISPR and IScPR.  
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9.1 Introduction 
As observed for homogeneous and heterogeneous catalysis, biocatalysts respond very 
sensitively to changes in reaction conditions, imposing a multivariate non-linear 
problem for optimising biocatalyst yield and productivity. Traditionally, in order to 
optimise the reaction conditions, a range of reaction conditions (e.g. pH, temperature 
and concentrations) and all the reaction components (i.e. substrate(s), product(s), 
cofactor(s), buffer(s), additive(s), solubiliser(s), etc.) must be considered. Such an 
approach leads to the generation of a large sampling space, which might imply that a 
vast number of experiments need to be carried out, often exceeding the experimental 
capacity (and time). In such cases, process modelling can help to reduce the 
experimental effort and quickly assess process alternatives or improvement strategies.  
The use of process models has long been established in the chemical industry. 
Specifically, for biocatalytic processes, process modelling is an established engineering 
tool towards an effective process implementation, process control, selection and 
operation of the process technologies [267]. Different methodological approaches 
have been proposed to guide mathematical modelling for biocatalytic processes in a 
one-step reaction system (e.g. [267]), multi-enzyme processes (e.g. [101]) and whole-
cell catalysed processes (e.g. [279]). Such models pose an excellent opportunity to 
assemble the available process knowledge, translated into process-relevant input 
(typically process variables) and output (process metrics) relationships that establish 
an optimal design space [100]. By using process models different scenarios can be 
investigated in-silico, reducing the number of time and resource consuming 
experiments. Hence, the use of mathematical modelling in the context of process 
development (and in particular for reaction engineering) can assist in the later 
development stages prior to pilot plant tests. Nevertheless, it is necessary to address 
the range of conditions (or scenarios) to which the model can be extrapolated. The 
extrapolation capacity of the process modelling is crucial, in order to avoid scoping for 
optimal scenarios where the model cannot predict the process behaviour. Therefore, 
at a later stage, extra experimentally collected data is required in order to validate the 
model-identified scenarios [100]. 
When applying process modelling, it is important to target on which performance or 
process metric the process development should be focused. For instance, the targets 
can be based on imposed space-time yield (STY), biocatalyst yield, reaction yield 
and/or product concentration, in order to improve the process economic performance 
(by reducing production costs), or ameliorate the process environmental profile. 
However, by putting the emphasis on improving one single process metric (or 
optimisation goal, such as TTNcofactor) when aiming at optimising the reaction 
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conditions, one can fall into unidentified trade-offs leading to less economic and 
environmentally-friendly processes (see Table 5.3). By applying a bottleneck analysis 
(Figure 9.1), as a tool to evaluate the effect of modifying the reaction conditions on the 
performance metrics, the main process bottlenecks can be identified. In addition, 
suitable operating conditions can be proposed where these bottlenecks can be 
(partially) overcome.  
 
9.2 Methodological framework 
The proposed routine for bottleneck analysis is a structured approach to improve and 
develop a process based on pre-existing knowledge. Ideally, this information is 
gathered following the process development guidelines suggested by previously 
applied development tools, such as cofactor and interaction matrices (Chapter 7) and 
windows of operation (Chapter 8). By doing so, the process model is built closer to the 
expected operating conditions at full-scale and its extrapolation capacity is thus more 
reliable. 
A methodological approach for the bottleneck analysis (Figure 9.1) proposes 
combining evaluation tools (economic and environmental analysis) with the predictive 
capabilities of process modelling by putting in place a series of ‘what-if’ simulations 
(scenario analysis) to identify optimised operating conditions. The key development in 
this methodology is the structured framework, rather than the tools put in place (see 
Section 3.2). 
 
9.2.1 Step 1. Define flowsheet, mass and energy balances 
In the first step of the bottleneck analysis, the information gathered in “Step 2. Define 
process constraints” of the generic methodological approach (see Figure 5.1) is put 
together in the form of a flowsheet (or several flowsheets). These flowsheet(s) include 
published scientific literature and/or the original process design. In order to compare 
these different process flowsheets it is necessary to calculate the corresponding mass 
and energy balances that characterise each operating unit of the flowsheet. 
 
9.2.2 Step 2. Process evaluation 
Tools for performance evaluation (i.e. economic and environmental assessment tools, 
see Section 4.2) are used in order assess process feasibility in terms of cost and 
environmental impact. Based on the assessment results the main cost drivers and/or 
contributors to the environmental profile (i.e. the process bottlenecks) are identified. 
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9.2.3 Step 3. Process debottlenecking 
The identified bottlenecks undergo a scenario analysis to evaluate the benefit of 
overcoming these. At this stage, reliable processing models can greatly assist in this 
task, since they allow a prompt evaluation of changes in the system (without the need 
for expensive and time-consuming experimental evaluation).  
 
9.2.4 Step 4. Identify potential flowsheets and strategies for 
development 
By using the methods described above, the potential of a process flowsheet for scale-
up can be evaluated. Potential process flowsheets, improved operating conditions and 
designs can be identified by using the analysis in Step 3. Hence, development efforts 
and targets for future research are identified. 
 
9.3 Case study 3: Chiral aliphatic alcohol production using 
alcohol dehydrogenase 
To demonstrate the proposed methodology, the synthesis of (R)-2-octanol from 2-
octanone using ADH as the biocatalyst was used as a case study.  
The unique enantio-, regio- and stereo-selectivity of enzymes makes biocatalysis a 
promising technology, in particular for the fine chemical and pharmaceutical sectors. 
Chiral aliphatic alcohols are of special interest to these industries as they are widely 
applicable as building blocks for functionalised products [280]. The biocatalytic 
production of enantiopure alcohols displays several advantages when compared with 
the well-established chemical reaction routes, since it avoids the need for transition 
metals, high pressures and high temperatures [281]. Moreover, when compared with 
other chemical routes like the Corey-Bakshi-Shibata (CBS) reduction, biocatalysis can 
avoid the use of borane and an expensive chiral oxazaborolidine as catalyst [282]. The 
biocatalytic synthesis of enantiopure alcohols can be achieved either by kinetic 
resolution using hydrolases [14] or by direct asymmetric synthesis by employing 
alcohol dehydrogenases (ADH, Figure 9.2). Due to the fact that the production of chiral 
alcohols by kinetic resolution is hampered by the maximum yield of 50%, the 
asymmetric synthesis route has been regarded with great interest. 
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Figure 9.2. Model alcohol dehydrogenase catalysed reaction *chiral centre 
 
Long-chain enantiopure alcohols (like (R)-2-octanol) are of particular interest in the 
fine-chemical sector due to their surfactant properties and have been used during the 
production of liquid crystals [280]. However, the large-scale production of chiral 
alcohols using ADH encounters several challenges, such as: requirement of expensive 
cofactor (requiring the implementation of effective cofactor recycling); industrially 
attractive products are often poorly water soluble ketones (leading to low 
productivity) and; the separation of the chiral alcohol from the reaction medium might 
be a laborious task. 
 
9.3.1 Biocatalyst considerations 
In recent years, the R-selective alcohol dehydrogenase from Lactobacillus brevis 
(LbADH, EC 1.1.1.2) has proven to be an attractive and outstanding biocatalyst for the 
enantioselective reduction of ketones, due to its wide substrate scope and high activity 
and stability in non-conventional reaction media (such as organic solvents, supercritical 
fluids and ionic liquids) [283]. LbADH requires NADP(H) as a cofactor, which is more 
expensive [130] and less stable [230] than NAD(H) and thus requires even more 
effective in-situ cofactor regeneration. Electrochemical methods for in-situ cofactor 
regeneration were proven to strongly affect the biocatalyst stability and reaction 
enantiomeric excess (ee) [283], and thus enzymatic cofactor regeneration can arise as 
suitable alternative for effective in-situ cofactor regeneration. 
 
9.3.2 Reaction considerations 
Enzymatic in-situ cofactor regeneration (in a network structure reaction) is a suitable 
alternative. NADP(H)-dependent glucose dehydrogenase (GDH) from Bacillus sp. (EC 
1.1.1.47) was proven suitable for cofactor regeneration using glucose as the electron 
donor [284-286] (Figure 9.3). However, due to the stoichiometric formation of gluconic 
acid (from spontaneous hydrolysis of glucono δ-lactone, Figure 9.3), it is necessary to 
implement a tight pH control strategy. 
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Figure 9.3. Biocatalytic production of (R)-2-octanol using LbADH; 1 2-octanone, 2 (R)-2-
octanol, 3 D-glucose, 4 Glucono δ-lactone (GDL), 5 D-gluconic acid 
 
9.3.3 Process considerations 
In order to overcome the low solubility often displayed by many of the industrially 
suitable ketones, the use of two-liquid-phase systems was already demonstrated 
[280,287]. However, products are often separated from the organic phase via 
distillation, implying high energy requirements [285]. Ionic liquids (ILs) have been 
discussed as a promising alternative to the two-phase systems, since they increase the 
solubility of the reaction components while improving activity, stability and selectivity 
of the biocatalysts [288-290]. Further, the use of a hydrophilic IL as a solubiliser was 
shown to increase the stability of cofactors [291].  
There is a vast number of potential ILs to be used as solubilisers in biocatalytic process. 
However, to date, there is neither a rational approach nor enough reported data to 
assist the selection. However, some important considerations are solubilisation 
properties, enzyme activity and stability, effect on product recovery and mass transfer 
limitations [284]. Previous studies have reported that the use of 10% (wt.) of 
AMMOENGTM 101 (AM-101) can increase nearly 11-fold the solubility of 2-octanone 
(from 7.9 mM to 94 mM [284]) with significant increase in activity and stability and 
lower product and substrate inhibition than observed in the buffer [284]. However, 
further increase in the IL concentration (to 20%) leads to a lower activity [284] and 
increases the solution viscosity, leading to problems in the equipment (pumps and 
membrane reactor) [285,286]. 
Due to the low solubility of long-chain chiral aliphatic alcohols, even when adopting ILs 
as solubiliser, it is necessary to continuously remove the product from the stream in 
order to increase the process productivity. The separation of long-chain chiral aliphatic 
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alcohols (also in IL containing solutions) can be performed using supercritical carbon 
dioxide (scCO2). The use of scCO2 in biocatalytic processes has several advantages, such 
as: the fact that is a non-flammable and non-toxic solvent; it is available at reasonable 
quantities and at a reasonable cost [292]; it can be an integration point in the plant 
(i.e. the CO2 produced in other points of the production site can be captured, treated 
and conditioned for this purpose) and; scCO2 has tuneable solvent properties, by 
changing the temperature and/or pressure and the reagents and products solubility 
can vary, facilitating the separation process [293]. However, when operating with an 
aqueous phase, CO2 reacts with water to form carbonic acid and thus, lowers the pH 
of reaction media. Further, CO2 might react with the protein amino-residues forming 
carbamides with consequences for the biocatalyst stability [294]. An increase in the 
system productivity avoiding the contact of scCO2 can be attained by adsorption into a 
solid-phase (solid-phase extraction, SPE). Previous studies have reported that the use 
of polystyrene divinylbenzene copolymer-based materials can effectively remove 2-
octanol and 2-octanone (product and prochiral ketone, respectively) [285,286]. Among 
the commercially available SPE materials, HR-P (highly porous polystyrene 
divinylbenzene copolymer) was identified as the best alternative [285]. However, a loss 
in capacity was observed when using some of the screened ILs as a reaction additive, 
due to its binding to the solid-phase [285]. Furthermore, the use of an IL also increases 
the selectivity of the SPE towards the prochiral ketone [286]. Nevertheless, the SPE 
material could be reused for more than 80 cycles with a product recovery higher than 
65% [286] using either scCO2 [285] or n-heptane/ethanol mixture [286] to elute the 
substrate and product from the SPE column. By adopting the aforementioned product 
recovery strategy, the effluent stream leaving the SPE is both product and substrate 
free. 
Moreover, for an economically viable process, a high biocatalyst yield is required. To 
this end, several methods are available: immobilisation [55-57], retention by ultra- or 
nano-filtration membranes [295,296]. Immobilisation procedures still represent an 
added-cost to the process that is not always translated into more effective catalysts 
[217], whereas the immobilisation of the cofactor might only be cost effective if there 
is a significant increase of the cofactor stability [216]. Membrane technology allows a 
straightforward reuse of the isolated enzyme [209]. However the retention of cofactor 
still remains an issue. Alternatively, applying nano-filtration can partially retain the 
cofactors [296]. However, the use of these membranes can cause a problem if other 
reaction components (such as substrates, products and additives) are within the 
molecular weight range of the cofactors. Finally, the use of these membranes implies 
an increase of the utility costs (due to the high energy requirements) and the 
operational costs (due to the membrane fouling, reducing its lifetime). Due to reaction 
kinetics [285,286] the reaction was operated in a continuous mode applying two 
sequential enzyme membrane reactors (EMRs), allowing high reaction and biocatalyst 
yield.  
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9.3.4 Step 1. Define flowsheet, mass and energy balances 
Based on the aforementioned biocatalyst, reaction and process considerations, 
previous studies have focused on the choice of reaction conditions, such as selection 
and concentration of the buffer, pH, selection and concentration of ionic liquid 
[285,286], leading to a very stable and promising process with more than 1000 hours 
of continuous operation and nearly no enzyme deactivation [286] (Figure 9.4). The 
conditions for the continuous synthesis of (R)-2-octanol taken for the base case can be 
found in Table 9.1. 
 
Figure 9.4. Process flowsheet for the synthesis of chiral aliphatic alcohols using LbADH;  
ADA- N-(2-acetamido)iminodiacetic acid; Si- on-line sampling; EMRi- Enzyme 
membrane reactor i; SPE- solid-phase extraction; Continuous Batch  
Recycled stream (Adapted from [286]) 
 
9.3.5 Step 2. Process evaluation 
Evaluation tools (see Section 4.2) were used in order to identify the process 
bottlenecks. Since the optimisation goal in the adopted case study is to identify the 
reaction pitfalls and decrease the operating costs (OPEX), the economic evaluation was 
based on the cost of goods (i.e. substrates, cofactors, enzymes, solubiliser and buffer). 
Additionally, when assessing the environmental impact of the process, green chemistry 
metrics (GCM, Section 4.2.2.1) were preferred rather than assessing the process 
sustainability through LCA. Performing an LCA requires considerably more resources 
than calculating GCMs to collect, verify and analyse material inventory data [297]. 
Hence, E-factor [153,154,298] and PMI [149,150] have been chosen to evaluate the 
process environmental profile. Despite the disadvantages of these mass-based metrics 
(e.g. it does not provide a holistic viewpoint of the process and it omits specific 
environmental, health and safety concerns about the materials involved and the types 
of waste produced), these metrics are intermediate steps to calculate LCAs and 
footprints, without requiring a large investment of time and effort [297]. 
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The process performance for the base case without recycling and for the case where 
90% of the SPE effluent stream (2-octanone and (R)-2-octanol free) is recycled is 
depicted in Figure 9.5.  
 
Table 9.1. Base case conditions for the continuous synthesis of (R)- 2-octanol [286] 
Reaction Conditions 
Temperature (T) 25 oC 
pH 7.5 
Volumetric flow rate (Q) 0.004 L/h 
Vreactor 0.015 L 
Residence time (Q) 3.75 h 
Enzyme loading in EMR1 and EMR2 5.2 mg 
Maximum enzyme loading in EMR1 and EMR2 30 mg 
E1:E2* in EMR1 and EMR2 19.2% (wt.) 
Concentration in the inlet 
Substrate: 2-octanone 60 mM 
Cofactor: NADP(H) 0.1 mM 
Glucose 200 mM 
ADA-buffer 150 mM 
Solubiliser: AM-101 10% (wt.) 
Process Metrics 
Reaction Yield 84% 
STY 0.862 g/(LEMR1+EMR2.h) 
C(R)-2-octanol, EMR2 6.57 g/L (50.5 mM) 
LbADH yield EMR1+EMR2 12900 g(R)-2-octanol/gLbADH 
GDH yield EMR1+EMR2 3080 g(R)-2-octanol/gGDH 
SPE Conditions 
VSPE column 13 mL 
H/D SPE column 30 
TscCO2 45 oC 
PscCO2 8 MPa 
n-heptane/EtOH mixture 50% (vv) 
VscCO2 or Vn-heptane/EtOH 5 x VSPE column 
*E1:E2- Enzyme ratio ADH
ADH+GDH
Lb
Lb
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A 
B 
C 
Figure 9.5. Process evaluation A. OPEX B. PMI C. E-factor for the base case (without 
recycling) and with 90% recycling of the aqueous phase when the SPE is eluted with 1: 
n-heptane/EtOH mixture or 2: scCO2; Legend:   ADA-buffer,  NADP(H),  LbADH,   
GDH,  glucose,  2-octanone,  AM-101,   SPE elution (n-heptane/EtOH mixture or 
scCO2) and  gluconic acid 
 
As expected, Figure 9.5 shows that there are major economic and environmental 
benefits in recycling the 2-octanone and (R)-2-octanol free stream. By partially 
recycling the feed-stream, the overall OPEX was reduced 33%, due to lower 
consumption of the IL (AM-101) and ADA-buffer. Further, when comparing the OPEX 
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for the different SPE elution techniques, no major differences can be seen between the 
use of n-heptane/EtOH mixture or scCO2 to extract the product and unreacted 
substrate from the SPE column. However, the use of scCO2 might imply an increase of 
the equipment cost for scCO2 conditioning (i.e. heaters and compressors) and thus, 
when considering only the process costs, the final decision has to be taken according 
to the equipment available on site, the required technical efforts and the required 
purity of the final product. However, when focusing on the environmental evaluation, 
for both PMI and E-factor the use of scCO2 proves more beneficial than the use of 
organic solvents (assuming 90% of solvent recycling [154]), for the conditions stated in 
Table 9.1, the n-heptane/EtOH mixture contributes up to 3 kg/kg Product for the process 
mass requirements. 
When focusing on the OPEX (Figure 9.5 A), the cost contribution of the cofactor to the 
process economic performance is evident: 56% and 85%, for the base case (no 
recycling) and when recycling the aqueous-phase, respectively (assuming a cofactor 
cost of 10000 €/kg NADP(H) [130], see also Appendix 2). Despite the low cost contribution 
of both enzymes (LbADH and GDH), due to their exceptional activity and operational 
stability, the strictly NADP(H)-dependence of LbADH is regarded as major drawback 
[283]. Due to the lower costs and higher stability of NAD(H) [130,230], attempts have 
been made using site-directed mutagenesis to increase the NAD(H) affinity of LbADH, 
regrettably without any major breakthrough [299,300]. Hence, for the state-of-the-art 
LbADH, the optimisation goal is to improve the cofactor total turnover number 
(TTNNADP(H)) by optimising the cofactor concentration and the reaction conditions, 
yielding higher cofactor stability in order to improve the process economic profile.  
Since PMI and E-factor are process mass metrics the compounds with higher 
contribution to these metrics are those with a higher mass contribution in the overall 
process and thus, IL, ADA-buffer and glucose are the major components contributing 
to the process environmental profile. However, from a holistic life cycle perspective 
smaller mass contributors (such as cofactors) might have a higher impact in the 
environmental profile. Nevertheless, inventory data on these types of compounds is 
still scarce and difficult to model and they are often modelled using a cost allocation 
approach. Further, an important mass contributor in such a biocatalytic process is 
water. In the two scenarios depicted in Figure 9.5, the water intensity (kg water/kg product) 
was reduced 89% (from 152 kg water/kg product to 17.5 kg water/kg product). Previous studies 
focused on optimising the IL [284] and buffer [286] concentrations. Hence, the 
optimisation goal of improving the process environmental profile must be focused on 
further reducing the glucose concentration, since at the base case glucose is dosed in 
2.3-fold excess. 
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9.3.6 Step 3. Process debottlenecking 
The first target of the optimisation exercise was to reduce the operating costs, by 
enhancing the cofactor utilisation. There are two main strategies to enhance 
TTNNADP(H): to optimise the operating conditions in order to increase the stability of the 
cofactors and to enhance the substrate/cofactor ratio without compromising the 
process performance (i.e. reaction yield). 
In view of recycling, NADP(H) is known to have a limited stability in aqueous solutions 
[230]. In general, the cofactor stability increases when the reaction is operated at a 
lower temperature. The pH effect is dependent on the cofactor oxidation state: lower 
pH increases the stability of reduced cofactor (NADPH) and at alkaline pH oxidised 
cofactors (NADP+) are more stable [130,216]. In particular, the reduced cofactor form 
(NADPH) is less stable than the oxidised one (NADP+) at neutral pH [130,190,301]. 
Hence, in order to identify the trade-off and determine the operating pH optima, the 
half-life for both reduced and oxidised cofactor species were determined at the 
operating conditions (Figure 9.6).  
 
Figure 9.6. Half-life of  reduced (NADPH) and  oxidised cofactor (NADP+)  
as a function of pH at operating conditions  
(Susanne Leuchs, personal communication, 2012) 
 
Despite the fact that the process is operated at conditions where the decay in stability 
of the NADP+ (blue curve) is substantial, the half-life of the oxidised cofactor is longer 
than 1000 hours and higher than the NADPH half-life for the pH range studied and is 
thus not limiting. However, as previously reported [301], at neutral pH, the stability of 
NADPH can prevent successful cofactor recyclability. Hence, in order to improve the 
cofactor stability, tight pH control is required after each EMR in order to keep the 
reaction media at pH 7.5. Ideally, the pH control should be placed at the reactor, 
where conversion of glucose to gluconic acid causes a decrease in pH and thus affects 
the stability of the reduced cofactor. However, this would require a good 
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understanding of the fluid dynamics in the reactor, as well as a more vigorous agitation 
together with a lower concentration of base, in order to avoid enzyme denaturation 
when encountering an alkaline ‘hotspot’ in the reactor. In addition, operating with 
diluted acid or base for pH correction might lead to a less robust process and more 
difficult process control, due to great changes in the reaction volume. 
Finally, varying the enzyme ratio (defined as ADH
ADH+GDH
Lb
Lb
) in the reactors leads to an 
increase in the steady-state ratio of oxidised:reduced cofactor (defined as +NADP
NADPH
), 
increases the NADP+ concentration in the reaction media, allowing higher cofactor 
stability throughout the process. The effects of varying the enzyme ratio on the 
NADP+/NADPH ratio and final reaction yield (i.e. reaction yield after EMR2) were 
predicted using a previously reported process model [286] (Figure 9.7, for model 
details see Appendix 4). 
A 
B 
Figure 9.7. A Modelled NADP+/NADPH ratio leaving EMR2 and B average reaction yield 
in EMR2 as a function of enzyme ratio in EMR1 and EMR2 at the operating conditions 1 
base case conditions 2 improved conditions  
1 
2 
1 
2 
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Due to the higher cost of LbADH (in €/kg catalyst) when compared with GDH (see 
Appendix 2), a low enzyme ratio in the first reactor was selected. Further, in order to 
increase the ratio of oxidised:reduced cofactor, without compromising the reaction 
yield (and consequently the SPE step), a high enzyme ratio was selected for the second 
reactor. Unfortunately, there is no overlapping area where the high ratio of 
oxidised:reduced cofactor meets high reaction yield and thus, there was a compromise 
between these two parameters. 
In order to enhance the substrate/cofactor ratio, the cofactor concentration was 
optimised. Since the reaction rate depends on the concentration of the cofactor, a 
decrease in the concentration might lead to a lower biocatalyst specific activity (for the 
same operating conditions) and thus, lower reaction yield (for the same retention 
time). Lower reaction yields lead to a less effective process performance, due to an 
increase in the raw materials cost contribution and higher downstream processing 
costs in order to effectively separate the product and the substrate from the SPE 
elution stream. The process model previously developed could assist in this task 
(Figure 9.8). Decreasing the cofactor concentration in the feed-stream from 0.1 mM to 
0.05 mM has little impact on the reaction yield in EMR2. 
 
Figure 9.8. Model predictions (see Appendix 4) for the average reaction yield in EMR2 
as a function of the cofactor concentration in the feed-stream at improved conditions 
 
The second target of the process debottlenecking is to improve the process 
environmental profile by optimising the concentration of glucose in the feed-stream. 
Previous studies have fixed the glucose concentration in the feed-stream to 200 mM 
[280]. Glucose was provided in excess in order to shift the equilibrium of the cofactor 
regenerating reaction and to ensure a stable concentration of glucose and gluconic 
acid in the reaction. However, this reaction is not particularly thermodynamically 
challenged [197] and thus the concentration of glucose can be further reduced to the 
stoichiometric equivalent of the product concentration, without any loss in the 
reaction yield (Figure 9.9). 
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Figure 9.9. Model predictions (see Appendix 4) for the average reaction yield in EMR2 
as function of glucose in the feed-stream at improved conditions 
 
9.3.6.1 Experimental evaluation of the improved process 
Based on the identified bottlenecks and the suggested improvements for reaction 
optimisation (Table 9.2), an experimental evaluation of the improved process was 
carried out in order to validate the modelled conditions (Figure 9.10). 
 
Figure 9.10. Comparison between experimental data and modelled simulated data for 
continuous production of (R)-2-octanol Legend:  Model predictions for reaction 
yield and  cofactor concentration after EMR2 (see Appendix 4); and  
experimental reaction yield (Susanne Leuchs, personal communication, 2012) 
 
The use of process modelling, a well-established engineering tool, was shown to be 
able to predict the system behaviour at the new operating conditions for at least the 
first 800 hours (Figure 9.10). By reaction engineering the cofactor total turnover 
number (TTNNADP(H)) was improved more than 2-fold (from 500 mol(R)-2-octonol/molNADP(H) 
in the base case to 1140 mol(R)-2-octonol/molNADP(H) for the improved scenario), while 
keeping the cofactor concentration in the system stable (Figure 9.10, blue curve). 
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However, for an economically feasible process, a further 10-fold increase in TTNNADP(H) 
is required [187].  
 
Table 9.2. Suggested improved reaction conditions for the continuous synthesis of (R)-
2-octanol 
Reaction Conditions Improved conditions 
T 25 oC 
pH 7.5 
Volumetric flow rate (Q) 0.004 L/h 
Residence time (W) 3.75 h 
Enzyme loading in EMR1 6 mg 
Enzyme loading inEMR2 18 mg 
E1:E2* in EMR1 25% (wt.) 
E1:E2* in EMR2 75% (wt.) 
Component 
Substrate: 2-octanone 60 mM 
Cofactor: NADP+ 0.05 mM 
Glucose 60 mM 
ADA-buffer 150 mM 
Solubiliser: AM-101 10% (wt.) 
Process Metrics 
Reaction Yield 96% 
STY 1.00 g/(LEMR1+EMR2.h) 
C(R)-2-octanol, EMR2 7.41 g/L (57.8 mM) 
LbADH yield EMR1+EMR2 1980 g(R)-2-octanol/gLbADH 
GDH yield EMR1+EMR2 3300 g(R)-2-octanol/gGDH 
*E1:E2- Enzyme ratio ADH
ADH+GDH
Lb
Lb
 
 
Finally, the enzyme enantioselectivity was not affected at the new reaction conditions, 
as the measured ee was ≥99.5% for (R)-2-octanol in line with the previous findings 
[284-286]. 
9.3.6.2 Performance evaluation of the improved process 
In order to identify the remaining process bottlenecks a new round of performance 
evaluation was carried out (Figure 9.11). In spite of the lower biocatalyst yield (Table 
9.2) obtained for the improved process the cost contribution (1.3% of OPEX) of the 
biocatalyst is still below the recommended guidelines for fine-chemical production 
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[16]. The OPEX for the improved process falls within the upper limit of the market 
value for fine chemicals [16]. Furthermore, reaction engineering towards improved 
cofactor and glucose utilisation led to a significant (49%) decrease of the OPEX. In 
particular, the cofactor cost contribution was reduced from 83% of the total OPEX to 
73%.  
The observed decrease in the mass-based environmental metrics (PMI and E-factor) 
show the benefits of reducing the glucose concentration to the stoichiometric 
equivalent required to keep the cofactor regeneration system balanced. Moreover, the 
engineered process contributed to an improved PMI on account of the high reaction 
yield, leading to lower mass requirements of substrates and additives per mass unit of 
(R)-2-octanol produced. A further reduction of PMI and E-factor requires the 
optimisation of the ADA-buffer concentration since decreasing the IL concentration 
affects the substrate solubility and thus the overall reaction yield [284,285]. Another 
strategy to decrease PMI is to consider a different electron donor and replacing 
glucose (MW= 180.2 g/mol) by isopropyl alcohol (MW= 60.1 g/mol) [280]. However, 
this reaction system is thermodynamically challenged [302,303] and thus, an excess of 
isopropyl alcohol is required in order to achieve comparable reaction yields [280]. 
Moreover, glucose is a cheaper co-substrate than isopropyl alcohol and thus, for an 
economically viable process, the unreacted isopropyl alcohol must be successfully 
recovered and recycled back to the process. 
Despite the great improvements in performance achieved with reaction engineering 
the process is still far from being feasible and the guidelines proposed for the process 
metrics (see Section 5.2.1) were not yet achieved. In particular further research efforts 
should be focused on improving final product concentration and space-time yield, 
without compromising the reaction yield and ee, in order to avoid jeopardising the 
downstream process (i.e. SPE efficiency), as with the current process highly purified 
product can be recovered without great effort and requiring rather simple recovery 
units. 
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A 
B 
C 
Figure 9.11. Process evaluation A. OPEX B. PMI C. E-factor for the base case with 
recycling and improved conditions with 90% recycling of the aqueous phase; Legend:  
 ADA-buffer,  NADP(H),  LbADH,   GDH,  glucose,  2-octanone,  AM-101,  
SPE elution (with scCO2) and   gluconic acid 
 
9.3.7 Step 4. Identify potential flowsheets and strategies for 
development 
In view of achieving the proposed guidelines for process metrics and performance 
increases in substrate concentration and volumetric flow rates must be addressed. 
Further improvements in the process would require a reconsideration of the process, 
by adopting a new catalyst formulation, reactor and/ or solubiliser. 
Due to the restricted solubility of substrate concentration in the IL-aqueous solution, 
the concentration can only be increased within the substrate solubility limits. Hence, 
using the process model, the concentrations of 2-octanone and glucose were increased 
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from 60 mM to 94 mM, the maximum reported 2-octanone solubility at 10% (wt.) of 
AM-101. At these conditions the reaction yield was only slightly affected (94% at 
94mM), but a higher final product concentration and space-time yield was obtained. 
The improved process metrics lead to enhanced economic and environmental 
performance, due to a higher utilisation of cofactor and reaction additives (IL and ADA-
buffer, Figure 9.12). Hence, increasing the substrate concentration leads to a 29% 
decrease of the OPEX (from 72.9 €/kg(R)-2-octanol to 51.7 €/kg(R)-2-octanol), mainly as a result 
of by a 1.5-fold increase in the TTNNADP(H), resulting in a lower cofactor cost 
contribution. While less significant to the OPEX, enhanced utilisation of IL and buffer 
(per product formed) in the process contributed to improved environmental 
performance. 
A 
B 
C 
Figure 9.12. Process evaluation A. OPEX B. PMI C. E- factor at improved conditions ([2-
octanone]inlet=60mM) and improved concentrations ([2-octanone]inlet=94mM); Legend:  
 ADA-buffer,  NADP(H),  LbADH,   GDH,  glucose,  2-octanone,  AM-101,  
SPE elution (with scCO2) and   gluconic acid 
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Increasing the IL concentration leads to an increase in the solubility of the substrate 
[284]. However, the viscosity of the reaction mixture increases with increasing 
concentrations of IL, resulting in limitations in the EMR. Ionic surfactants (such as AM-
101) can interact with polyethersulfone (PES) membranes and promote its early 
fouling, reducing the membrane lifetime and thus increasing operating costs [284,286]. 
Besides, previous studies have reported a decrease in the enzyme activity and stability 
for concentrations of IL higher than 10% (wt.) [284]. Moreover, the efficiency of the 
SPE was also demonstrated to be affected by higher concentrations of IL, by affecting 
the partition coefficient and thus, the selectivity of the separation [286]. Hence, a 
further increase in the concentration requires a new round of screening for a suitable 
solubiliser, where the aforementioned selection criteria should be included. 
Achieving higher space-time yields (STY, g(R)-2-octanol/(Lreactors.h)) leads to lower capital 
costs (not accounted for here). STY can be increased when operating at high 
volumetric flow rates. However, running the process at higher flow rates implies higher 
biocatalyst loading in the reactor in order to avoid jeopardising the final reaction yield 
(Figure 9.13). Hence, there is a trade-off between the catalyst cost and the capital cost 
(here represented by STY), that must be achieved. Using the process model and 
engineering evaluation tools (economic and environmental assessment), an operating 
area where the process can be operated at high reaction yield and STY was found 
(Figure 9.13, marked with point 2).  
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A 
B 
Figure 9.13. Operating space for the synthesis of (R)-2-octanol at A EMR1 (at fixed 
EMR2 enzyme loading) and B EMR2 (at fixed EMR2 enzyme loading) at different 
volumetric flow rate and enzyme loading; 1 conditions according with Table 9.2 and [2-
octanone]inlet=94mM and 2 optimised flow rate and enzyme loading 
 
In order to get to the proposed optimised conditions the volumetric flow rate was 
fixed to a maximum of 7 mL/h since it was experimentally observed that, at a constant 
flow of 8 mL/h there is an increase in the reactor pressure, limiting the continuous 
operation of the process. A further constraint when selecting the new operating 
conditions was the amount of catalyst dosed to the reactor (in order to keep the 
catalyst cost below 5%), while keeping the enzyme ratio constant according with the 
conditions in Table 9.2. The newly identified operating conditions were evaluated in 
terms of its performance (Figure 9.14). Increasing the flow rate from 4 mL/h to 7 mL/h, 
together with simultaneous rise of the enzyme loading in both reactors, lead to an 
average reaction yield of 96% (comparable with the conditions reported in Table 9.2), 
while doubling the STY (2.73 g(R)-2-octanol/(Lreactors.h) at 7 mL/h, Table 9.3). 
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Table 9.3. Suggested improved reaction conditions for the continuous synthesis of (R)-
2-octanol (2nd round) 
Reaction Conditions Improved conditions 
T 25 oC 
pH 7.5 
Volumetric flow rate (Q) 0.007 L/h 
Residence time (W) 2.14 h 
Enzyme loading in EMR1 15 mg 
Enzyme loading inEMR2 25 mg 
E1:E2* in EMR1 25% (wt.) 
E1:E2* in EMR2 75% (wt.) 
Component 
Substrate: 2-octanone 94 mM 
Cofactor: NADP+ 0.05 mM 
Glucose 94 mM 
ADA-buffer 150 mM 
Solubiliser: AM-101 10% (wt.) 
Process Metrics 
Reaction Yield 96% 
STY 2.73 g/(LEMR1+EMR2.h) 
C(R)-2-octanol, EMR2 11.7 g/L (89.9 mM) 
LbADH yield EMR1+EMR2 1320 g(R)-2-octanol/gLbADH 
GDH yield EMR1+EMR2 1700 g(R)-2-octanol/gGDH 
*E1:E2- Enzyme ratio ADH
ADH+GDH
Lb
Lb
 
 
Despite the increase in enzyme loading (and consequently a lower biocatalyst yield, 
Table 9.3) this represents a minor contribution to the OPEX (Figure 9.14). Besides, 
when operating at higher volumetric flow rates, the amount of volume processed 
increased and there is even a small increment of the biocatalyst yield across the overall 
operating time when applying the reaction dynamic simulation. The same trend was 
observed for the cofactor utilisation (TTNNADP(H)=1780 mol(R)-2-octonol/molNADP(H)). Further, 
a more efficient reutilisation of process additives, as well as cofactor led to an 
enhanced environmental performance (Figure 9.14 B and C). Despite the small 
improvements in OPEX, a nearly 3-fold improvement in STY might have major 
implications for the capital cost, when considering a full-scale implementation. 
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A 
B 
C 
Figure 9.14. Process evaluation A. OPEX B. PMI C. E- factor for improved conditions 
and concentrations ([2-octanone]inlet=94mM) for base case flow (4 mL/h) and 7 mL/h; 
Legend:   ADA-buffer,  NADP(H),  LbADH,   GDH,  glucose,  2-octanone,  
AM-101,  SPE elution (with scCO2) and  gluconic acid 
 
Nevertheless, the main cost contributor remains the cofactor. One suggested strategy 
to lower the cofactor cost is by using NAD-kinase (EC 2.7.1.23, NADK). NADK converts 
NAD(H) (a cofactor 5-fold cheaper than NADP(H) [130]) into NADP(H), by catalysing the 
transference of a phosphate (PO43-) from (typically) ATP to NAD+ [304]. NADK has been 
used in fermentation processes to enhance the yield coefficient of the product on the 
substrate (Ysp) [305,306]. However, in the context of a biocatalytic process using 
isolated enzymes [305] the introduction of a third enzyme and expensive cofactors 
(ATP) will certainly not bring the OPEX costs down. Hence, a suitable strategy would be 
to perform the enzymatic reduction of prochiral ketones using whole-cells. Apart from 
circumventing the use of expensive cofactors, the biocatalyst cost contribution can 
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also be significantly reduced [16]. Whole-cells of recombinant microorganisms 
overexpressing LbADH have already been reported for production of chiral alcohols 
[279,307-309]. However, the regeneration of the cofactor and LbADH expression were 
identified as limiting [279]. To avoid cofactor depletion it is necessary to co-express the 
NADP(H)- dependent alcohol dehydrogenase, such as formate dehydrogenase (FDH) 
[279] or GDH [310]. As previously mentioned (in Chapter 7), one of the remaining 
challenges when operating multi-enzyme systems in a whole-cell is to be able to 
regulate the overexpression of the two enzymes. Nonetheless, due to recent advances 
in metabolic engineering and increased understanding of gene expression regulation, a 
promising future for whole-cell biocatalytic processes is foreseen [245], enabling cost-
effective processes in particular when cofactor regeneration systems are required. 
Moreover, the use of process additives, such as solubilisers, might present an 
additional challenge to the use of whole-cells, as ILs can affect the membrane integrity 
and thus, the biocatalyst stability [307,308]. 
 
9.4 Concluding remarks 
The bottleneck analysis presented in this chapter proved to be a valuable tool for 
identifying the most suitable operating conditions, overcoming initial process 
bottlenecks and ensuring a more sustainable process. Bottleneck analysis incorporates 
process modelling and engineering evaluation tools (economic and environmental 
assessment). The combined use of process modelling and evaluation tools was able to 
assist in the reaction engineering, examine optimised reaction conditions leading 
towards a decrease in the operating costs and improved environmental performance. 
The real benefit of such models when integrated with evaluation tools is that they can 
be used to predict the process performance and identify more favourable operating 
conditions without requiring experimental examination and reducing the resources 
and time for process development. 
In this chapter, bottleneck analysis has been applied to the biocatalytic synthesis of 
chiral alcohols. Overall, this methodology was able to indicate the operating conditions 
under which the OPEX is reduced 65%, from 144 €/kg(R)-2-octanol in the base case 
conditions [286] to 50.3 €/kg(R)-2-octanol, by improving cofactor utilisation, concentration 
and volumetric flow rate.  
At the current state-of-the-art, the cost of the cofactors can still prove a major 
obstacle preventing a successful large-scale implementation, as the cofactor cost 
contribution still represent 68% of the OPEX. Nevertheless, recent advances in 
recombinant DNA technology might enable the use of a whole-cell catalyst, 
circumventing the cofactor costs, which is often the most sustainable solution when 
employing biocatalysis to carry out redox reactions. 
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Furthermore, process development efforts envisaging scale-up should be focused on 
increasing the final product concentrations (at least) 10-fold by screening for a more 
efficient solubiliser, since with the current optimised scenario the final product 
concentration leaving EMR2 is 11.7 g(R)-2-octanol /L. Since the recovery step (SPE) can 
selectively and effectively remove the product and the co-product from the EMR2 
effluent stream, it is equally important to keep a high reaction yield as this leads to a 
simplified downstream process. Hence, the screening criteria for a new solubiliser 
should include: product solubility, partition coefficient in SPE, activity and stability of 
the biocatalyst (isolated enzymes or whole-cell), effect of membrane fouling (if using 
isolated enzymes) and operating constraints (e.g. viscosity). 
The structured approach for bottleneck analysis used in this case was able to:  
x Optimise the cofactor utilisation, leading to savings in the operating costs.  
x Reduce glucose requirements, leading to savings in the environmental profile; 
x Increase the system productivity (by increasing concentration and space-time 
yield), leading to a more suitable process. 
x  Nevertheless, the final product concentration is still lower than the threshold 
values established in Section 5.2.1, due to the low substrate solubility and 
therefore it is necessary to screen for a more efficient solubiliser. 
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10 General discussion 
Biocatalytic processes (as well as bioprocesses in general) have been emerging as a 
suitable replacement technology for conventional chemical synthesis (e.g. 
homogeneous and heterogeneous catalysis), driven by the need to produce chemicals 
from renewable raw materials, adopt greener synthetic routes, generate less toxic by-
products and waste without compromising product quality. Biocatalytic processes are 
of particular relevance when the current process exposes considerable safety concerns 
(e.g. oxidation reactions in organic solvents [311]), stereo- and regio- selective synthesis 
is required [312], and/or there is a need to replace noble and/or transition metal 
catalysts (e.g. Rh, Ru, Pd and Pt), which are scarce and non-renewable resources. For 
some higher value market niches, biocatalytic processes provide a unique route for the 
synthesis of the desired product [313]. However, the most common situation is that 
there are other competing routes to the same product. Thus, the success of the 
biocatalytic process is determined by its performance when compared with the 
competing technologies. This thesis has suggested that the implementation of 
biocatalytic processes is dependent on a profound knowledge of the fundamental 
considerations (reaction, biocatalyst and process) that strongly influence the process 
viability. The application of a systematic methodology, integrating the aforementioned 
considerations, is of great benefit in guiding experimental work, indicating the required 
information for decision-making and suggesting guidelines for process metrics threshold 
values to be achieved with further research efforts (such as improvement in the 
biocatalyst activity) aiming at a full-scale implementation. 
Moreover, an interesting factor for process design (although outside the scope of this 
thesis) is the speed of development of a process. Indeed, the process economics of a 
novel product may be less noteworthy than the time required to market launch or to 
pass Phase 1 and 2 of the clinical trials (for production of APIs). At this stage, the 
proposed methodology can assist in searching for the most suitable operating conditions 
and thus, speed up the initial development stage. As soon as the product comes off-
patent or after it passes the initial phases of the clinical trial the speed of development 
becomes less crucial, while identifying and decreasing the production costs becomes 
vital for the process success. Thus, at this stage the implementation of the proposed 
methodology as a structured process development approach might prove beneficial in 
implementing a competitive process at full-scale. 
 
10.1 Methodology 
Many of the underlying constraints preventing successful process implementation can 
often be tackled either by improvements in the process, in the biocatalyst, or in both. 
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Indeed, a particular feature of biocatalytic processes is the possibility of modifying and 
improving the biocatalyst by advances in biochemistry, protein chemistry, molecular 
cloning, directed evolution, random and site-directed mutagenesis [314]. Improved 
enzymes may display new tolerance to reactor conditions such as temperature or pH 
and may also have improved selectivity or reactivity (i.e. activity) on an unnatural 
substrate and/or reagent. However, most of the screening efforts to tailor the catalyst 
properties are addressing the reaction itself by expanding the enzyme toolbox for 
organic synthesis. Nevertheless, future developments in this area should be addressed 
in the context of the industrial process in which the enzyme is applied, by trying to match 
high activities with the operating conditions (such as high substrate and product 
concentrations and presence of solvents) and providing cost-effective means for large-
scale production of the biocatalyst [67].  
The proposed methodology intends to understand and identify the balance between 
biocatalyst and process development for a competitive process at large-scale (by 
proposing guideline for process threshold metrics). By adopting a methodological 
approach during the early development stage, the type of information required for 
design and decision-making is identified as well as targets for further development are 
provided (e.g. biocatalyst screening and solvent selection). This greatly enhances the 
communication between those involved in process design and the chemists, protein and 
genetic engineers. For instance, in this thesis the lack of communication between the 
different disciplines is evident when the use of large amine donor excess (often more 
than 5-fold excess) is put in place to shift the unfavourable thermodynamic equilibrium 
in transaminase-catalysed reactions. This strategy, although suitable at bench-scale, has 
proven unfeasible at large-scale due to the donor aqueous solubility and cost. 
Traditionally, developing biocatalytic processes is a time-consuming task and the holistic 
understanding of the process is limited. Solutions are designed for a specific reaction 
system and they are often non-generalizable and not able to be adapted to other similar 
systems. The current nature of process development in biocatalytic processes (Figure 
10.1 A) is particularly disadvantageous for industries that require generic approaches 
and solutions that can be applied across several processes (such as the fine and 
pharmaceutical industries [315]). However, by applying a systematic approach to the 
early development stage (Figure 10.1 B) the number of experiments can be reduced, 
since the methodological approach is able to identify the information required for 
decision-making, while providing targets and guidelines for further development. This 
methodology is particularly relevant not only for the next generation of enzyme-
catalysed reactions (see Chapter 2), catalysing particularly challenging reactions (e.g. 
reactions which are thermodynamically challenged or that involve hardly-water soluble 
substrates) where improvements in the process convey significant economic return, but 
also for multi-enzyme systems, due to their high complexity. Despite the time and 
resources consumed during in-silico process development and model implementation, 
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it is expected that the overall process development time is reduced, since these can 
provide a basis for experimental design, shortening the time spent in the laboratory 
(Figure 10.1 B). Furthermore, process modelling (including kinetic modelling) can be 
exploited to analyse potential scenarios at full-scale (Figure 10.1 B). In this way, the 
overall time and resources spent in the process development before pilot plant 
implementation is reduced. 
 A 
 B 
Figure 10.1. Basic steps of process development for A conventional process 
implementation and B the proposed process implementation 
 
This thesis proposed three different engineering evaluation tools to be applied in 
different stages of the process development (cofactor and interaction matrices, 
windows of operation and bottleneck analysis) that were illustrated for the three 
different case studies (synthesis of H-caprolactam, chiral amine and chiral aliphatic 
alcohols, respectively). Ultimately, a truly rational approach for process development 
will use all the proposed engineering tools. For instance, for the production of H-
caprolactam (see Chapter 7), the methodology was able to identify the most promising 
solution regarding the biocatalyst formulation. However, many questions regarding the 
process remained open, such as protein expression, biocatalyst activity (affecting the 
reaction kinetics) and mass transfer that need to be answered experimentally. This 
information can be fed in to a window of operation to create an operation map based 
upon the process technologies chosen (as shown for the biocatalytic production of chiral 
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amine in Chapter 8). Finally, bottleneck analysis integrating economic and 
environmental analysis is used to identify the most relevant parameters influencing the 
process viability during scale-up, where a final tuning of the process conditions can be 
performed (see Chapter 9). The amount of information gathered to feed each tool 
increases, as well as the need for reliable mathematical models describing the designed 
process. 
Furthermore, this methodology is also able to assess the complexity of the biocatalytic 
process at large-scale. The process complexity is often reflected in the production costs 
and thus, the process development strategy is dependent on the industrial sector (bulk, 
fine and pharmaceutical chemicals). For bulk chemicals, the margin between raw 
material cost and product selling price is often quite small and therefore a competitive 
process implies effective conversion of the raw materials, while the allowable cost for 
the biocatalyst and downstream process is reduced. Therefore, for the effective 
production of bulk chemicals the process requires high reaction yields, high biocatalyst 
yields and high concentrations. Hence, the focus during process development should be 
on optimising the reaction conditions and the biocatalyst activity and stability (by either 
protein or process engineering). Due to the tight margin between the purchasing cost of 
the raw materials and the product selling price in bulk and commodity chemicals the 
implementation of process technologies (such as ISPR) is often limited for this industrial 
sector. At the other end of the spectrum, when developing a process for a 
pharmaceutical chemical, there is a bigger margin between the substrates and the 
product. For this industrial sector, obtaining a highly pure product is more important 
than obtaining a large reaction yield and thus, biocatalytic processes are especially 
attractive. Nevertheless, these are often challenged by either the unfavourable reaction 
thermodynamics, substrate(s) solubility, substrate(s) or product(s) inhibition, among 
others. Hence, apart from the often required biocatalyst development [47], it is also 
necessary to put in place multiple process technologies to overcome the challenges that 
are inherent to the process and reaction but are not biocatalyst-related (e.g. reaction 
thermodynamics, the properties of reagents and products), by putting in place, for 
instance, in-situ product and co-product removal and in-situ substrate supply (as shown 
in Chapter 8). 
Finally, this methodology suggested the implementation of environmental assessment 
at early development stage, raising the question of comparability of the results. Despite 
the great and increasing concern of the chemical industry in promoting greener 
processes, the truth is that when comparing the environmental profile of two different 
synthetic routes this tool works only as a ‘tiebreaker’ when both processes display 
similar economic profiles. Nevertheless, this is not necessarily a less green management 
decision, as economic savings often translate into reduced emissions. Therefore, it is 
proposed that process evaluation at early development stage should be performed 
using process metrics, as they include both the economic and environmental aspects of 
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the process. Furthermore, the data required in the green chemistry metrics to assess 
the process environmental profile is based on the same original data as for process 
metrics. 
 
10.2 Data collection 
Step 2. of the proposed methodology (constraints definition) is considered one of the 
most important steps, since structured and accurate input influences the decisions in 
the process design and the development target setting step (Step 4.). It has also been 
experienced that the ranking and compiling of data about reaction, biocatalyst and 
process constraints is a challenging task. This thesis also proposed a structured 
evaluation of the constraints into hard constraints (such as reaction thermodynamic 
equilibrium and maximum overexpression level of the recombinant protein), soft 
constraints (e.g. biocatalyst activity) and an intermediate group (such as resin capacity 
and selectivity). Hard constraints are typically fixed boundaries of the process and thus, 
must be solved in the first place, as shown for the transaminase-catalysed production of 
chiral amine (Chapter 8), where the reaction thermodynamic equilibrium is the greatest 
challenge in the process. A typical soft constraint is the biocatalyst activity, as generally 
improved biocatalyst activity is required prior to full-scale implementation, since the 
conditions of the wild-type enzymes are far removed from industrially relevant 
conditions. In the intermediate group of constraints are those that can be partially 
overcome by applying a selection guide or screening. During screening trade-offs are 
often identified and therefore it is important to rank the scores for selection. Solvent, 
solubiliser or resin selection for in-situ product removal (ISPR) is included in this group. 
The main drawback encountered in this thesis has been the low quality and quantity of 
suitable experimental data in the scientific literature for decision-making, such as 
measuring the resin selectivity and capacity at operating conditions (i.e. in the presence 
of other reaction compounds, Chapter 8). In the early stage of development, available 
databases such as the enzyme-catalysed reaction thermodynamics database (NIST 
Thermodynamics of Enzyme-Catalysed Reactions [176]) and enzyme activity database 
(BRENDA [316]) or property prediction tools might be used to overcome the lack of data. 
However, it is recommended that the conditions reported are as close as possible to the 
desired process, as much of the scientific literature is still focused on reporting new 
technologies at bench-scale conditions (i.e. at low concentrations) which might not 
always match the conditions of the designed process. 
Moreover, due to the low solubility of substrates and products of relevant biocatalytic 
reactions (in particular for fine and pharmaceutical chemicals), many of the relevant 
reactions are performed in non-conventional media. Thus, solvent selection is one of 
the major concerns in early development [317]. To date there is a general lack of 
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rationale for solvent selection in biocatalytic processes. However, computer-aided 
property estimation (CAPE) tools for selection and design of solvents have been applied 
to generate a shorter list of chemicals that could be considered as potential solvents, 
based on environmental impact, reaction performance, separation and recovery criteria 
[318]. Nonetheless, when applying solvent selection rationale to the biocatalytic process 
framework, there is one more degree of freedom that is lost since it is necessary to 
ensure the solvent biocompatibility. Furthermore, the ranking of each of the factors is 
dependent on the stage of development of the process, as seen for the selection of the 
solubiliser in Chapter 9 for the production of chiral aliphatic alcohols, where the 
solubiliser can affect the downstream process efficiency as well as membrane fouling.  
In general, there is a dearth of short-cut methods for selecting between different 
process technologies for biocatalytic processes. For instance, given that for a 
competitive process, it is necessary to implement ISPR with a given specification (i.e. 
required concentration in the reactive phase) the selection between membrane 
technology, resin or solvents can only be answered on a case-by-case approach. 
Experimental data collection is time-consuming and thus the development of prediction 
tools suitable for generating generic solutions for biocatalytic processes would be 
beneficial in order to narrow down the search space for experimentation. Further, 
computational fluid dynamics (CFD) simulations, as well as automated micro-reactor 
platforms offer excellent opportunities for quick data collection and to assist during 
formulation of process models (empirical or mechanistic). Moreover, high throughput 
data collection (using parallelised miniaturised systems) can be of great benefit for quick 
screening of a large number of different process technologies while reducing the 
consumable costs (e.g. only small amounts of expensive biocatalyst are consumed). 
 
10.3 The future of chemical processes 
Advances in recombinant DNA technology, combined with high throughput screening 
techniques, knowledge-base and statistical tools have been shown to be suitable for 
enzyme improvement by increasing stability at higher temperatures, in the presence of 
organic solvents, accepting new substrates and catalysing new non-natural reactions 
[65]. It is expected in the near future enzymes will be engineered at reasonable cost to 
fit the process specifications, making the task of the process engineer easier. Thus, it is 
for these engineers (process, protein and genetic engineers) that the methodological 
approach put together in this thesis, will be most interesting.  
Further, new plant design might become a less common practice in the coming decades 
[319]. However, this does not necessarily mean that there is no space for novel design 
solutions. New synthetic processes (including biocatalytic processes) will be put in place 
in retrofitted plant design, either to increase capacity, improve EHS compliance, or 
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improve the process economics. Moreover, there is an increasing demand for modular 
generic solutions (building-blocks) to carry out one or more units of operation, in a 
standardised and well-characterised way [315] having a flexible capacity and operation, 
as well as being easily adaptable to new reaction chemistries. Hence, the development 
of systematic approaches able to assist during process design and in particular during 
the design of generic solutions for biocatalysis is a priority in order that these processes 
can gain a competitive position within the chemical industry. 
 
This thesis has tried to cover several relevant aspects within the industrial application of 
biocatalysis, with application of three different case studies each representing different 
levels of underlying knowledge. Retrospectively, the methodological approach of (at 
least one of) the tools would have benefitted if the focus of the project had been on one 
single case study. In particular, for complex process designs (such as those proposed in 
Case Study 2, Chapter 8) the structured selection of the process technology(ies) for 
displacing the thermodynamic equilibrium was not fully achieved. However, this issue 
has been partly addressed in current and past PhD projects at our research group. 
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11 Concluding remarks and future perspectives 
The main goal of this thesis was to establish a methodology to assist biocatalytic process 
development in its early stage. The methodology applies three different tools for 
different levels of knowledge that were able to assess the process feasibility at 
industrially relevant and competitive conditions. The difference of this methodology 
compared with others commonly put in place by the conventional chemical industry is 
that the particular features of the biocatalytic process have been introduced for each 
tool (e.g. catalyst formulation or catalyst improvements, etc.).  
 
11.1 Achievements 
The work done in the framework of this thesis has resulted in the following 
achievements: 
x A general structure for a systematic methodology for process design in 
biocatalysis has been proposed. The methodology suggests guidelines for 
threshold process metrics (as a short-cut for integration of economic and 
environmental analysis), as well as the application of engineering tools for 
different stages of process development (Figure 11.1). The generic methodology 
was applied to different case studies (as sub-problem examples) bringing distinct 
understanding of the process and intrinsic constraints, from initial route scouting 
(Case Study 1, Chapter 7) to later development stages in process design (Case 
Study 3, Chapter 9). Although the proposed methodology is still in its infancy 
when compared with other PSE tools and methods, a good overview of the whole 
reaction system was achieved for each sub-problem, a systematic evaluation of 
different process options was performed and fundamental data collection for 
further development stages was suggested by putting in place this methodology. 
However, this methodology could be greatly enhanced by the implementation 
and integration of mechanistic models that are able to describe the mass and 
energy balances occurring in the reaction system. 
 
Figure 11.1. Environmental and economic evaluation tools for different development 
stages 
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The selected case studies illustrate different complexity levels and challenges and their 
intention is to demonstrate different tools developed to assist during process synthesis. 
For the case studies developed here, conclusions have been presented in the 
corresponding chapters. The main conclusions are:  
x Cofactor and interaction matrices were applied to assist the selection of a 
suitable catalyst formulation for the multi-enzyme process yielding the synthesis 
of H-caprolactam. This tool was proven to be of relevance for the understanding 
of the overall system, by identifying the interactions between the different 
reaction components and the enzymes involved in the multi-enzyme processes. 
Within the framework of the proposed methodology, this tool was used to: 
identify the requirements in cofactor regeneration; and narrow down the 
number of process options regarding the number of reactors required for the 
synthesis. The application of evaluation tools (economic and environmental 
evaluation) was able to identify the most promising catalyst formulation for each 
reaction (whole-cell), as well as the bottlenecks for further development 
(improved alanine total turnover number, TTNAla). However, rough assumptions 
were made in the ability of overexpression of more than one recombinant 
protein (enzyme) within the resting cell, as well as in the biocatalyst activity at 
the designed conditions. In addition, there is a trade-off not fully identified (due 
to the lack of data) regarding the expected lower enzyme activity (with 
consequent higher reactor occupancy and the possibility of side-reactions) and 
the use of isolated enzymes and cofactors (but with consequent increase in the 
purity of the product). From this case study it could also be concluded that the 
use of whole-cells in reactions where co-factors are required as a biocatalyst can 
lead to more economically competitive and greener processes, when compared 
with the isolated enzymes, as the cost of the co-factors often represent a big 
percentage of the raw materials costs. However, some disadvantages of the 
whole-cells were not considered (such as the transport limitations across the cell 
membrane). 
x In the second case study, windows of operation were used to visualise the 
process performance and feasibility of the transaminase-catalysed synthesis of 
chiral amine. The application of this methodology requires a more in depth 
knowledge than required by the previous tool. This fundamental knowledge 
should not only cover the reaction system itself but also the process technologies 
put in place to attain a defined performance level. The outcome of this tool is an 
operating map, suggesting a combination of process technologies (i.e. different 
ISPR and IScPR techniques) where the process can be successfully operated. The 
integration of kinetic modelling in this tool enabled the identification of threshold 
values for biocatalyst activity improvement by protein and genetic engineering. 
Further, it identified a general lack of available technologies to selectively recover 
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the product and the co-product, essential for shifting the thermodynamic 
equilibrium and achieving the threshold values for reaction yield. Finally, this case 
study also showed that at large-scale, the success of thermodynamically 
challenged reactions (such as the synthesis of chiral amine) requires a 
combination of solutions (ISPR and IScPR), while the use of a high excess of amine 
donor (a more common solution in the scientific literature) might not be possible 
due to the amine donor solubility limit and inhibitory concentrations at relevant 
full-scale conditions. 
x Finally, bottleneck analysis was applied to guide improvements in the 
continuous production process of chiral aliphatic alcohols in a bi-enzymatic 
system for cofactor regeneration (parallel reactions). The information required 
to apply this tool went beyond that necessary for the previously presented tools. 
For this case study, mass and energy balances gathered in the initial process 
design were compiled. The bottleneck analysis tool applies modelling, costing 
and environmental evaluation to identify the main process limitations. Further, 
application of kinetic modelling, describing the process, allows the evaluation of 
modifications of the process conditions and reaction optimisation in-silico.  
 
11.2 Open challenges and future perspectives 
The development of biocatalytic processes (as for any emerging technology) is still a 
challenging task that requires time to achieve a certain maturity and to become 
established as a competitive alternative to the current synthetic processes. It is believed 
that the application of a systematic approach can channel research efforts (eliminating 
less promising solutions). In general, it is hoped that this thesis will “catalyse” the 
discussion and implementation of general and systematic methodologies to improve 
design in biocatalytic processes. However, there are still many different fields that 
require further development, which can only be beneficial for future systematic 
frameworks for process development.  
x It is necessary to develop in-silico predictive tools for property and 
thermodynamic data at operating conditions for biocatalytic processes (aqueous 
solutions). This can reduce the experimental work and assist in selection of 
process technologies (e.g. predictive tools for predict the partition coefficient 
and selectivity in ISPR resins and solvents). 
x Most of the current mathematical models describe biocatalyst behaviour in 
terms of enzyme selectivity, mechanism and initial reaction rate kinetics. Further, 
these have generally been subject to considerable simplification and they are 
only able to describe the reaction kinetics at dilute conditions. There is however, 
a need for integration of these models with mass transfer phenomena at more 
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global operating conditions, e.g. ISPR mass transfer phenomena should also be 
integrated into the process model (Case Study 2, Chapter 8). 
x Economic and environmental assessments might lead to trade-offs in the 
process and thus, this methodology would strongly benefit from the integration 
of a MINLP methods as well as an uncertainty and sensitivity analysis of the 
obtained results. 
x For whole-cell catalysed reactions (Case Study 1, Chapter 7), the methodology 
would benefit from integration of models describing metabolic control in resting 
cells (whole-cell biocatalysts), but also the mass transfer diffusion of unnatural 
substrates and products across the cell membrane. 
x The interest in continuous production and process intensification is increasing 
rapidly in the chemical industry. Hence, biocatalytic processes should also follow 
this trend, as it is likely that the biocatalytic step(s) would be integrated in a larger 
chemo-enzymatic framework for synthesis of relevant compounds. 
x Many of the commonly applied PSE tools and methods for acquiring process 
knowledge in the conventional chemical industry (e.g. chemometrics, design of 
experiments, etc.) will also need to find their space within biocatalytic process 
design. 
x Due to the huge development potential of the biocatalytic processes, target 
setting is essential, not only for biocatalyst development but also to the process 
technologies. However, these targets should not be reached at any cost. Many of 
the potential biocatalytic processes will simply be discontinued due to the 
complexity and costly research efforts required. Integrating assessment cost for 
development of a given technology or catalyst will be essential to support this 
decision. 
x Finally, it would be desirable to prove the sequential application of the three 
developed tools and assess the development time by implementing the 
methodology proposed in this thesis. 
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Appendix 2: Data for economical assessment 
Table A2.1. List of prices of consumables used for costing in case study 1 (Chapter 7) 
and case study 3 (Chapter 9) 
Consumable Cost Reference 
2-Octanone 10 €/kg Assumed 
ADA-buffer 10 €/kg Assumed from Carl-Roth 
Alanine 6 €/kg Estimated from Sigma-Aldrich 
AM-101 2.19 Our personal contact with Evonik, 2012 
Carrier 50 €/kg [16] 
Cyclohexanol 1.37 €/kg Our personal contact with Evonik, 2011 
GDH 700 €/kg Our personal contact with X-zyme, 2013 
Glucose 0.5 €/kg www.icis.com, 2010 
Kanamycin 38 €/kg Our personal contact with Evonik, 2010 
LbADH 1600 €/kg Our personal contact with X-zyme, 2012 
NAD(H) 2000 €/kg Estimated from [130] 
NADP(H) 10000 €/kg Estimated from [130] 
NH4Cl 0.38 €/kg www.icis.com, 2011 
n-heptane/EtOH mixture 0.29 €/L www.icis.com, 2012 
Peptone 3 €/kg Our personal contact with Evonik, 2010 
PLP 420 €/kg MP Biomedicals, 2011 
Salts and minerals 0.5 €/kg Our personal contact with Evonik, 2010; www.icis.com, 2010 
Utility Cost Reference 
Electricity 0.1 €/kWh European Energy Portal (www.energy.eu) 
Process water 0.01 €/L Our personal contact with Evonik, 2010 
Wastewater handling 1 €/m3 [141] 
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Appendix 3: Economic and environmental assessment for 
biocatalytic production of H-caprolactam 
A3.1 General Assumptions 
The general assumptions for the fermentation are: 
x Plant is located in Western Europe; 
x The facility will be a multi-purpose plant with shared utility and services systems; 
x The production of H-caprolactam is 10 000 tons/year; 
x The plant operates 8 000 hours/year 
x Costs are given in Euro (€)  
 
A3.2 Process Overview 
A3.2.1 Fermentation 
1. Fermenter size: A fermenter of 10m3 with 80% working volume is used in the base 
case. 
2. The fermenter is inoculated and run as a fed-batch fermentation for a total of 48h 
3. Total process time, including preparation, fermentation, harvesting and cleaning is 
3 working days. 
4. Equipment is used for running 120 successful batches per year for the production 
of all the biocatalyst in the plant site 
5. Fermentation media is prepared in a tank with a mixer and then passed through a 
heat exchanger for sterilization at 121°C 
6. The expression of the recombinant protein(s) is done by auto-induced media 
7. Aeration of 1 fermenter volume per minute is accomplished with a compressor 
(5kW/m3) 
8. Mixing power input is 5kW/m3 
9. Water content in the cells after centrifugation is 10% of cell dry weight 
10. Fermentation metrics: 
a. Cell density: 50 gCDW/L 
b. Yield coefficient of biomass on glucose (Ysx) is 0.4 g biomass/g glucose 
c. Total Protein content in the host is 0.5 g Total Protein/ g biomass 
d. Maximum overexpressed recombinant protein(s) is  
0.25 g Recombinant Protein(s)/ g biomass 
e. Yield coefficient of recombinant protein(s) on glucose (YsRE) is  
0.05 g Recombinant Protein(s)/g glucose 
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Figure A3.1. Process scheme for base case fed-batch fermentation in 10 m3 fermenter 
 
A3.2.1.1 Process Costs 
Table A3.2. Fermentation medium (raw materials) cost 
 
 
 
 
 
Table A3.3. Utilities cost 
Utilities  kWh Cost (€/batch) 
Sterilization 4.1813 kJ/(kg.K) 1175 118 
Aeration (1 vvm ) 5 kW/m3 2400 240 
Stirring (500rpm) 5 kW/m3 2400 240 
Centrifugation 2 kW/m3 20 2 
Drier  4.1813 kJ/(kg.K) 2257 kJ/kg 35 3.5 
 m3 Price (€/m3) 
Cost 
(€/batch) 
Wastewater handling 10 1 100 
Total raw material cost 703 
 
Table A3.4. Labour cost 
Labour  
Labour cost 30 €/h 
Labour requirements, man h/batch Team of 2 workers for 1 week 
Supervision, quality control etc. +100% 
Total labour costs 7200 €/batch 
 
  
Raw materials 
Weight Price Cost 
(kg) (€/kg) (€/batch) 
Glucose 1250 0.50 625 
Peptone 1250 3.03 3788 
Kanamycin (50 mg/L) 0.5 37.80 19 
Salts and minerals 200 0.49 98 
Water 10000 0.01 100 
Total raw material cost 4630 
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Table A3.5. Capital investment cost 
Equipment Size Purchasing cost (€) 
TIC a) 
(€) 
Annuityb) 
(€/year) 
Maintenancec) 
 (€/year) 
Othersd) 
(€/year) 
Cost 
(€/batch) 
Storage tank 12.5 m3 6500 32500 4627 463 694 47 
Pump 5 m3/h 7200 36000 5126 513 769 52 
Heat exchanger  1 m2 4000 20000 2848 285 427 29 
Compressor 12.5 m3/min 36000 180000 25628 2563 3844 260 
Pre-Fermenter  1.25 m3 52000 260000 37018 3702 5553 376 
Fermenter  12.5 m3 165000 825000 117461 11746 17619 1193 
Centrifuge  1 m3 12000 60000 8543 854 1281 87 
Drier  10 m2 305000 152500 21713 2171 3257 221 
Total Equipment cost (€/batch) 2265 
a) TIC – Total Installed cost Lang Factor = 5  
b) 7% interest rate and 10 year life-time 
c) Maintenance is 10% of TIC 
d) Other including taxes, insurance, etc. is 15% of TIC 
 
A3.2.2 Catalyst purification 
The cost of the isolated recombinant enzyme increases when compared with their 
whole-cell or crude extract preparation. Aiming the enzyme purification: the whole-cell 
was recovered by microfiltration; the crude enzyme the cells were run through a 
homogenizer, centrifuged to remove cell debris and finally ultrafiltration was applied. 
Partially purified enzyme was prepared by additionally running ion-exchange and gel-
filtration chromatography as well as two additional ultrafiltration steps. The added cost 
in each step is significant. The preparation of crude enzyme from recombinant whole-
cell adds to the specific cost of the enzyme by a factor of two. Purification by 
chromatography increases the cost per kg of biocatalyst 10-fold, where the major cost 
contribution comes from the consumables such as the resin material. [16] 
 
A3.2.3 Immobilisation 
1. Tank size: A mixing tank of 1.5 m3 with 80% working volume is used in the base case 
for preparing 130 kg of biocatalyst; 
2. Equipment is used for 4000h per year 
3. Total process time, including preparation, immobilisation, filtering, drying and 
cleaning is 32 hours; 
4. Immobilisation solution is prepared in a mixing tank to the concentration of 6 g/L; 
5. Carrier material is added to start the immobilisation; 
6. After the time required to immobilise more than 90 % of the protein, the immobilised 
enzyme is filtered from the immobilisation solution; 
7. The catalyst is dried; 
8. The equipment is emptied and cleaned; 
9. The final biocatalyst has an enzyme loading of 50 g enzyme/kg immobilised biocatalyst. 
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Figure A3.2. Process scheme for base case immobilised biocatalyst 
 
A3.2.3.1 Process Costs 
Table A3.6. Enzyme Immobilisation raw materials cost 
Raw materials 
Weight Price Cost 
(kg) (€/kg) (€/batch) 
Carrier 124 50 6175 
Isolated Enzyme 7.22 2368 17100 
Water 1358 0.01 14 
Total raw material cost 23288 
 
Table A3.7. Utilities cost 
Utilities  kWh Cost (€/batch) 
Stirring (500rpm) 5 kW/m3 170 17 
Filtration 2 kW/m3 2716 272 
Drier  4.1813 kJ/(kg.K) 2257 kJ/kg 9 0.9 
 m3 Price (€/m3) 
Cost 
(€/batch) 
Wastewater handling 1.36 1 76 
Total raw material cost 365 
 
Table A3.8. Labour cost 
Labour  
Labour cost 30 €/h 
Labour requirements, man h/batch 1 worker for 32 hours 
Supervision, quality control etc. +100% 
Total labour costs 1920 €/batch 
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Table A3.9. Capital investment cost 
Equipment Size Purchasing cost (€) 
TIC a) 
(€) 
Annuityb) 
(€/year) 
Maintenancec) 
(€/year) 
Othersd) 
(€/year) 
Cost 
(€/batch) 
Mixing 
tank  1.7 m
3 72000 360000 51256 5126 7688 521 
Pump 5 m3/h 7200 36000 5126 513 769 52 
Filter 7 m2 110000 550000 78308 7831 11746 795 
Drier 10 m2 34000 170000 24204 2420 3631 246 
Total Equipment cost (€/batch) 1614 
a) TIC – Total Installed cost Lang Factor = 5  
b) 7% interest rate and 10 year life-time 
c) Maintenance is 10% of TIC 
d) Other including taxes, insurance, etc. is 15% of TIC 
 
A3.2.4 Reaction 
1. Set of series of three or two reactors (option 1 or option 2 or 3, respectively) with 40 
m3 with 80% working volume is used in the base case. 
2. The reactor is dosed with the biocatalyst, substrate(s), cofactors and other process 
adjuvants as a batch reaction for a total of 8h 
3. Total process time, including preparation, reaction and cleaning is 12h 
4. Equipment is used for running 900 successful batches per year for the production of 
all the biocatalyst in the plant site 
5. Aeration of 1 reactor volume per minute is accomplished with a compressor 
(5kW/m3) 
6. Mixing power input is 5kW/m3 
7. Cyclisation of 6AHA to H-caprolactam reaction yield 99% 
8. Biocatalytic reaction metrics: 
a. Reaction Yield: 90%  
b. For whole-cell catalyst, glucose requirement: 10% (wt.) of the CDW 
c. TTNNAD(H): 105 molProduct formed/molNAD(H) 
d. TTNNADP(H): 104 molProduct formed/molNADP(H) 
e. TTNPLP: 90 molProduct formed/molPLP 
f. TTNAla: 1 molProduct formed/molAla 
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Figure A3.3. Process scheme for Option 1.12 for biocatalytic production of 6AHA 
 
1.1.1.1 Process Costs 
Table A3.10. Biocatalytic production of 6AHA raw materials cost 
Raw Material Weight (kg/batch) 
Price 
(€/kg) 
Cost 
(€/batch) 
Whole-cell 
(containing ADH-NADP and CHMO) 11.41 29 332 
Lipase 1.59* 4788 38 
Whole-cell 
(containing ADH-NAD, TAm and AlaDH) 19.70 29 574 
 Weight (kg/batch) 
Price 
(€/kg) 
Cost 
(€/batch) 
Cyclohexanol 8484 1.37 11632 
NH4Cl 4531 0.38 1699 
Alanine 6792 6 40752 
NAD(H) 0 2000 0 
NADP(H) 0 10000 0 
PLP 0 420 0 
Glucose 31 0.50 16 
Water 40000 0.01 400 
Total raw material cost   55443 
* recycled 200 times    
 
Table A3.11. Utilities cost 
Utilities kWh Price (€/kWh) 
Cost 
(€/batch) 
Stirring 3200 0.10 320 
Heating 698 0.10 70 
Aeration for 1vvm 1274 0.10 127 
N2 Sparging 1274 0.10 127 
 m3 Price (€/m3) 
Cost 
(€/batch) 
Wastewater handling 40 1 40 
 kg Prices (€/kg) 
Cost 
(€/batch) 
Biocatalyst waste 31 0.03 0.8 
Total utilities cost   685 
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Table A3.12. Labour cost 
Labour  
Labour cost 30 €/h 
Labour requirements, man h/batch 3 workers for 12 hours 
Supervision, quality control etc. +100% 
Total labour costs 2160 €/batch 
 
Table A3.13. Capital investment cost 
Equipment Size Purchasing cost (€) 
No. 
units 
TICa) 
(€) 
Annuityb) 
 (€/year) 
Maintenancec) 
(€/year) 
Othersd) 
(€/year) 
Cost 
(€/batch) 
Storage tank 48 m3 14000 3 210000 29899 2990 4485 47 
Stirred Tank Reactor 48 m3 430000 2 4300000 612223 61222 91834 957 
Column Reactor 48 m3 14000 1 70000 9966 997 1495 16 
Compressor 40 m3/min 150000 2 1500000 213566 21357 32035 334 
Pump 10 m3/h 11000 3 165000 23492 2349 3524 37 
Filter (m2) 10 m2 140000 2 1400000 199329 19933 29899 312 
Total Equipment cost (€/batch) 1701 
a) TIC – Total Installed cost Lang Factor = 5  
b) 7% interest rate and 10 year life-time 
c) Maintenance is 10% of TIC 
d) Other including taxes, insurance, etc. is 15% of TIC 
 
A3.3 Life cycle assessment in GaBi Product Sustainability 
Software (in collaboration with Evonik Industries AG) 
A3.3.1 Fermentation 
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A3.3.2 Catalyst formulation 
A3.3.2.1 Whole-cell 
 
A3.3.2.2 Isolated Enzyme 
 
 
A3.3.2.3 Immobilised Enzyme 
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A3.3.3 Reaction 
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Appendix 4: MATLAB® scripts for kinetic modelling of 
aliphatic alcohol production using alcohol dehydrogenase 
function dy = LbADHGDH(t,y) 
%  1 = NADPH 
%  2 = NADP 
%  3 = ON 
%  4 = OL 
%  5 = Gluc 
%  6 = GDL 
%  7 = NADPH2 
%  8 = NADP2 
%  9 = ON2 
%  10 = OL2 
%  11 = Gluc2 
%  12 = GDL2 
%  13 = LbADH1 
%  14 = GDH1 
%  15 = LbADH2 
%  16 = GDH2 
%  17 = Flow 
%  18 = NADPinitial 
 
dy = zeros (18,1); 
Kinetic Parameters 
Vmf=(17.50084735/60000) ;%{mmol/L/s} Vmax for the forward 
LbADH reaction 
KMON=0.205999742  ;%{mmol/L} KM for 2-octanone 
KMNADPHON=0.037041599 ;%{mmol/L} KM for NADPH 
KP2OL=0.208178602  ;%{mmol/L} Kp for 2-octanol 
KSON=163.0470923  ;%{mmol/L} Ks for 2-octanone 
KPNADPON=0.212141656 ;%{mmol/L} Kp for NADPH 
 
Vb=(9.961666509/60000) ;%{mmol/L/s} Vmax for the backward 
LbADH reaction 
KMOL=0.033190703  ;%{mmol/L KM for 2-octanol 
KMNADPb=0.834689069  ;%{mmol/L} KM for NADP+ 
KPON=0.012225455  ;%{mmol/L} Kp for 2-octanone 
KPNADPHOL=0.358861502 ;%{mmol/L} Kp for NADP+ 
KSb=6065.242184  ;%{mmol/L/s} Ks for 2-octanol 
 
VGDH=(5.822557/60000) ;%{mmol/L/s} Vmax for the backward GDH 
reaction 
KMGluc=2.729106  ;%{mmol/L} KM for glucose 
KMNADPGDH=0.025828  ;%{mmol/L} KM for NADP+ 
KPNADPHGDH=0.028013  ;%{mmol/L} Kp for NADH 
KSGluc=3783.912343  ;%{mmol/L} Ks for glucose 
%Flow1=0.004/3600  ;%{L/h/s} Flow 
 
dy(17)=0; 
dy(18)=0; 
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Initial conditions 
NADPHinitial=0.0  ;%{mmol/L} 
ONinitial=94   ;%{mmol/L} 
OLinitial=0   ;%{mmol/L} 
Glucinitial=94  ;%{mmol/L} 
GDLinitial=0   ;%{mmol/L} 
VolReactor=0.015  ;%{L} 
Reaction: 
Forw1 = 
Vmf.*y(13).*y(3)./(KMON.*(1+y(4)./KP2OL)+y(3).*(1+y(3)./KSON))*y(
1)./(KMNADPHON.*(1+y(2)./KPNADPON)+y(1)); 
Back1 = 
Vb.*y(13).*y(4)./(KMOL.*(1+y(3)./KPON)+y(4).*(1+y(4)./KSb))*y(2).
/(KMNADPb.*(1+y(1)./KPNADPHOL)+y(2)); 
Reg1  =  VGDH.*y(14).*y(5)./(KMGluc + 
y(5)*(1+y(5)./KSGluc))*y(2)./(KMNADPGDH.*(1+y(1)/KPNADPHGDH)+y(2)
); 
 
Forw2 = 
Vmf.*y(15).*y(9)./(KMON.*(1+y(10)./KP2OL)+y(9).*(1+y(9)./KSON))*y
(7)./(KMNADPHON.*(1+y(8)./KPNADPON)+y(7)); 
Back2 = 
Vb.*y(15).*y(10)./(KMOL.*(1+y(9)./KPON)+y(10).*(1+y(10)./KSb))*y(
8)./(KMNADPb.*(1+y(7)./KPNADPHOL)+y(8)); 
Reg2  =  VGDH.*y(16).*y(11)./(KMGluc + 
y(11)*(1+y(11)./KSGluc))*y(8)./(KMNADPGDH.*(1+y(7)/KPNADPHGDH)+y(
8)); 
 
% Cofactor stability 
deacnadphr1 = y(1)*(-4.10844e-06); 
deacnadphr2 = y(7)*(-4.10844e-06); 
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Mass Balance to EMR 
%{           Input                                       Reaction           
 Output     } 
dy(1)=(y(17)./VolReactor.*NADPHinitial)     -Forw1 +Back1 + Reg1 
- deacnadphr1 - (y(17)./VolReactor.*y(1)); 
dy(2)=(y(17)./VolReactor.*y(18))            +Forw1 - Back1 -Reg1 
-               (y(17)./VolReactor.*y(2)); 
dy(3)=(y(17)./VolReactor.*ONinitial)        -Forw1 +Back1 -                 
(y(17)./VolReactor.*y(3)); 
dy(4)=(y(17)./VolReactor.*OLinitial)        +Forw1 -Back1 -                 
(y(17)./VolReactor.*y(4)); 
dy(5)=(y(17)./VolReactor.*Glucinitial)      -Reg1-                          
(y(17)./VolReactor.*y(5)); 
dy(6)=(y(17)./VolReactor.*GDLinitial)       +Reg1-                          
(y(17)./VolReactor.*y(6)); 
dy(7)=(y(17)./VolReactor.*y(1))             -Forw2 +Back2 + Reg2 
- deacnadphr2-  (y(17)./VolReactor.*y(7)); 
dy(8)=(y(17)./VolReactor.*y(2))             +Forw2 - Back2 -Reg2 
-               (y(17)./VolReactor.*y(8)); 
dy(9)=(y(17)./VolReactor.*y(3))             -Forw2 +Back2 -                 
(y(17)./VolReactor.*y(9)); 
dy(10)=(y(17)./VolReactor.*y(4))            +Forw2 -Back2 -                 
(y(17)./VolReactor.*y(10)); 
dy(11)=(y(17)./VolReactor.*y(5))            -Reg2-                          
(y(17)./VolReactor.*y(11)); 
dy(12)=(y(17)./VolReactor.*y(6))            +Reg2-                          
(y(17)./VolReactor.*y(12)); 
Deactivation LbADH (13;15) and GDH (14;16) 
dy(13)= y(13)*(-1.925e-7); 
dy(14)= y(14)*(-1.925e-7); 
dy(15)= y(15)*(-1.925e-7); 
dy(16)= y(16)*(-1.925e-7); 
 
%X1=y(4)/(y(4)+y(5)); 
%X2=y(10)/(y(10)+y(11)); 
Published with MATLAB® R2012b 
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clc 
clear all 
close all 
A=[]; 
B= []; 
ONinitial=94; %mM 
for i=1:1 
flow=[ 0.005 0.012 0.020 ]; 
for k=1:1; %k=1:4 
%  adh=[ 50 250 500 1000]; 
adh=[100]; 
for m=1:1; %m=1:4 
%  gdh=[ 50 250 500 1000]; 
 gdh=[300]; 
 for l=1:1; %l=1:4 
%  adh2=[ 50 250 500 1000]; 
adh2=[900]; 
for n=1:1; %n=1:4 
%  gdh2=[ 50 250 500 1000]; 
gdh2=[300]; 
 for p=6:6 
 nadp=[ 0.1 0.09 0.08 0.07 0.06 0.05 0.04 0.03 0.02 0.01 ]; 
     
[t,y]=ode15s(@LbADHGDH,[0:5000:(1000*3600)],[0.0001;0.0001;0.1;0.
1;0.1;0.1;0.0001;0.0001;0.1;0.1;0.1;0.1;adh(k);gdh(m);adh2(l);gdh
2(n);flow(i)/3600;nadp(p)]); 
 
 
cond=[t y]; 
A= mean(y); 
B= [B A'] ; 
R2Ol=y(:,10); 
Yield=R2Ol/ONinitial; 
 
csvwrite(['Flow_' num2str(i) num2str(k) num2str(m) num2str(l) 
num2str(n) num2str(p)] ,cond) 
 eval(['Flow_' num2str(i) num2str(k) num2str(m) num2str(l) 
num2str(n) num2str(p) '=cond']) 
 eval(['Mean_' num2str(i) num2str(k) num2str(m) num2str(l) 
num2str(n) num2str(p) '=A']) 
 clear ['Flow_' num2str(i) num2str(k) num2str(m) num2str(l) 
num2str(n) num2str(p)] 
end 
end 
end 
end 
end 
end 
 
R2Ol=y(:,10); 
Yield=R2Ol/ONinitial; 
Published with MATLAB® R2012b 
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